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 ABSTRACT 
 
Increasing epidemiological evidence suggests a link between atherosclerosis and age-
related macular degeneration (AMD). There are two main hypotheses that explain the link. 
One hypothesis is that AMD and atherosclerosis are tissue responses to injury. The 
‘Response to Injury’ hypothesis defined as ‘abnormal reparative response to chronic, 
recurrent injurious stimuli’ speculates that AMD and atherosclerosis may be cellular effects 
of chronic or repetitive risk factors. The second hypothesis suggests that AMD is secondary 
to vascular insufficiency caused by atherosclerosis. 
The research in this thesis is an attempt to test these hypotheses to better understand the 
correlation of AMD and atherosclerosis. Both basic and clinical science approaches are 
employed. 
Part one focuses on the role of extracellular matrix (ECM) proteins in the pathogenesis of 
AMD. Both serum elastin derived peptides (S-EDP) and matrix metalloproteinases (MMP-
2 and MMP-9) are raised in subjects with atherosclerosis. The circulating levels of these 
matrix components were tested in patients with varying degree of severity of AMD and 
compared to age-matched controls. Both S-EDP and MMP-9 were found to be significantly 
raised in patients with AMD, while MMP-2 did not correlate with it. 
S-EDP is elevated in abdominal aortic aneurysm (AAA), a manifestation of atherosclerosis. 
Since S-EDP correlates with size of both AAA and severity of AMD, this research looked 
at a possible association between the two diseases but found no significant correlation. 
The second part of this thesis investigates whether chronic inflammation may explain the 
co-existence of the two diseases. With the recent finding that Complement Factor H (CFH) 
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is related to AMD, this study focused on the role of complement activation in AMD, 
speculating that the final common pathway of both diseases may be chronic inflammation. 
Increased systemic complement activation was found in neovascular AMD, as assessed by 
the measurement of C3a des Arg. 
Part three of this thesis tested the second hypothesis that AMD is secondary to the vascular 
insufficiency caused by atherosclerosis. Both the choroidal blood flow and retinal vessel 
calibre in patients with asymmetric AMD were studied and no significant changes in ocular 
haemodynamics were noted. 
In conclusion, this research favours the concept that atherosclerosis and AMD are parallel 
responses to chronic, recurrent injurious stimuli, with extracellular matrix remodelling and 
probably inflammatory response being the common cellular responses. This research did 
not find any significant ocular haemodynamic changes in subjects with asymmetric AMD. 
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CHAPTER 1: INTRODUCTION 
1.1 Age-related macular degeneration  
1.1.1 Definition of age-related macular degeneration 
 
Age related macular degeneration (AMD) is a progressive disease affecting the retina of the 
elderly. The macula lutea, meaning ‘yellow spot’ is the central part of the retina (fig.1.1) 
and the dysfunction of this area results in the inability to read, recognize faces and drive, 
thus compromising the lifestyle. The visual disability it imposes on the elderly depends on 
the extent and nature of the disease. 
 
 
Fig 1.1: Colour photograph of fundus indicating Macula (the outer circle). 
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1.1.2 Diagnosis of age-related macular degeneration 
 
AMD is a heterogeneous disorder and not all patients suffer degeneration of the macula. 
Bird proposed a more appropriate name for the condition as ‘age related macular disease’ 
(Bird, 2003). 
According to the current nomenclature of the International AMD Epidemiological Study 
Group, all early and late signs of AMD are called age-related maculopathy (ARM) (Bird, 
1995). Drusen are yellow spots that appear on the fundus.  There is almost no risk of 
progression to AMD if these drusen are small (<63µm diameter) and few.  However, with 
time some patients develop larger drusen (>125µm diameter) or develop retinal pigmentary 
abnormalities (with hyper- or hypo-pigmentation). These changes are termed early age-
related maculopathy (fig 1.2). In this thesis, ARM is used to denote early disease. 
 
Fig 1.2 : Early age-related maculopathy 
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The two late stages of the disease are the dry type, also called geographic atrophy (fig. 1.3), 
and the wet type, called neovascular AMD. Fig. 1.3 shows a central area of geographic 
atrophy.  
 
 
Fig 1.3: Geographic atrophy 
 
Choroidal neovascularisation (CNV) is the hallmark of wet or neovascular AMD. Fig 1.4 
shows how the CNV breaks through the Bruch’s membrane (BM) to lie external to the 
retinal pigment epithelium (RPE) or under the sensory retina. These subtypes of CNV are 
clinically diagnosed by fundus fluorescein angiography as shown in fig.1.5. The 
fluorescein angiographic leakage patterns of CNV are classified according to the proportion 
of classic component defined as area of early hyper-fluorescence that increases in intensity 
and area in late frames. Eligibility criteria for treatment of these CNVs are at present 
determined by the pattern of angiographic leakage, site and size of lesion.  
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RPE
BM
Choriocapillaries
RPE
BM
Choriocapillaries  
Fig 1.4: Schematic representation of CNV  
 
 
Fig.1. 5: Colour photograph and fluorescein angiographic evidence of CNV 
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1.1.3 The patho-physiology of AMD 
 
Numerous epidemiological and basic science studies have provided suggestions for 
potential causal mechanisms for AMD. These include genetic influence, cumulative 
exposure to oxidative stress, vascular insufficiency secondary to atherosclerosis and 
immune and inflammatory mediated process (Ambati et al. 2003a).  
Several genes have been studied in AMD and the latest evidence suggests increased risk of 
AMD in subjects with CFH gene mutation (Klein et al. 2005; Edwards et al. 2005; Haines 
et al. 2005). The exact role of this gene in AMD remains to be demonstrated though many 
elegant studies have demonstrated immune mediated biogenesis of drusen (Anderson et al. 
2002; Crabb et al. 2002; Johnson et al. 2001).  
AMD, like many other age-related diseases, have also been attributed to oxidative stress 
caused by reactive oxygen intermediates. The retina is particularly susceptible to oxidative 
damage due to the high oxygen tension, life time exposure to irradiation, high proportion of 
polyunsaturated fat, the presence of numerous chromophores in the retina and the 
phagocytic function of the RPE. Oxidative damage results from an mbalanace between 
reactive oxidative intermediates and thelevels of anti-oxidants in the retina. Superoxide 
dismutase, catalase and glutathione peroxidase and vitamins C, E, carotenoids and zinc 
form part of the complex system that protects the retina from oxidative damage while the 
pro-oxidants include lipofuscin, glycation and oxidation of lipoproteins (Beatty et al. 
2000). 
Hydrodynamic changes of the Bruch’s membrane with age can also impede the two-way 
conduit through this strategically situated membrane and influence the development of 
AMD (Moore et al. 1995). 
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Ocular blood flow alterations may also contribute to the pathogenesis of AMD though the 
exact nature of impairment has not been elucidated (Friedman, 2000). 
The intricate interplay and complexity of the multiple molecular processes involved make 
the understanding of AMD still quite elusive.  
1.2 Atherosclerosis 
1.2.1 Definition 
 
Atherosclerosis is a degenerative disease of blood vessels and is a major cause of morbidity 
and mortality in the elderly. 
1.2.2 Pathogenesis 
 
The primary site of injury is thought to be the endothelial cells. The transmigration of lipids 
and monocytes through the dysfunctional endothelium initiate the initial lesion of 
atherosclerosis, namely fatty streak. The fatty streak evolves to the complex atherosclerotic 
plaque, which consists of a lipid core covered by a fibrous cap. Plaques are prone to 
rupture, leading to atherosclerotic advanced lesions. The traditional cardiovascular risk 
factors activate a complex cascade of events including inflammation, ECM remodelling 
and release of growth factors and cytokines and adhesion molecules. 
 
Fig.1. 6: Schematic representation of an atherosclerotic vascular wall 
 
 21
1.3 The link between atherosclerosis and AMD 
1.3.1 Hypotheses 
 
There are two main hypotheses that link atherosclerosis and AMD. The first hypothesis is 
that AMD is a tissue response to injurious stimuli parallel to the ‘Response to Injury’ 
hypothesis that explains atherosclerosis (Lim, 2002). The response to injury is defined as 
‘abnormal reparative response induced by exposure to chronic, recurrent injurious stimuli’ 
(Ross, 1999). Both genetic and environmental factors can contribute to injury or repair. In 
AMD, the photoreceptors, RPE, BM and choriocapillaris may all be relevant potential 
targets. Similarly, the endothelial cells of the blood vessel wall were once thought to be the 
prime site of injury. However, recent research has shown that all layers of the vessel wall 
undergo significant changes due to the continuous or recurrent insults (Libby, 2003). 
Cellular repair responses of the blood vessel wall and the BM are manifested by a wide 
spectrum of changes such as alteration in the synthesis of collagen and elastin, matrix 
metalloproteinases and other matrix molecules; by increasing production of chemotactic 
signals and angiogenic factors; and inflammatory and immune responses. 
Regardless of the stimuli, the extracellular deposits that occur in both AMD and 
atherosclerosis share several common constituents (Mullins, 2000). These deposits may act 
as substrate for activation of a non-specific chronic inflammatory process (Hageman, 
2001). The recent evidence that genetic polymorphism of Complement Factor H (CFH) 
contributes to the pathogenesis of AMD suggests that complement activation and 
inflammation may be crucial in the genesis of AMD (Klein et al, 2005; Haines et al, 2005; 
Edwards et al, 2005). This complement regulator has also been observed in the vascular 
intima in atherosclerosis and is thought to bind to proteoglycans (Oksjoki et al. 2003). 
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 The second hypothesis is explained by Friedman’s vascular model (Friedman, 2000). This 
haemodynamic model that focuses on the co-morbidity of atherosclerosis and AMD, 
proposes that AMD is secondary to vascular insufficiency induced by atherosclerosis. 
Arterial intimal thickening, which is a hallmark for atherosclerosis may affect the choroidal 
vessels. The thickening and stiffening of the walls of the choroidal vessels result in 
decreased lumen diameter, increased blood flow resistance, elevated hydrostatic pressure 
and resultant RPE dysfunction (Friedman, 1997).  This process is accelerated by age-
related decreased density of choriocapillaris (Ramrattan al, 1999). Moreover, carotid 
arteriosclerosis can cause diminution of blood flow through the retinal and choroidal 
circulation and thereby interfere with the high metabolic rate of RPE resulting in sub-RPE 
deposits and RPE dysfunction (van Leeuwen, 2003). 
1.3.2 Epidemiological evidence of co-morbidity of Atherosclerosis and AMD 
 
Although both diseases are thought to be multi-factorial, the aetiology of AMD remains 
largely unclear and treatment options are limited. In contrast, several risk factors have been 
identified for atherosclerosis resulting in effective primary prevention and improved 
treatment. Increasing epidemiological evidence suggest a link between AMD and 
atherosclerosis. 
About 300 risk factors have been identified for atherosclerosis. The established risk factors 
include advancing age, smoking, dyslipidemia, hypertension, obesity, impaired glucose 
metabolism and sedentary life.  These risk factors have also been studied in AMD and only 
increasing age and smoking are found to be the most consistent risk factors. 
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 a) Age 
 
Of all the factors considered to affect atherogenesis, age has the strongest and most 
consistent association. This holds good for AMD as well. It is not possible to state that 
aging itself is implicated in the disease process or whether the effects of age represent a 
longer period of exposure to other risk factors such as smoking. 
Several case studies have examined the incidence and prevalence of AMD with age. 
Different case definitions and diagnostic procedures have made it difficult to assess the 
exact risk involved. However, it is universally shown that risk of AMD increases 
exponentially with advancing age in men and post-menopausal women (Holz, 2003). 
b) Post-menopausal women 
 
Age and oestrogen deficiency are together the most important cause of risk for 
atherosclerosis in post-menopausal women. The risk is due to the abrupt interruption of 
oestrogen that has indirect protective effects on lipid metabolism and direct effect on blood 
vessel function. Studies that looked at the risk of AMD in post-menopausal women showed 
consistent results for various definitions of AMD and menopause. Most of the studies 
suggested positive co-relation of AMD with early menopause (EDCCS, 1992; Smith, 1997; 
Vingerling, 1995). The role of hormone replacement therapy on AMD remains unclear 
(EDCCS, 1992; Klein 1994; Klein 2000). 
c) Smoking 
 
Smoking is a strong modifiable dose-dependent risk factor for both atherosclerosis and 
AMD. Smoking more than doubles the risk for coronary heart disease (Snow and Sneddon, 
1999). 
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The accumulated evidence from epidemiological studies provides strong causal relationship 
between cigarette smoking and AMD (Deblack, 2003). This established risk factor affects 
the eye mainly through its role in oxidative stress by reducing the levels of anti-oxidants. It 
can also decrease the choroidal blood flow, increase platelet adhesiveness, increase 
fibrinogen levels, decrease high-density lipoproteins levels and increase 
carboxyhaemoglobin in blood.  In addition, it may affect the eye by decreasing CFH levels. 
The dose-dependent relationship indicates that these effects depend on cumulative lifetime 
exposure to smoking. The finding that former smokers have a higher risk compared to non-
smokers shows that these effects diminish slowly unlike in atherosclerosis where cessation 
of smoking reduces the risk immediately and the risk declines to level of non-smokers 
within 2-5 years after cessation. 
d) Hypertension 
 
Hypertension is a strong modifiable risk factor for atherosclerosis. It increases 
cardiovascular morbidity and mortality two to four fold. However, many case control and 
cohort studies addressed the association between AMD and systolic or diastolic 
hypertension, hypertension or use of anti-hypertensives with inconclusive results 
(Sperduto, 1986; Evans, 2001). The risk of hypertension seems to be more concordant for 
neovascular AMD than for ARM (AREDS, 2000; Hyman, 2000; MPS, 1997; Klein et al, 
1997a).  In conclusion, there seems to be only a weak association of hypertension and 
AMD. It seems that hypertension and atherosclerosis may be independent risk factors for 
AMD. 
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e) Hyperlipidemia 
 
Hyperlipidemia is another modifiable dose dependent risk factor for atherosclerosis, 
especially total serum lipids and low-density lipoprotein and an inverse relation with the 
high-density lipoprotein fraction (Zemel and Sowers, 1990). 
The association between serum cholesterol and AMD is inconsistent. A positive association 
between AMD and serum cholesterol have been implied in two studies (EDCCS, 1992; 
Belda Sanchis et al. 2001). However, most studies on total serum cholesterol and AMD did 
not find any association (Smith et al. 2001; Klein et al. 1997a; Smith et al. 1998; Sanders et 
al. 1993; Cruickshanks et al. 1997; Klein et al. 1993; Delcourt et al. 2001). A few studies 
have also reported increased risk of early AMD with high serum HDL level (Abalain et al. 
2000; Delcourt et al. 2001, Hyman et al. 2000; Klein et al. 2003c, van Leeuwen et al. 
2004a, Watcher et al. 2004). These studies imply that serum HDL has an adverse effect on 
AMD in contrast to its protective effect on atherosclerosis. 
f) Dietary intake 
 
An inverse association was noted with omega 3 fatty acids intake and fish with early 
disease (Seddon et al. 2001, Smith et al. 2000). Similar protective roles of these dietary 
components have been suggested in atherosclerosis. 
A number of studies have linked increased dietary fat intake to both early and late AMD 
(Heuberger et al. 2001, Hyman et al. 2000; Mares-Perlman et al. 1995; Seddon et al. 2001). 
These studies indicate a possible association between atherosclerosis and AMD.  However, 
the inconsistent association with hyperlipidemia also hints that dietary fat may induce a 
local effect in the RPE-Bruch’s membrane complex and so the effects may not totally 
correspond with serum levels. This fact is substantiated by the inconclusive role of lipid 
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lowering agents such as statins in AMD (Guymer et al. 2005). The anti-inflammatory 
effects of statins may also be responsible for the effect of statins on AMD (McGwin et al, 
2005). 
g) Genetic link 
 
These speculations are further substantiated by genetic studies on AMD. A candidate gene 
for AMD is the cholesterol transporter gene apolipoprotein E (ApoE) that plays an 
important role in lipoprotein metabolism. This gene is polymorphic with 3 alleles ε2, ε3 
and ε4. ε3 allele is neutral, while ε2 allele is associated with lower and ε4 allele with higher 
serum LDL levels. Thus, the presence of ε2 allele is considered a protective factor against 
atherosclerosis while ε4 is associated with coronary heart disease (Davignon et al. 1999). 
However, for AMD, studies have consistently reported the opposite findings with a 
significant protective effect of ε4 (Baird et al. 2002, Klaver et al, 1998, Souied et al. 1998). 
Some studies have also reported a weak increased risk of AMD associated with ε2 (Baird et 
al. 2002, Klaver et al. 1998). Souied proposed two different explanations to explain the 
protective effect of ε4 in AMD. ε4, unlike ε2 and ε3, does not contain disulfide bridges and 
the resultant smaller size may allow more efficient lipid transport across the BM. Secondly, 
ε4 presents positive charges which reduces the hydrophobicity of BM thereby favouring 
clearance of debris (Souied et al. 1998). Therefore, the varied effect of apoE polymorphism 
in the two diseases may be best explained again by its local effect in different tissues. 
Another lipid related gene, the paraoxonase gene (PON 1) has been implicated in AMD. 
Paraoxonase is a polymorphic protein that prevents LDL oxidation. BB and LL genotype of 
this gene has been found more frequently in Japanese subjects with neovascular AMD 
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(Ikeda et al. 2001). In conclusion, it seems that though the two diseases are dependent on 
lipoprotein metabolism, the cellular effects may be different. 
h) Diabetes mellitus 
 
Diabetes accelerates atherosclerosis. The risk of myocardial infarction is two to three times 
more for diabetic men and three to seven times higher in diabetic women. Through its 
effects on the choroidal circulation and local effects on the RPE, diabetes has been 
hypothesized to increase the risk of AMD (Kohner et al. 1995). However, only a weak 
positive association between diabetes and AMD can be established from a number of 
studies that investigated the relationship (Kahn et al. 1977, EDCCS, 1992; Hyman et al. 
1983; Delaney and Oates, 1982; Blumenkranz et al. 1986, Vidaurri et al. 1984, Klein et al. 
1997a, Klein et al. 1992b, Watcher et al. 2004). 
i) Obesity and physical activity 
 
Obesity is an established cause of atherosclerosis. The risk of coronary artery disease is 2-3 
times higher in obese subjects compared to lean subjects. Though the link is not as well 
established as in atherosclerosis, a positive link between AMD and body mass index (BMI) 
have been noted in several studies (Delcourt et al. 2001, Hirvela et al. 1996, Klein et al. 
2001, Schaumberg et al. 2001, Smith et al. 1998). Waist to hip ratio, another marker of 
adiposity has been found to be increased in early AMD in women (Klein et al. 2001) 
However, lean individuals also appeared to be at increased risk of early AMD suggesting 
that the relationship between adiposity and AMD is J-shaped (Smith et al. 1998). Sedentary 
lifestyle is a modifiable risk factor for atherosclerosis. The relative risk of death from 
coronary artery disease (CHD) is two times higher than in active subjects. However there 
are only two case control studies that looked at physical activity in AMD and the results are 
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inconsistent (Seddon et al. 2003; Klein et al. 2003b).  The mechanism by which obesity 
increases the risk of AMD may be related to the physiologic changes that occur with this 
condition. These include increased oxidative stress, changes in the lipoprotein profile, and 
increased inflammation. These changes would also result in an increased destruction and a 
decreased circulatory delivery of lutein and zeaxanthin to the macula of the eye. Therefore, 
the mechanism by which obesity is related to AMD risk may be through indirect effects on 
changes in lutein and zeaxanthin status and metabolism. 
j) Alcohol intake 
 
While non-alcoholics and heavy alcoholics have increased risk of cardiovascular disease, 
moderate alcohol intake is cardio-protective indicating a J-shaped relationship. However, 
the evidence for an association between alcohol intake and AMD is weak (Smith and 
Mitchell, 1996; Ajani et al. 1999, Cho et al. 2000, Ritter et al. 1995, Klein et al. 2002a). 
k) History of cardiovascular disease 
 
Self reported history of cardiovascular disease is potentially biased by misclassification. 
Most of the studies on the association of AMD and history of cardiovascular disease did 
not find an association (McCarty et al. 2001, EDCCS, 1992; Hyman et al. 2000; AREDS 
2000). Positive associations were found by two groups (Hyman et al. 1983; Goldberg et al. 
1998). No association was found with low dose aspirin, a cardioprotective drug, and the 
incidence of AMD (Christen et al. 2001). No increased risk of mortality has been 
associated with AMD after adjusting for risk factors that affect mortality (Borger et al. 
2003). 
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l) Objective evidence of atherosclerosis 
 
Several studies looked at objective evidence of atherosclerosis in patients with AMD. 
Vingerling at al reported that subjects below the age of 85 years with plaques at the carotid 
bifurcation were 4.7 times as likely to have late AMD as those without plaques. An ankle-
arm index below 0.9 was also significantly associated with the presence of AMD. They did 
not find an association between intima-medial wall thickness (IMT) of the common carotid 
artery and AMD (Vingerling et al. 1995). The Rotterdam study also noted that 
calcifications in the abdominal aorta and peripheral arterial disease were not associated 
with AMD. These findings made them postulate that the atherosclerosis affecting the 
cerebral circulation may be more associated with AMD rather than atherosclerosis of aorta 
or the peripheral arteries (Klein et al. 1997a).  
Their findings were not supported by other studies. The ARIC study found only retinal 
pigment epithelial depigmentation to be associated with carotid artery plaque and focal 
retinal arteriolar narrowing.  
However, many other investigators found different indicators of atherosclerosis to be 
associated with AMD. Left ventricular hypertrophy was associated with AMD in the 
Framingham Eye Study (Kahn et al. 1977). A 2.5 fold increased risk of AMD was noted in 
patients with lower extremity disease in one study (Klein et al. 1999). The Beaver Dam 
study found that higher pulse pressure to be associated with 30% increased 5-year 
incidence and 25% increased progression of neovascular AMD in subjects aged 65 years or 
older (Klein et al. 1997a). The Cardiovascular Health and Age Related Maculopathy 
(CHARM) Study estimated pulse wave velocity, IMT and augmentation index in subjects 
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with AMD and found an association between poor cardiovascular parameters and 
progression of AMD (Guymer et al. 2005).  
However, retinal arteriosclerosis defined as generalized narrowing of retinal arteriolar 
diameter has been studied by different groups with varying results. Hirvela et al., using a 
subjective analysis of retinal arteriolar calibre, found higher prevalence of AMD in subjects 
with retinal arterial narrowing (Hirvela et al. 1996).  This is supported by two studies that 
used newer objective analysis of retinal vascular calibre (Klein et al. 2004, Wang et al. 
2004) but not by the Rotterdam study group (Ikram et al. 2005). 
Summary of evidence to date 
 
Epidemiologic studies have evaluated several cardiovascular risk factors in patients with 
AMD and suggest an overlap of some of these vascular factors and AMD. The differential 
susceptibility of AMD to cardiovascular risk factors suggests that the nature of the 
injurious stimuli of these risk factors is more parallel than convergent. They seem to 
produce different cellular effects. The findings also suggest a possible relationship between 
carotid atherosclerosis and AMD. Further research in these areas may possibly lead to new 
insights into the aetiologic factors for AMD and identify methods of preventing or slowing 
the progression of AMD in susceptible individuals. 
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1.4 Aims and Objectives of this project 
 
 
The aim of the first part of the project was to assess the correlation of systemic ECM 
proteins with the severity of AMD. A review that compares the changes of the vascular 
wall in atherosclerosis with the Bruch’s membrane in AMD was done to better understand 
the similarities and differences between these two structures with particular emphasis on 
ECM proteins. The subsequent experimental objectives were: 
a) Analysis of serum elastin-derived peptides (S-EDP) by ELISA to investigate the elastic 
tissue degradation of the ECM in AMD patients and age-matched controls. 
b) Measurement of serum MMP-2 and MMP-9 by ELISA, to investigate the role of matrix 
metalloproteinases in AMD patients and age-matched controls. 
c) Assessment of the correlation between S-EDP and MMP-2 and MMP-9 to note whether 
MMPs are responsible for the degradation of elastin in AMD 
d) Assessment of the possible link between atherosclerosis and AMD by retinal 
examination of patients with abdominal aortic aneurysm (AAA). 
 
The aim of the second part of the project was to assess the role of complement activation in 
AMD. As atherosclerosis is redefined as an inflammatory disease, the role of inflammation 
in AMD was reviewed. Experimentally, serum C3a des Arg, which determines the role of 
complement pathway in the pathogenesis of AMD, was analysed in subjects with varying 
severity of AMD and compared to age matched controls. 
 
The aim of the third part of the project was to assess ocular blood flow in AMD. A review 
of ocular haemodynamics in AMD was performed.  Choroidal blood flow and retinal 
 32
vascular calibre was measured and compared in both eyes in patients with asymmetric 
AMD. The choroidal blood flow was assessed by measuring the pulsatile ocular blood 
flow. The retinal vascular calibre was measured using computer software adapted from the 
Atherosclerosis Risk in Communities study (ARIC) study.   
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Chapter II 
 
 
 
 
 
EXTRACELLULAR MATRIX 
 
 
 
 
 
 
 
Is the concurrence of atherosclerosis and age related macular 
degeneration due to similar extracellular tissue remodelling? 
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CHAPTER 2: EXTRACELLULAR MATRIX 
 
This chapter reviews the evidence published to date that suggests a link between the BM 
and the vascular intima, then describes experimental investigations carried out in attempt to 
provide further evidence for this link. 
 
2.1 Bruch’s Membrane and the Vascular Intima:  Is There a Common 
Basis for Age-related Changes and Disease? 
 
This review examined the morphological and biochemical alterations in the senescent BM 
and its analogy to the vascular wall to evaluate the concurrence of atherosclerosis and 
AMD. 
2.1.1 Structural Comparison of the Bruch’s Membrane and the Vascular Wall 
 
The BM is a thin (2-4µm) connective tissue interposed between the metabolically active 
RPE and its source of nutrition, the choriocapillaris. This penta-laminar structure is 
classically described as consisting of the basement membrane of the RPE, an inner 
collagenous zone (ICZ), a fenestrated elastic layer, an outer collagenous zone (OCZ) and 
the basement membrane of the endothelium of the choriocapillaris (Hogan and Alvarado, 
1967).  In contrast, a healthy arterial wall of a major blood vessel such as  aorta is 
composed of only three histologically specific layers:  the innermost layer (intima) consists 
of a single layer of endothelial cells; the media is composed of smooth muscle cells, 
collagen and elastic fibrils and the third distinct layer is a fibrous adventitia (Lakatta and 
Levy, 2003). 
In order to investigate the co-morbidity of atherosclerosis and AMD, a useful analogy of 
the BM is the arterial wall. The fenestrated choriocapillaris and the endothelial monolayer 
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of the arterial wall possess a similar sub-cellular stratified ECM: the BM for the 
choriocapillaris and the media and adventitia for the vascular intima. However, the key 
difference is the virtual absence of smooth muscle cells in the BM.  Moreover, unlike the 
vascular ECM, the BM is strategically located between an endothelium and an epithelium 
(RPE) and is therefore, subject to changes from both sides. In contrast, the vascular wall 
matrix is affected by changes caused by endothelial dysfunction only. 
While the causes for endothelial dysfunction of the choriocapillaris may be akin to that of 
atherosclerosis, RPE dysfunction may arise secondary to causes that do not primarily affect 
its nutrition from the choricapillaris, and this includes oxidative insults, local inflammatory 
processes, senescence and genetic defects. This may further explain the differential 
susceptibility of AMD to cardiovascular risk factors. 
2.1.2 Macroscopic Changes of the BM and the Vascular Wall 
 
The fundamental age-related change in both structures is typified by increased thickness. 
The age-associated thickening of the arterial wall consists mainly of intimal thickening.   
The carotid IMT increases 2-3 fold between 20 and 90 years of age (Virmani et al. 2000).   
Similarly, the BM undergoes diffuse thickening, with thickness being reported to increase 
by 135% in ten decades (Ramrattan et al. 1994). The maximum thickness occurs in the 
substrata of the OCZ (Killingsworth, 1987). However, there is marked heterogeneity in the 
intimal and BM thickness among individuals at a given age (Lakatta and Levy, 2003; Bird, 
1992).
Disease risk is associated with age-related thickness of these structures. Carotid intima-
media thickness is used as a predictive non-invasive test for atherosclerotic burden 
(Meschia and Gerber, 2003) Likewise, a prolonged choroidal filling phase during 
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fluorescein angiography signals the presence of diffuse BM thickening (Pauleikhoff et al. 
1992). In addition, serial measurement of the thickness of the BM may be a useful 
prognostic parameter in longitudinal studies of AMD. 
2.1.3 Cell biology of the BM and the vascular wall  
 
The three anatomical changes that occur in the BM with age are the progressive 
accumulation of debris, lipid deposition and alteration of the ECM. A similar build up is 
seen in the arterial wall with accumulation of lipids, cellular waste products, and fibrin and 
calcium deposits resulting in plaque formation (Virmani et al. 2000). 
The deposition of PAS positive granular, vesicular and filamentary deposits in the ICZ of 
BM has been identified as early as the first decade of life (Hogan and Alvarado, 1967). 
As age advances, the debris accumulates and contaminates all the collagenous layer of the 
BM, and is seen on both sides of the elastic lamina thus forming the bulk of the age-related 
debris in the collagenous layers, especially in the OCZ. Depending on their proximity to 
the RPE, deposits may represent incompletely digested waste material emanating from a 
dysfunctional RPE (Burns and Feeney-Burns, 1980; Ishibashi et al. 1986; Young, 1987; El 
Baba et al. 1986) or it may be the sequelae of dysfunctional endothelium of the 
choriocapillaries (Friedman et al.1963). Experimental evidence also suggests that these 
deposits may be due to altered remodelling of the membrane (Newsome et al. 1987) or an 
inappropriately directed immune response (Hageman et al, 2001; Penfold et al. 2001). 
The cell biology of the arterial intima suggests abundant granulo-vesicular debris in the 
intima, probably originates from disintegration of vascular smooth muscle cells and dead 
macrophage foam cells (Klurfield, 1985). Though the source of the deposits in both 
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diseases may not be directly linked, a common component may be that the cellular debris 
in both structures acts as a focus for inflammation and local immune response. 
The link between atherosclerosis and AMD is further substantiated by the similarity of 
molecular composition of drusen and atherosclerotic deposits (Mullins et al. 2000). The 
proteins identified in the drusen/ BM include both locally derived (neural retina, RPE and 
choroid) and extracellular non-ocular components. The oxidative modifications of some of 
these components may also be the primary catalyst in drusen formation. Most of these non-
ocular components are also present in atherosclerotic lesions. 
The complement system also plays a role in both the diseases. C5b-9 complexes have been 
isolated in intact cells, disintegrated cells and cell debris enmeshed in the extracellular 
matrix (ECM) of thickened vascular intima and atherosclerotic plaque (Rus et al. 1988). 
Some of these cells represent activated or dead macrophages. They trigger inflammatory 
events and progression of atherosclerotic lesions. Likewise, immunohistochemical analyses 
of all phenotypes of drusen and the BM have also revealed C3, the terminal complement 
complex C5 and the membrane attack complex C5b-9 terminal complexes. While C3 and 
C5 mRNA are present in the neural retina, RPE and choroid (Anderson et al. 2002), the 
source of most of the complement factors may be from plasma. In addition, several 
complement inhibitors have been identified in drusen such as clusterin, CD46 and CR1 
(Johnson et al. 2001). The localisation of these complements proteins and their regulators 
provide evidence of local inflammatory response. The granulo-vesicular nuclear fragments, 
oxidized lipoproteins and AGE may be potential activators of the complement cascade in 
both the vascular intima and BM (Libby, 2002; Hageman et al. 2001). The fact that 
immunological injury may be an initiating factor in the development of AMD and 
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atherosclerosis is further substantiated by the isolation of HLA antigen markers in drusen 
and atherosclerotic lesions (Dahlen et al. 1994; Goverdhan et al. 2004). However, the 
multifactorial nature of both disease processes makes a simple relationship with a single 
MHC determinant unlikely. The recent evidence that CFH polymorphism is associated with 
increased risk of AMD (Klein et al. 2005; Haines et al. 2005, Edwards et al.2005) suggest 
that that complement activation is a crucial step in AMD. The role of CFH in 
atherosclerosis showed that proteoglycans, because of their ability to bind the CFH, may 
inhibit complement activation in the superficial layer of the arterial intima. In contrast, 
deeper in the intima, where CFH and proteoglycans are absent, complement may be 
activated and proceed to C5b-9. Thus, the superficial and the deep layers of the human 
coronary artery atherosclerotic lesions appear to differ in their ability to regulate 
complement activation (Oksjoki et al. 2003). 
2.1.4 Lipid accumulation 
 
An important age-related change that forms the base for atherosclerosis is lipid 
accumulation in the thickened intima. In the arterial intima, plasma lipoproteins are 
transported across the endothelium and trapped amongst fibrils of ECM (Berliner et al. 
1995). These initial lesions are characterised by microscopically visible lipid droplets 
which coalesce to form fatty streaks, and finally stratified pools of lipid are found in the 
intimal thickening. 
A similar age-related exponential accumulation of lipids occurs in the BM. The BM 
becomes sudanophilic and exhibits increased staining with Oil red O (Holz et al. 1994; 
Spaide et al. 1999; Farkas et al. 1971; Sheraidah et al. 1993; Pauleikhoff  et al. 1992). In 
eyes of patients less than 60 years old, these lipid-containing small round solid particles are 
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scarcely scattered in both collagen layers. In older eyes, the lipid droplets occupy up to one 
third of the ICL and also form a thin lipid layer external to the RPE basement membrane 
(Ruberti et. 2003). 
Although both the BM and the arterial intima become lipid laden with age, the lipid 
composition is dissimilar. Unlike the plasma-derived low density lipoproteins (LDL) 
infiltration in the vascular intima, the predominant lipids in the BM consist of 
phospholipids and fatty acids (Holz et al. 1994; Spaide et al. 1999; Farkas et al. 1971; 
Sheraidah et al. 1993; Pauleikhoff et al. 1992). About 50% of the phospholipids are 
phosphatidylcholine suggesting that the lipids in the BM are more likely of a cellular origin 
(a potential source being the photoreceptor outer segment membranes) than from plasma. 
However, recent studies using filipin histochemistry and hot stage polarizing microscopy 
revealed that lipid content of BM also consist of both esterified and unesterified cholesterol 
but a vascular origin for the lipids is unlikely (Curcio et al. 2001; Ruberti et al. 2003; 
Haimovici et al. 2001).
2.1.5 Matrix dysregulation 
 
The matrix changes associated with age-related arterial changes include: increased collagen 
content, increased collagen cross-linking, increased fibronectin, decreased elastin 
associated with calcification and fragmentation of the elastic lamina, and increased 
glycosaminoglycans (Goncalves et al. 2003). Similar changes are observed in the aging 
BM. 
Collagen synthesis increases with age in both structures (Barnes and Farndale, 1999; 
Karwatowski et al. 1995).  Type I and III collagens form the bulk of the total plaque protein 
in atherosclerosis. Likewise, Newsome et al found an age-related increase in collagen I in 
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the BM with age (Newsome et al. 1987). Other collagens noted in the BM include types III, 
IV and V (Karwatowski et al. 1995). In addition, atypical banding periodicity has been 
observed in the collagen produced. The ICZ consists more of 640A type collagen while the 
OCZ contains more 1000A type collagen with age (Hogan and Alvarado, 1967). The 
meshes formed by the tightly interwoven collagen fibres in the ICZ also become irregular 
and coarse with age (Yamamoto et al. 1989). Increased cross-linking results in a linear 
decline of solubility of the collagens with age (Karwatowski et al.1995). The long spacing 
collagen is a material with periodicity ranging between 100-140nm found mainly in the 
OCZ and extends as intercapillary pegs to areas where choriocapillaris have undergone 
age-related atrophy (Krey, 1975). This material has also been isolated in the aortic media 
(Morris et al. 1978). In both structures, the increased insoluble collagen may contribute to 
debris accumulation and serve as a depot for lipoproteins, growth factors and cytokines. 
The amount of non-collagen protein in BM also increases significantly with age as 
suggested by an increase in deposition of non-collagen amino acids in the macular area 
(Karwatowski et al. 1995). The elastic layer becomes basophilic; the elastic fibres increase 
in number and become more electron dense. Needle like crystals are deposited within the 
fibres (Hogan and Alvarado, 1967) The BM also undergoes calcification and 
fragmentation, rendering the membrane to loose its elasticity and become more brittle. The 
degree of calcification and fragmentation of BM correlates with the severity of wet AMD, 
although it is seen in both types of AMD (Spraul et al.1999). 
Similar changes occur in the elastic layer of the arterial wall. The exact mechanism of 
calcification of the elastic fibres is not known, but it may be the result of production of 
abnormal elastic fibres, degeneration of elastic fibres or other alterations in the ECM 
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(Walker et al. 1989). Degradation of the arterial wall elastin is a characteristic feature in 
atherogenesis. Serum concentrations of elastin-derived peptides (S-EDP) are elevated in 
atherosclerotic patients and reflects elastin turnover (Baydanoff et al. 1987). Increased S-
EDP is a potential indicator of advanced atherosclerosis such as plaque instability and is 
also a predictor of rupture in atherosclerotic aortic aneurysms (Petersen et al. 2002).
Changes in glycosaminoglycans (GAG) also occur in the ECM of both the vascular intima 
and Bruch’s membrane. Sulfated GAG, which are components of the vascular matrix, 
increase during the early stages of atherosclerosis (Stevens et al. 1976).  Binding of 
dermatan sulfates to low density lipoproteins correlates positively with lipid accumulation 
in the intima and progression of atherosclerotic lesions respectively. Chondroitin sulphate 
normally retards the passage of plasma particles and maintains the viscoelastic property of 
the vessel wall which is structurally altered in advanced lesions (Stary et al, 1994). On the 
contrary, heparan sulphate, a major component of basement membrane, reduces with the 
severity of atherosclerotic lesions (Williams and Tabas, 1995).  These changes do not 
correspond with changes in the Bruch’s membrane. An increase in the content and structure 
of GAG in BM has been identified (Kliffen et al. 1996). The increased volume of GAG 
may partially be responsible for the altered metabolism of the collagens and the resultant 
increased negative field may also contribute to the decreased filtration across the BM 
(Hewitt et al. 1989). An increased proportion of heparan sulfate in the basement 
membranes of the BM and simultaneous decrease in proteoglycan filaments containing 
chondroitin sulfate and dermatan sulfate associated with the collagen fibrils have been 
noted (Hewitt et al. 1989, Takada et al.1994). It may be that the main source of dermatan 
sulphate in the intima is the smooth muscle cells and the absence of these cells in the BM 
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correlates with the scarcity of this GAG. In addition, there may be differences in 
macrophage recruitment and accumulation in the two structures and proteolytic degradation 
by the macrophages may account for the significant differences in changes in proteoglycan 
subtypes. The difference in the proteoglycan subtypes may partially be also responsible for 
the altered lipid content in these structures. 
2.1.6 Matrix metalloproteinases 
 
Matrix metalloproteinases (MMPs) are required both by BM and arterial intima for ECM 
remodelling, protein processing and angiogenesis (Visse and Nagase, 2003) The age-
related increased collagen content, the release of reactive oxygen radicals by the lipid-laden 
BM and intima, and the presence of inflammatory cytokines, cellular transformation and 
growth hormones in both the structures may upregulate these enzymes, especially MMP-2 
and MMP-9 (Sethi et al. 2000; George, 1998). Both MMP-2 and MMP-9 are gelatinases 
and readily digest denatured collagen. In addition MMP-2 digests type I, II and III 
collagens (Visse and Nagase, 2003). Localisation of MMP-2 and MMP-9 expression to 
areas of new vessel formation in the BM and to areas of adventitial vasovasorum suggests 
their role in the growth of neovascular complexes in both AMD and atherosclerosis 
(George, 1998; Steen et al. 1998). 
One of the endogenous tissue inhibitors of MMPs (TIMPs) regulates the activation of 
MMPs and also has other independent actions. Of the four TIMPs characterised to date, 
TIMP-3 is the only member found exclusively in ECM explaining the presence of TIMP-3 
in both the intima and BM (George, 1998). In addition, it binds tightly to sulphated 
glycosaminoglcans. Western blotting and quantitative reverse zymography have 
demonstrated an age-related increase in TIMP-3 in BM and its concentration is shown to 
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correlate with the amount of ECM and the quantity of drusen (Kamei and Hollyfield, 
1999). In BM, TIMP-3 controls ECM turnover, limits neovascularisation (Moses and 
Langer, 1991) and may play a role in apoptosis (Baker et al.1998). Mutations of TIMP-3 
associated with Sorsby’s fundus dystrophy suggest that TIMP-3 may result in aberrant 
protein interaction and increased cell adhesiveness, which may cause defective turnover of 
the BM (Yeow et al. 2002). A similar up-regulation of TIMP-3 in atherosclerotic aorta has 
been noted (Carrell et al. 2002). 
2.1.7 Conclusion from Literature Review 
 
It is clear that the vascular intima and the Bruch’s membrane share several age-related 
changes with the involvement of several common molecules. This may be because they are 
exposed to similar genetic variations, oxidative stress or they may be exposed to the same 
immune or inflammatory disease complexes. On the basis of this review, one may argue 
that atherosclerosis and AMD may share some aspects in a response to the resultant tissue 
damage. 
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 2.2 Serum Elastin Derived Peptides in Age-related Macular Degeneration 
 
2.2.1 Introduction 
 
The pathogenesis of AMD is undoubtedly complex and multifactorial (Ambati et al. 
2003a). Several investigators have shown that changes in matrix biology play an important 
role in the pathogenesis of AMD (Johnson and Anderson, 2004, Newsome et al. 1987). 
Elastin is an extremely insoluble fibrous protein constituent of the ECM (Partridge, 1962). 
It is the main protein of the elastic fibre and contributes to the elastic property of several 
tissues such as the vascular wall, lungs and skin. In the eyes, elastin is present in the BM 
and choroidal vessels (Chong et al. 2000). Partial proteolysis of elastin by activated 
proteinases results in the release of soluble elastin derived peptides (S-EDP) into the 
circulation. Therefore, S-EDP measurement is indicative of systemic elastin turnover 
(Bouissou et al. 1985). 
Large amounts of S-EDP are produced during several pathological processes (Fulop et al. 
1990, Bizbiz et al. 1997). The measurement of S-EDP has been proposed as a method for 
monitoring disease processes such as emphysema and as a predictor of expansion of small 
abdominal aortic aneurysms (Pardo et al. 1999, Lindolt et al. 1997). Accelerated elastolysis 
has also been reported in patients with various manifestations of atherosclerosis (Petersen 
et al, 2002). Several clinical and epidemiological studies have concurrently illuminated 
established cardiovascular risk factors and markers of atherosclerosis with AMD (Snow 
and Sneddon, 1999). Therefore, we postulated that both the vascular wall matrix and the 
Bruch’s membrane may share several common changes including degradation of elastin 
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and release of S-EDP into the circulation. In this study, we analysed S-EDP levels in 
patients with AMD compared to S-EDP in age matched controls. 
2.2.2 Materials and Methods 
2.2.2.a) Subjects 
Fifty-six subjects with a clinical diagnosis of AMD were included in the study. The control 
group consisted of 15 healthy subjects without AMD (defined as the absence of drusen, 
pigmentary abnormalities and neovascular AMD). All enrolled subjects underwent a 
complete ophthalmic examination by the recruiting retinal specialist: visual acuity, slit 
lamp examination and retinal examination after pupil dilation were documented. Each 
subject also had 30° colour stereo fundus photographs of both eyes taken (Topcon TRC-
50X, Topcon Ltd. Tokyo, Japan). Fluorescein angiography was also performed if there was 
a clinical suspicion of CNV. Subjects with co-existent fundus pathologies and subjects with 
un-gradable photographs were excluded from the study. 
A detailed medical history of each subject was taken. Particular care was taken to note 
history of hypertension (defined as being prescribed anti-hypertensives), angina pectoris, 
myocardiac infarction, intermittent claudication, chronic obstructive airway disease 
(COAD), abdominal aortic aneurysm (AAA) and hypercholesterolemia (defined as being 
prescribed statins).  History of smoking was classified into: never smoked, ex-smoker, or 
current smoker. All current smokers were excluded. 
This research adhered to the tenets of the Declaration of Helsinki. Institutional ethics 
committee approval was obtained and all subjects gave their full informed consent. The 
patients in this study were recruited as part of a Medical Research Council (UK) funded 
project on AMD. 
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2.2.2.b) Grading of AMD 
 
Colour fundus photographs of the subjects were graded by two graders using the 
nomenclature and classification recommended by The International ARM Epidemiological 
Study Group (Bird et al. 1995). Fundus fluorescein angiography was available to exclude 
CNV in patients classified as early ARM by fundus appearance. The graders were masked 
for the age and clinical history of the participants. Double grading for intra-observer and 
inter-observer variability was performed. Discrepancies were resolved by discussion.  The 
subjects were classified as either early age related maculopathy (ARM) or neovascular 
AMD. Early age-related maculopathy was defined as the presence of intermediate soft 
distinct drusen (>63µm) with retinal pigment epithelial depigmentation or 
hyperpigmentation, soft indistinct drusen (>125µm), or reticular drusen;   Neovascular 
AMD consisted of subjects with CNV. If the grades in the two eyes were different, the 
subject was categorized according to the severity of changes in the worse eye. 
2.2.2.c) Blood samples 
 
Venous blood was collected from all subjects in serum separator tube (SST-BD Vacutainer, 
BD Diagnostics, Oxford UK), allowed to clot for 30 minutes and then centrifuged for 10 
minutes at 1500 g at room temperature. Serum was aliquoted and stored at –70°C within an 
hour of collection and then thawed when required. The samples were randomized so that 
the scientist who analyzed the samples was masked of the clinical history of the subjects. 
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2.2.2.d) Estimation of S-EDP 
 
a) Optimization of ELISA 
 
i) Defining the starting condition  
Construction of a direct binding of α-elastin at 1.25µg/l with varying concentration of 
primary antibody (0-3µg/ml) was performed. The initial capture antibody tested was mouse 
monoclonal antibody to bovine α-elastin (Abcam Ltd, Cambridge, UK). This antibody 
recognizes insoluble elastin and soluble α-elastin and cross-reacts with human elastin. 
Binding was carried out at various incubation periods of 30mins, 1 hr, 2 hr and 24 hours 
and at varying temperature of 40C, 200C and 370C. The wells were rinsed with PBST and 
binding was detected by HRP-labelled goat anti-mouse IgG antibody (Santa Cruz 
Technology, Autogen Bioclear, Wiltshire, UK) at 1: 1000 dilutions at 1 hr in room 
temperature. The plates were rinsed and reacted with the substrate (100µl/well of ABTS). 
Absorbance was read at 495nm. 
ii) Optimization of the sensitisation stage 
 
A varying range of α-elastin concentration (1-3 µg/ml) without modification of the sodium 
carbonate buffer was used to coat the microtiter plate and the test repeated with all other 
variables unchanged. 
iii) Optimization of secondary antibody 
 
The same protocol was followed with α-elastin concentration fixed at 1.25µg/ml and 
capture antibody at 2µg/ml. The concentration of secondary antibody was tested at 1:500, 
1:1000, 1:2000 and 1:4000. 
iv) Confirmation of antibody specificity by dot-blot 
This procedure was carried out to check the suitability of capture antibodies for use in 
enzyme-linked immuno-sorbent assay (ELISA). On a membrane (Hybond C, Amersham 
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Bioscience, Buckinghamshire, UK), 10µl aliquots of 1.25µg/ml of α-elastin from human 
aorta (Sigma-Aldrich, Poole, UK) in 0.1M sodium carbonate (pH 9) were placed in dots in 
grid formation and allowed to dry. The membrane was blocked with blocking solution 
consisting of 5% w/v low fat milk powder (‘Marvel’, Premier Foods, St. Albans, UK) in 
TBS (Tris-Buffered Saline) for one hour on an orbital shaker. The capture antibodies tested 
included a mouse monoclonal antibody to α-elastin (Abcam Ltd, Cambridge, UK) and a 
rabbit polyclonal antibody to α-elastin (Elastin products Co, Missouri, USA). Each capture 
antibody was added to blocking solution (described above) at a range of dilutions, and 
applied to a strip of membrane with an α-elastin ‘dot’ for one hour at room temperature. 
The membrane was then washed with TBST (Tris-Buffered Saline containing 0.05% v/v 
Tween 20) five times, for five minutes each. The strips were then incubated with 
appropriate detection antibody (both HRP-conjugated antibodies purchased from Santa 
Cruz Technology, Autogen Bioclear, Wiltshire, UK). Donkey anti-mouse detection 
antibody was used for the monoclonal capture antibody (1:1000 in 5% w/v milk in TBS), 
and goat anti-rabbit detection antibody for the polyclonal capture antibody (1:1000 in 5% 
w/v low-fat milk powder in TBS), both incubated for one hour at room temperature.  
Membranes were then washed again in TBST for five minutes five times. 
Chemiluminesence detection was then performed using an ECL detection kit (Amersham 
Bioscience, Buckinghamshire, UK) and the membrane strips were placed in a cassette with 
a high performance chemiluminesence hyperfilm ECL (Amersham Bioscience, 
Buckinghamshire, UK) prior to developing the film for analysis. 
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 b) Competitive Enzyme linked Immunosorbent assay (ELISA) 
 
The concentration of S-EDP was determined using a competitive enzyme-linked 
immunoassay (ELISA) adapted from a protocol described by Peterson et al (Petersen et al. 
2002). Soluble α-elastin was obtained from human aorta (Sigma-Aldrich, Poole, UK). The 
rabbit anti-human elastin IgG (Elastin Products Company, MO, USA) was raised against α-
elastin prepared from human aorta. 
The wells of a microtitre plate (Nunc, Fischer Scientific, UK) were coated with 150 µl of 
α-elastin (1.25 µg/ml) in 0.1M sodium carbonate, pH 9 by incubating at 40C for 12 hours.  
The plate was then washed four times with 150 µl phosphate buffered saline (PBS) 
containing 0.05% (v/v) Tween 20 (PBST). A standard curve was generated using dilutions 
of human aortic α-elastin (0-100 ng/ml). Anti α-elastin antibodies (1:1000) in PBST and 
7% (w/v) bovine serum albumin (PBST-7% BSA) were pre-incubated with variable 
dilutions of α-elastin in PBST-7% BSA overnight at 40C. These solutions were then 
transferred to the coated plate and incubated at room temperature for one hour.  The pre-
incubation period prior to addition to the α-elastin coated microtitre plate therefore creates 
the ‘competitive’ aspect of the ELISA.  Before addition of the detection antibody, the 
microtitre plate wells were washed with PBST four times. Then, 150 µl of HRP-conjugated 
goat anti-rabbit IgG antibody (Santa Cruz technology / Autogen Bioclear, Wiltshire, UK) 
was added to each well (1:2000 dilution in PBST-7% BSA). The plate was incubated for 1 
hr at room temperature and again washed with PBST four times. Thereafter, 100 µl of 
ABTS (3-ethyl-benzthiazoline-6-sulphonic acid; Roche, Lewes, UK) buffer was added and 
the plate incubated for a further hour at room temperature. Absorbance was read at 495 nm 
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using an automated plate reader (Dynex Technologies, West Sussex, UK). A standard 
curve was generated from the absorbance readings obtained from the α-elastin dilutions. 
During the assay optimization process, pooled human sera from healthy volunteers were 
used as a diluent for the standard curve instead of the assay buffer (PBST-7% BSA).  This 
was done to examine the potential effect of serum components on the ELISA. The standard 
curves generated with standards in pooled human sera and assay buffer were correlated and 
the level of significance tested by sign test. Since the standard curves were well correlated 
and there was no significant difference between them, subsequent standard curves were 
based on α-elastin in assay buffer. 
Standards and serum samples were analyzed in duplicate. The S-EDP concentrations were 
calculated from the standard curve and expressed as ng/ml. 
The following controls of the reaction were employed: a) substrate control: only assay 
buffer, wash solutions and ABTS substrate were added to the polystyrene wells coated with 
α-elastin; b) no capture antibody control: the detection antibody was added directly to the 
wells coated with α-elastin and then the wells were incubated with the ABTS substrate 
solution; c) negative control to assess the specificity of the reaction: The tested samples 
were replaced with human albumin solution and serum samples from healthy volunteers 
and assayed using the standard protocol; d) positive control: the tested sample was replaced 
with human aortic α-elastin at 1g/ml in assay buffer. 
Intra-plate and inter-plate reproducibility tests were also performed. For the former, a pair 
of positive and negative controls was each tested 30 times in the same ELISA plate (intra-
plate). In the latter test, the positive and the negative serum controls were tested 30 times 
using different plates from the same lot on different dates (inter-plate). The mean, standard 
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deviation (SD) and coefficient of variation (CV) were calculated for both the inter-plate 
and intra-plate optical density (OD) values.  The ELISA was considered reproducible if the 
variations of each of the 30 positive and 30 negative control OD value was within ±2 SD of 
the mean of the individual runs. Sample results were discounted if the duplicates disagreed 
by more than 5%. 
2.2.2.e) Statistical methods 
 
Analysis was done using the Statistical Package of the Social Sciences (SSPS version 
11.0). Results were reported as mean ± standard error of mean (SEM). The normal 
distribution of S-EDP values was assessed using the Shapiro-Wilk test. The standard curves 
generated with standards in pooled human sera and assay buffer were correlated and the 
level of significance tested by sign test. Multiple regression analysis was performed using 
S-EDP as the dependent variable and the disease status of the subjects as independent 
variable. The relationship of aging to S-EDP levels was analyzed independently and in the 
three groups using correlation coefficient. Student’s t-test and ANOVA one-way was used 
for analysis of results. Probability values less than 0.05 were considered statistically 
significant. 
2.2.3 Results 
2.2.3.a) Characteristics of subjects 
 
Serum was analysed from 71 subjects consisting of 30 with ARM, 26 with neovascular 
AMD, and 15 controls.  Table 2.1 presents the demographic details and baseline clinical 
data of the population. Age and gender distribution were similar in both groups of AMD 
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and controls. No statistically significant differences in clinical data were observed between 
subjects in the three groups. 
Table 2.1: Characteristics of the subjects 
 ARM 
(n=30) 
Neovascula
r AMD 
(n=26) 
Controls 
(n=15) 
p-value 
Age(years) 
Mean [range] 
77 [65-88] 79 [62-92] 75.2 [61-91] 0.7 
Gender M:F 12:18 10:16 6:9 0.5 
Ex-smoker (%) 3.3 3.8 0 0.9 
Hypertension (%) 16.6 15.4 13.3 0.8 
Myocardiac infarction 
(%) 
3.3 3.8 0 0.9 
Angina Pectoris (%) 0 0 6.6 0.2 
Intermittent 
Claudication (%) 
0 3.8 0 0.4 
Stroke (%) 3.3 0 0 0.5 
COAD (%) 3.3 0 0 0.5 
AAA (%) 0 0 0 1.0 
Hypercholesterolemia 
(%) 
3.3 3.8 0 0.9 
 
2.2.3.b) Optimization of ELISA 
 
i) Defining the starting condition 
  
Construction of a direct binding of α-elastin at 1.25µg/l with varying concentration of 
primary antibody (0-3µg/ml) was performed. There was no significant binding in any well 
and no standard curve could be plotted. It was inferred that the initial concentration of α-
elastin 1.25ug/ml may not be sufficient or the secondary antibody concentration was fixed 
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using the manufacturer’s recommended dilution and that stronger concentration of 
secondary antibody may be required to detect the binding. 
ii) Optimization of the sensitisation stage 
 
A varying range of α-elastin concentration (1-3 µg/ml) was used to coat the microtiter plate 
and the test repeated with all other variables unchanged. However, no binding was noted. 
In addition, the incubation of the α-elastin coated plates was varied from 1 hr, 2hr and 24 
hr. No binding was again noted. So it was inferred that the optimal concentration for α-
elastin is 1.25µg/ml but the concentration of secondary antibody had to be optimized. 
iii) Optimization of secondary antibody 
 
The same protocol was followed with α-elastin concentration fixed at 1.25µg/ml and 
primary antibody at 2µg/ml. The concentration of secondary antibody was tested at 1:500, 
1:1000, 1:2000 and 1:4000. A level of absorbance was noted in all wells at 1:500 
suggesting too high a concentration of secondary antibody. The best colour and absorbance 
was at 1:2000. 
iv) Antibody Specificity 
 
The results of dot blot analysis demonstrated that only the polyclonal capture antibody 
tested would consistently detect human α-elastin.  The mouse monoclonal antibody tested 
failed to indicate binding to the antigen using either a dot-blot or ELISA protocol. 
Figure 2.1 shows the consistent binding of the rabbit polyclonal antibody of various 
concentrations with α-elastin. 
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Fig 2.1: Dot blot test showing the binding of various concentrations of polyclonal capture antibody with 
soluble α-elastin of human aorta. The binding with α-elastin was best with the antibody concentration of 
1:1000. So polyclonal rabbit anti human antibody 1:1000 was used for the ELISA. 
 
 
v) Optimisation with different α-elastin  
 
The ELISA was repeated in triplicate with different makes of α-elastin (Sigma soluble α-
elastin of human aorta, Sigma soluble α-elastin to rat lung and elastin derived peptides.) 
The binding was best and the gradient steepest with soluble α-elastin of human aorta 
(Sigma) (Fig. 2.2) 
ELISA with various types of elastin
0
0.2
0.4
0.6
0.8
1
1.2
0 50 100 150 200
elastin ng/ml
Ab
so
rb
an
ce
 a
t 4
95 human aorta elastin
rat lung elastin
elastin derived
peptides
Linear (human aorta
 
Fig. 2.2:  Graph showing the standard curve with various types of elastin.  
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vi) Introduction of matrix 
 
There was an excellent correlation between the standard curve created with α-elastin in 
PBS containing BSA and a standard curve created with α-elastin in pooled serum from 
healthy volunteers.  Levels of α-elastin detected were slightly higher in pooled sera than in 
PBS containing BSA, but the difference was not statistically significant (p=0.13, sign test). 
Figure 2.3 compares the standard curve with assay buffers with that in pooled human sera. 
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Fig. 2.3: Graph comparing the standard curve with assay buffers with that in pooled human 
sera. 
 
vii) Standard curve 
 
The typical standard curve shown below (fig. 2.4) is obtained with soluble α-elastin from 
human aorta, capture antibody used was rabbit anti human elastin IgG 1:1000 and 
secondary antibody used was goat anti-rabbit antibody at concentration of 1: 2000. The 
standard curve is plotted with optical density in y-axis and the concentrations of α-elastin 
in x-axis. A linear standard curve was obtained.  
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Standard curve of S-EDP
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Fig. 2.4: Typical standard curve of competitive ELISA for S-EDP. 
(Error bars: ±2 standard deviations) 
 
 
2.2.3.c) Assay Reproducibility 
 
The assay was found to be sensitive from 0.5-100ng/ml of α-elastin. For the intra-plate and 
inter-plate reproducibility studies, OD values of the individual positive and negative 
control were all within ±2 SD of the mean OD values as shown in Table 2.2. 
 
Table 2.2: Reproducibility of S-EDP ELISA 
S-EDP Intra-plate precision Inter-plate precision 
n OD mean ± S.D CV (%) n OD mean ± S.D CV (%)  
0  ng/ml 
30 1.125 ± 1.67 31.0 % 30 1.089 ± 0.53 12.5 % 
75 ng/ml 30 0.645 ± 0.42 11.3 % 30 0.625 ± 0.18 6.7% 
S.D: standard deviation, CV: Coefficient of variation 
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2.2.3.d) Estimation of S-EDP in AMD and controls 
 
The mean ± SEM of S-EDP in AMD (n=56) was 29.6± 3.95ng/ml compared to control 
group (n=15) with 15.4± 2.71ng/ml (p<0.05, student’s t-test). The mean ± SEM of S-EDP 
in ARM (n=30) and neovascular AMD (n=26) was 23.9 ± 1.75 ng /ml and 36.2 ng ± 4.52ng 
/ml respectively (p, 0.05, student’s t-test). 
Figure 2.5 depicts the progressive increase in S-EDP with increase in severity of AMD 
(p<0.05, ANOVA). 
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Fig. 2.5: Box-chart showing progressive increase of S-EDP with increasing severity of 
AMD 
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The multiple regression analysis showed that the various clinical conditions did not 
significantly influence the levels of S-EDP in this cohort (Table 2.3). 
Table 2.3: Robustness check of S-EDP 
Independent variable Multiple regression analysis with 
S-EDP as dependent variable 
Age(years) 
Mean [range] 
0.53 
Gender (females) 0.61 
Ex-smoker 0.68 
Hypertension 0.31 
Myocardial infarction 0.56 
Angina Pectoris 0.35 
Intermittent 
Claudication 
0.62 
Stroke 0.63 
COAD 0.54 
AAA 1.00 
Hypercholesterolemia 0.54 
 
2.2.3.e) Correlation of S-EDP with aging 
 
The levels of S-EDP of control and pathological sera did not correlate with age of the 
subjects. There was a strong dispersion of results (r=-0.01). The separate evaluation of 
AMD patient groups did not yield a significant age-dependent trend for the values of S-
EDP (r=0.02). 
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2.2.4 Discussion 
 
Elastin is the main protein of elastic tissue contributing to the elastic properties of many 
tissues such as vascular wall, skin and lung (Partridge, 1962). In the eye, elastin is found in 
many structures including the trabecular meshwork, uvea and optic nerve. The major sites 
of elastin deposition in the uvea include the choroidal blood vessels and the BM. The 
elastic lamina of the BM is thinner and less abundant in the macula than the periphery and 
it is also thinner and less abundant in the macular region for AMD eyes (Chong et al. 
2005). Age-related changes in the BM include lipid accumulation, calcification and 
fragmentation (Guymer et al. 1999). In a study by van der Schaft and colleagues, age-
related calcification of the BM was noted to commence as early as the third decade of life 
(van der Schaft et al. 1992). Calcification and fragmentation of BM facilitates ingrowth of 
choroidal neovascular membranes with consecutive development of neovascular AMD 
(Spraul et al.1999). Moreover, elastin complexed with lipids and calcium favours its 
degradation compared to native elastin (Saulnier et al. 1991). In a case-controlled study, 
Blumenkranz et al noted elastotic degeneration in non-sun exposed skin in AMD patients 
suggesting that photic insults are not primarily responsible for this change but that there are 
inherent, systemic differences in elastin synthesis/ degradation. This change in elastic fibres 
is an important risk factor for CNV (Blumenkranz et al. 1986).
Elastolytic enzymes mediate the degradation of elastic fibres. These enzymes include: 
elastase from neutrophils and platelets, Cathepsin G and metalloproteinases (MMPs) such 
as gelatinase A (MMP-2), gelatinase B (MMP-9), matrilysin (MMP-7) and the macrophage 
metalloelastase (MMP-12) (Robert et al. 1998). Degradation of the elastic fibres by these 
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enzymes results in the release of S-EDP into the circulation. Therefore, the quantification 
of increased S-EDP may reflect the increased production or activity of these enzymes. 
Several immunological methods have been used to estimate S-EDP (Baydanoff et al. 
1987). As elastin is insoluble, it cannot be used directly in immunoassays. Therefore, 
elastin has to be solubilized before use. Insoluble elastin can be solubilized by treatment 
with 0.25M oxalic acid to obtain soluble α elastin, treatment with potassium hydroxide to 
obtain κ-elastin, or by enzymatic digestion of elastin using pancreatic or leucocyte elastase, 
or other enzymes such as pepsin, papin and ficin (Mecham and Lange, 1982). However, a 
major problem in elastin histochemistry is that the purification and preparation of elastin 
and the reactivity of the antibodies influence the reported normal value of mean S-EDP 
(Wei et al. 1993). This phenomenon may explain, in part, the difference between the 
reported mean of control samples in our study versus that obtained by Petersen et al (15 
ng/ml compared to 26 ng/ml respectively), since different capture antibodies were used 
(Petersen et al. 2002)..  An improvement on our methodology would have been to include 
antibodies to peptides other than α-elastin, but the current study was limited to use of those 
antibodies that were readily commercially available. Although the absolute S-EDP 
concentrations have been found to be variable, other authors suggest that it is the variation 
of S-EDP between individuals which is more significant than the absolute values 
(Baydanoff et al. 1987; Kucich et al. 1983). 
It is also important to consider factors that may influence the levels of S-EDP that can be 
detected by an immunoassay: Circulating elastin auto-antibodies may play a role in the 
interpretation of our results. Natural auto-antibodies constitute a proportion of normal 
circulating immunoglobulins (Dighiero et al. 1986), and S-EDP has been shown to induce 
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production of anti-elastin antibodies (Colburn et al. 2003). The levels of these antibodies in 
the serum or the BM may therefore indirectly influence the levels of S-EDP. Moreover, our 
results could also be influenced by the presence of elastin-binding proteins and elastin-
receptor interactions. 
Despite the potential limitations of the immunoassay as described, this study suggested that 
S-EDP was significantly higher in subjects with AMD compared to controls indicating 
increased elastin turnover in subjects with AMD. S-EDP was also found to increase 
progressively from early disease to neovascular AMD. 
The precise source of circulating S-EDP is unclear, but there would seem to be several 
possibilities: Although tissues such as lung parenchyma and skin could contribute to elastin 
degradation, most of the elastic fibres are present in the vascular wall, with thoracic aorta 
containing 30-40% elastin and abdominal aorta about 20%, indicating the most likely 
source of increased circulating S-EDP (Bizbiz et al. 1997).  Increased elastin degradation 
may help explain the association of AMD with atherosclerosis (van Leeuwen et al. 2003a) 
and emphysema (Klein et al. 2003a). The contribution of the BM and choroidal vessels to 
the circulating S-EDP is presumably negligible, so it is not thought likely that increased S-
EDP occurs as a result of AMD progression in the first instance. However, higher levels of 
MMP-2 and MMP-9 have been found in BM of patients with AMD compared to age 
matched controls, and these enzymes may have a role in the degradation of elastic fibres of 
the BM (Lambert et al. 2002, Lambert et al. 2003). This suggests that higher levels of EDP 
at a local level in patients with neovascular AMD may be relevant. Fragmentation of the 
BM is a pre-requisite for the invasion of CNV into the sub-retinal space.  Higher levels of 
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S-EDP in neovascular AMD suggest that S-EDP may be directly involved in the 
pathogenesis of CNV. 
S-EDP interacts with cell membrane receptors such as the elastin-laminin receptor and the 
integrins (Hynes, 1987, Hornebeck et al. 1986). These interactions activate intracellular 
signalling pathways that lead to diverse cellular events (Labat-Robert, 2004). Thus,  S-EDP 
are defined as matrikines as they originate from fragmentation of a matrix protein, and have 
distinct cellular effects such as increased elastase production, free radical release, induction 
of LDL (low density lipoproteins) oxidation, stimulation of endogenous cholesterol 
production and chemotactic activity (Hunninghake et al. 1981; Senior et al. 1980; Fulop et 
al. 1998}. These peptides also act with various growth factors; cytokines and vasoactive 
molecules released as a response to injury and stimulate endothelial cells to proliferate 
(Anderson et al. 2004; Nackman et al. 1996). Thus, the disruption of elastin is not just an 
end-product of elastin turnover. It may be an important contributor to the pathogenesis of 
neovascular AMD. 
Several reports indicate the role of inflammation in AMD. Vine and Powell showed a 
correlation between elastolytic activity and inflammatory cell infiltrates in degenerative 
vascular disease (Vine and Powell, 1991). Likewise, the Bruch’s membrane in AMD is also 
populated by macrophages and lymphocytes in AMD (Penfold et al. 2001; Hageman et al. 
2001). Macrophages elaborate an array of proteinases including metalloelastase (MMP-12). 
In addition, macrophages and lymphocytes are potential sources of cytokines which can 
activate other cells to produce degradative enzymes. Therefore, the release of leucocyte 
elastase can also lead to a collapse of the elastin network and fragmentation of the BM. 
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Another mechanism that should be considered in light of our results is the possibility of 
altered elastin gene transcription in AMD.  Indeed, many cytokines already studied in 
AMD have the ability to modulate elastin expression (Carreras et al. 2002; Kuang et al. 
2003). Further insight into transcriptional mechanisms accompanying tissue responses to 
the elastolytic events can lead to the design and testing of intervention strategies pertinent 
to AMD.  
Although further studies are needed to clarify the influence of S-EDP on AMD, this work 
demonstrates a potential role for elastin peptides in the pathogenesis of AMD.  Larger 
studies are also needed to determine whether the serum level of S-EDP can be used as a 
predictor for the conversion of early ARM to neovascular AMD. 
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2.3 Plasma levels of Matrix Metalloproteinase- 2 and 9    (MMP-2 and 
MMP-9) in Age-related Macular Degeneration 
 
2.3.1 Introduction 
 
The data linking aberrations in ECM biology and AMD are mounting. Numerous 
histopathological studies have shown that each component of the ECM in Bruch's 
membrane undergoes substantial changes in AMD.  
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that 
possess catalytic activity against ECM components such as elastin and collagen.  These 
enzymes are expressed constitutively but under pathological states their expression can be 
increased.  An accumulation of MMP-2 and MMP-9 and TIMP-3 have been identified in 
the Bruch's membrane of AMD eyes, suggesting the presence of a pathologic local 
enzymatic process (Guo et al. 1999; Kamei and Hollyfield, 1999). In addition, elegant 
studies have document the synergistic effect of MMP-2 and MMP-9 in the development of 
CNV (Lambert et al. 2002; Lambert et al. 2003).  
Compositional similarity between drusen and atherosclerotic plaques may indicate that 
AMD and atherosclerosis may be parallel tissue responses to abnormal ECM homeostasis 
(Mullins et al. 2000). 
 MMPs have been implicated in several stages of atherosclerosis. Among them, circulating 
MMP-9 (gelatinase-B) has been identified as a predictor of cardiovascular mortality in 
patients with coronary artery disease (Blankenberg et al. 2003). Likewise, MMP-2 
(gelatinase-A) plays a pivotal role in oxLDL-induced activation of various signalling 
pathways potentially involved in atherosclerosis (Auge et al. 2004). 
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We hypothesize that if atherosclerosis and AMD are tissue responses to altered ECM 
turnover, circulating MMP-2 and MMP-9 may also be elevated in patients with AMD 
compared to controls. 
2.3.2 Materials and Methods 
2.3.2.a) Subjects 
 
Thirty three subjects with varying grades of AMD were recruited for the study from the 
Macula Clinic of King’s College Hospital. Participants of the control group (n=17) were 
selected among subjects from the Cataract Clinic.  They were included if they were 50 
years or older and fundus examination revealed the absence of drusen, pigmentary 
abnormalities and late AMD.  Exclusion criteria were: subjects with co-existent fundus 
pathology and subjects with un-gradable photographs.  The study did not include any 
subject with a history of neoplastic, hepatic, infectious or autoimmune disease; or any 
surgical procedure in the preceding 6 months.  
All enrolled subjects underwent a complete ophthalmic examination by the recruiting 
retinal specialist: visual acuity, slit lamp examination and retinal examination after pupil 
dilation were documented. Each subject had 35° colour stereo fundus photographs of both 
eyes taken (Topcon TRC 50IX, Topcon Ltd. Tokyo, Japan). Fluorescein angiography was 
performed if there was a clinical suspicion of CNV. A detailed medical history of each 
patient was taken with particular care taken to note history of cardiovascular disease.  
This research adhered to the tenets of the Declaration of Helsinki. Institutional ethics 
committee approval was obtained and all subjects gave their full informed consent. The 
subjects in this study were recruited as part of a Medical Research Council (UK) funded 
project on AMD.  
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2.3.2.b) Grading of AMD 
 
Fundus photographs of these subjects were randomized and graded by two retinal 
specialists using the nomenclature and classification recommended by the International 
ARM Epidemiological Study Group (Bird et al. 1995). The graders were masked of the age 
and clinical history of the participants. Double grading for intra-observer and inter-observer 
variability was performed. Discrepancies were resolved by discussion.   
Briefly, we classified the subjects into three groups: a) control group consisted of subjects 
with no evidence of drusen, retinal pigmentary abnormalities or late AMD b) ARM group 
included subjects with the presence of either large (≥63 µm) soft distinct drusen with 
pigmentary abnormalities, or indistinct drusen (≥125 µm) or reticular drusen) c) 
Neovascular AMD group included subjects with fluorescein angiographic evidence of 
CNV. If the grades in the two eyes were different, the subject was categorized according to 
the severity of changes in the worse eye.  
2.3.2.c) Plasma Collection 
 
Venous samples were collected into Heparin tubes (Vacutainer, BD Diagnostics, Oxford 
UK), centrifuged at 1000 x g for 15 minutes at room temperature and plasma was 
transferred to a fresh tube within an hour of collection and kept frozen at -80’C.  Plasma 
samples were thawed on ice and used for MMP measurements.  The samples were 
randomized so that the scientist who analyzed the samples was blinded of the clinical 
history of the subjects.  
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2.3.2.d) Measurement of total plasma protein concentration  
 
The Coomassie Blue Protein Assay reagent (Pierce, Rockford IL) was used to determine 
the total protein level of each plasma sample.  2ul of BSA standards (0-2mg/ml) and 
samples were added to 100ul of substrate solution and incubated for 10 minutes at room 
temperature. The absorbance was read at 575nm. A standard curve was prepared by 
plotting the average blank-corrected 595nm reading for each BSA standard against its 
concentration. The standard curve was used to determine the protein concentration of each 
sample. Any sample with a reading that was significantly different from the average value 
was excluded. 
2.3.2.e) Measurement of total plasma MMP-2 concentration 
 
Plasma MMP-2 levels were quantified with a sandwich ELISA using the Quantikine total 
human MMP-2 kit (R&D Systems Inc, Minneapolis MN).  The kit assayed the proactive 
and active forms of the MMP-2. The assays were processed according to the 
manufacturer’s instruction (see protocol in appendix 2).  
In short, the standards of 7 serial dilutions of recombinant standard (rMMP-2) and the 
samples of 3 serial dilutions 1:45, 1:90 and 1:180 were prepared.  A polyclonal antibody 
specific for MMP-2 was pre-coated in the microtiter plates. 100 µl of assay diluent and 50 
µl of standard and sample were added to each well and incubated for 2 hours on the shaker 
at 250 rpm at room temperature. The wells are then aspirated and washed twice.  
Then to each well 200 µl of the MMP-2 Conjugate was added (enzyme linked polyclonal 
antibody specific for MMP-2). The plates were incubated for 2 hours on the shaker at 250 
rpm at room temperature and then washed three times. The substrate solution (200 µl) was 
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added and incubated for a further 30 minutes and the reaction was terminated with 50 µl of 
stop solution. The absorbance was read at 450 nm. The standard curve was constructed in 
each assay for sample calculation.  All samples were measured in duplicate and in 3 serial 
dilutions and the results were averaged as mean ± standard error of mean (SEM) ng/ml. 
2.3.2.f) Measurement of total plasma MMP-9 concentration  
 
 Plasma MMP-9 levels were also quantified with a sandwich ELISA using the Quantikine 
total human MMP-9 kit (R&D Systems Inc, Minneapolis MN).  The kit assayed the 
proactive and active forms of the MMP-9. The assays were processed according to the 
manufacturer’s instruction (see protocol in appendix 2). The standards of 6 serial dilutions 
of recombinant standard (rMMP-9) and the samples of 3 serial dilutions 1:25, 1:75 and 
1:225 respectively were prepared. 
This assay utilized specific mouse monoclonal antibodies against MMP-9 coated in 96-well 
microtitre plates. 100 µl of assay diluent and 100 µl of standard and sample were added to 
each well and incubated for 2 hours on the shaker at 250 rpm at room temperature. The 
wells are then aspirated and washed twice.  
Then to each well 200 µl of the MMP-9 Conjugate was added (enzyme linked polyclonal 
antibody specific for MMP-9). The plates were incubated for 1 hour on the shaker at 250 
rpm at room temperature and then washed three times. The substrate solution (200 µl) was 
added and incubated for 30 minutes. The reaction was terminated with 50 µl of stop 
solution and the absorbance read at 450 nm. The standard curve was constructed in each 
assay for sample calculation.  All samples were measured in duplicate and in 3 serial 
dilutions and the results were averaged as mean ± standard error of mean (SEM) ng/ml. 
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2.3.2.g) Statistical methods 
 
MMP-2 and MMP-9 levels in the three groups were analysed using Student’s t-test. The 
ANOVA one way was also used to identify relationship between patient parameters.  
Statistical significance was set as p<0.05. 
2.3.3 Results  
2.3.3.a) Characteristics of the subjects 
Plasma was analysed from 50 subjects consisting of 15 with ARM, 18 with neovascular 
AMD, and 17 controls. There were no significant differences in average age, gender 
distribution or prevalence of major risk factors among the three groups (Table 2.4).  
Table 2.4: Characteristics of subjects in the three groups 
 ARM 
(n=15) 
Neovascular 
AMD 
(n=18) 
Controls 
(n=17) 
p-value 
Age(years with range) 74 [61-81] 75 [62-91] 76 [61-81] 0.5 
Gender M:F 5:10 7:11 6:11 0.5 
Smoker (%) 6.6 5.5 0 0.7 
Hypertension (%) 33.3 27.7 35.3 0.7 
Myocardial infarction (%) 6.6 11.11 5.9 0.6 
Angina Pectoris (%) 0 0 5.9 0.3 
Stroke (%) 6.6 0 0 0.3 
Hypercholesterolemia (%) 13.3 11.11 17.6 0.6 
2.3.3.b) Quality of plasma samples 
 
Total protein measurements were performed as a preliminary test for the quality of plasma 
samples collected.  Statistical analysis showed that there was no significant difference 
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(p>0.05) in the protein level of the samples between subjects in the 3 identified groups.  
The average measurement is 3.3 ± 0.3 mg/ml. 
2.3.3.c) Total Plasma MMP-2 levels 
 
The typical standard curve for plasma MMP-2 is shown in fig 2.6. The assay was 
reproducible in both the intra-plate and inter-plate studies. OD of the individual positive 
and negative control were within ± 2 SD of the mean OD values. 
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Fig. 2.6: Typical standard curve of ELISA for plasma MMP-2 (error bars denote 2 SD). 
 
The mean plasma levels of MMP-2 in control (495 ± 124 ng/ml), ARM (507 ± 145 ng/ml) 
and CNV patients (523 ± 100 ng/ml) were not significantly different (p=0.8) as shown in 
fig. 2.7. 
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Fig 2.7: Mean plasma MMP-2 levels in the three groups 
2.3.3 d) Total MMP-9 levels 
Fig. 2.8 shows the standard curve for the MMP-9 assay. The assay was reproducible in 
both the intra-plate and inter-plate studies. OD of the individual positive and negative 
control was within ± 2 SD of the mean OD values. 
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Fig 2.8: Typical standard curve of ELISA for plasma MMP-9  
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The mean plasma MMP-9 levels were significantly higher in ARM (659 ± 315 ng/ml) and 
CNV (740 ± 494 ng/ml) compared to that of control patients (265 ± 134 ng/ml) (p=0.008), 
as demonstrated by fig. 2.9. 
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Fig. 2.9: Mean serum plasma MMP-9 levels in the three groups 
2.3.4 Discussion 
 
In this study, plasma MMP-9 levels in AMD subjects were found to be approximately 3 
fold higher than controls. However, there was no significant difference in MMP-9 levels 
between the ARM and CNV groups. Plasma MMP-2 levels were noted to be similar in the 
three groups 
There is growing evidence that MMPs play important roles in many disease processes, but 
most of these enzymes are likely to be active at a local tissue level.  
Nonetheless, raised plasma MMP-9 levels have been documented in cancer, hepatic and 
lung diseases and rheumatoid arthritis (Farias et al. 2000; Chung et al. 2004; Ohbayashi, 
2002; Tchetverikov et al. 2004). Subjects with history of these conditions were excluded 
from this study. The level of circulating MMP-9 is raised in several stages of 
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atherosclerosis (Kai et al. 1998). No statistically significant differences in clinical data 
related to atherosclerosis were observed between subjects in the three groups in this study. 
The levels of plasma MMP-9 also vary in different ethnic groups but all the patients in this 
cohort were Caucasians (Tayebjee et al. 2005). Therefore, these findings of raised plasma 
MMP-9 in this study is most probably associated with AMD. There may be other unknown 
confounding factors that may influence the results. However, they should be highly 
associated with MMP-9 to explain these results.  
Total MMP-2 and MMP-9 (pro and active forms) were measured in this study. All MMPs 
require activation from precursors to attain enzymatic activity. The antibodies used did not 
distinguish the active form of these enzymes from their proenzyme forms. Gelatin 
zymography is a more sensitive assay for detection of both latent and active forms of 
MMP-2 and MMP-9. In addition, TIMPs dissociate from MMPs during electrophoresis 
thus preventing TIMPs from inhibiting enzymatic activity (Kleiner and Stetler-Stevenson, 
1994). Therefore, increased MMP-9 immunoreactivity in this study does not necessarily 
correspond to its augmented enzymatic activity.  
Nevertheless, the source of increased MMP-9 in the circulation in AMD patients remains 
unclear. The contribution of the RPE-BM complex to the circulating MMP-9 is presumably 
negligible, so it is not thought likely that increased MMP-9 occurs as a result of AMD in 
the first instance. Other important sources of MMPs include astrocytes, neurons, microglia, 
leucocytes and macrophages (Lorenzl et al. 2003). It is therefore possible that circulating 
leucocytes may contribute to the increased levels of MMP-9. The recent evidence of raised 
C-reactive protein (CRP) in intermediate and advanced AMD suggests a state of low grade 
inflammation (Seddon et al. 2004). Proinflammatory cytokines may also account for 
 74
macrophage activation and subsequent release of MMP-9 (Beuche et al. 2000). 
Furthermore, oxidative stress can result in enhanced expression and activation of MMPs 
(Okamoto et al. 2001). Further investigations are needed to address these issues.  
The lack of an increase in MMP-2 levels may reflect its more constitutive expression, 
whereas MMP-9 levels are more responsive to reactive oxygen species and inflammatory 
cytokines (Girolama et al. 2004).   
In summary, this is the first study that reveals an association of circulating MMP-9 with 
AMD.  It is difficult to make wide ranging conclusions/ assumptions based on these 
observations in view of the small sample size. However, this is an important starting point. 
Larger scale future studies will be required to clarify these findings including the link with 
systemic inflammatory markers.  
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2.4 The correlation of S-EDP and MMPs in Age-related macular 
degeneration 
 
2.4.1 Introduction 
 
Dysregulation of the ECM plays an important role in the pathogenesis of AMD. In the 
earlier part of this chapter (section 2.2), we found that elastin degradation products in 
serum (S-EDP) increases with increasing severity of AMD. Elastolytic enzymes mediate 
the degradation of elastin.  These enzymes include: elastase from neutrophils and platelets, 
Cathepsin G and metalloproteinases (MMPs) such as gelatinase A (MMP-2), gelatinase B 
(MMP-9), matrilysin (MMP-7) and the macrophage metalloelastase (MMP-12) (Robert et 
al. 1998). We also noted that plasma MMP-9 is increased in patients with AMD (both early 
and late disease) (section 2.3). From these findings, we postulated that increased S-EDP in 
patients with AMD may be due to an increase in MMP-9 in circulation. Therefore, in this 
pilot study, we estimated and compared the S-EDP, MMP-2 and MMP-9 levels in the sera 
of patients with AMD and age matched controls. 
2.4.2 Materials and Methods 
2.4.2.a) Subjects 
 
Thirty subjects with a clinical diagnosis of AMD were included in the study. The control 
group consisted of 10 healthy subjects without AMD (defined as the absence of drusen, 
pigmentary abnormalities and neovascular AMD). All enrolled subjects underwent a 
complete ophthalmic examination and subjects with AMD were graded as described in 
section 2.2.2.  
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2.4.2.b) Blood samples 
 
Venous blood was collected from all subjects into two tubes: serum separator tube and 
heparin tubes (Vacutainer, BD Diagnostics, Oxford UK), then centrifuged for 10 minutes at 
1000 g at room temperature. Serum was aliquoted and stored at –70°C within an hour of 
collection and then thawed for S-EDP estimation while plasma was transferred from the 
heparin tubes and used for MMP measurements.  The samples were randomized so that the 
scientist who analyzed the samples was blinded of the clinical history of the subjects. 
2.4.2.c) Estimation of S-EDP 
 
The concentration of S-EDP was determined using a competitive enzyme-linked 
immunoassay (ELISA) as described in chapter 2.2 of this thesis.  
2.4.2.d) Measurement of plasma MMP-2 AND MMP-9 levels 
 
MMP-2 and MMP-9 were quantified with the enzyme-linked immunosorbent assay 
(ELISA) using the Quantikine total human MMP-2 and MMP-9 ELISA kits (R&D Systems 
Inc, Minneapolis MN) as described in chapter 2.3 of this thesis. 
2.4.2.e) Statistical methods 
 
Pearson’s correlation coefficient (r2) was used to compare the S-EDP and MMP-2 and 
MMP-9 in the three groups. Statistical significance was set as p<0.05. 
2.4.3 Results 
2.4.3.a) Characteristics of subjects 
 
Serum was analysed from 30 subjects consisting of 10 with ARM, 20 with neovascular 
AMD, and 10 controls. Age and gender distribution were similar in both groups of AMD 
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and controls. No statistically significant differences in clinical data were observed between 
subjects in the three groups. 
2.4.3.b) Mean S-EDP levels 
 
The mean serum levels of S-EDP in CNV group (39.08 ± 4.62ng/ml) were significantly 
higher than ARM (21.23 ± 3.21ng/ml) and control group (20.99 ± 2.4ng/ml) (p <0.05). 
2.4.3.c) Mean MMP-2 levels 
 
The mean plasma levels of MMP-2 in control (523 ± 31ng/ml), ARM (423 ± 22ng/ml) and 
CNV patients (498 ± 26ng/ml) were not significantly different (p>0.05). 
2.4.3.d) Mean MMP-9 levels 
 
The mean plasma MMP-9 levels were significantly higher in ARM (888 ± 126ng/ml) and 
CNV (729 ± 130ng/ml) compared to that of control patients (413 ± 39ng/ml) (p <0.05). 
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Fig. 2.10 Means of S-EDP and MMP2 and MMP-9 in the three groups 
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Fig 2.10 demonstrates the relation between the means of S-EDP and the MMPs. Though S-
EDP and MMP-9 are raised in the AMD subjects, their levels do not correspond showing 
no significant relation between their levels. 
2.4.3.e) Correlation of S-EDP with MMP-2 and MMP-9 
 
Using Pearson’s correlation coefficient, the control group showed a positive trend between 
MMP-9 and S-EDP that disappeared completely in the ARM and neovascular groups as 
shown in figs. 2.11, 2.12 and 2.13. However, MMP-2 did not show any correlation with S-
EDP in any groups. 
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Figure 2.11: Correlation between MMP-9, MMP-2 and S-EDP in controls 
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Fig. 2.12: Correlation between MMP-9, MMP-2 and S-EDP in early disease 
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Fig. 2.12: Correlation between MMP-9, MMP-2 and S-EDP in neovascular AMD 
2.4.4 Discussion 
 
The three dimensional organization of elastin, collagen and proteoglycans is optimal for the 
integrity and function of the BM. In AMD, the BM is subjected to injury: lipid deposition, 
hypoxia, macrophage infiltration and accumulation of reactive oxygen species and 
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phagocytic material (Ambati et al. 2003a). The ECM molecules are hydrolysed by 
proteases with resultant degradation of the framework and invasion of the CNV. 
The MMPs are zinc dependent proteolytic enzymes. Both MMP-2 and MMP-9 have been 
isolated in CNV suggesting that they are involved in the degradation of the Bruch’s 
membrane (Guo et al. 1999; Lambert et al. 2003). The proteolytic activities of MMPs are 
precisely controlled at the level of transcription, activation of the precursor zymogens 
interaction with specific ECM molecules and inhibition by endogenous inhibitors. 
In this study, we found that the levels of systemic MMP-9 levels showed a trend with the 
elastin degradation in the control group indicating the precise controlled activity of MMP-9 
in physiological conditions. The balance tilts to increased elastin degradation that does not 
correlate with MMP-9 levels in the neovascular AMD though both S-EDP and serum 
MMP-9 levels are increased. The results suggest that other elastolytic enzymes may also 
play an important role in neovascular AMD. Both MMP-7 and MMP-9 have been shown to 
participate in the degradation of dermal elastic fibres (Ghomrasseni et al. 2003). 
Blumenkranz et al noted that senile dermal elastosis is associated with AMD (Blumenkranz 
et al. 1986). It may be that additional upregulation of other metalloproteinases such as 
MMP-7 may account for increased S-EDP in neovascular AMD.  
Many elastolytic enzymes are confined to areas of inflammatory cell infiltrations and these 
cells have been shown to infiltrate the BM and CNV (Penfold et al. 2001). The elastolytic 
enzymes are formed of four groups of proteinases (serine-, metallo-, aspartic and cysteine 
proteinases). They are released from different cells including granulocytes, monocytes, 
lymphocytes, skin fibroblasts, cancer cells and others.  Among cysteine proteases, 
cathepsins S and K have been considered as the most potent elastolytic activities with 
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cathepsin K exhibiting a slightly higher activity than cathepsin S (Sukhova et al. 1998). 
Glycosaminoglycans (GAGs) such as chondroitin sulfate specifically inhibit the elastolytic 
activities of cathepsins V and K via the formation of specific cathepsin-GAG complexes 
(Yasuda et al. 2004). Because the GAG content is reduced in AMD, an increase of 
cathepsins may also accelerate the destruction of the elastin matrix in the BM. 
An increased elastin turnover can occur in several disorders such as atherosclerosis and 
emphysema. These diseases are associated with AMD indicating that ECM dysregulation 
may be the common factor. Most studies concentrate on the balance of MMP and their 
endogenous inhibitors in assessing ECM degradation in AMD. Although the analyzed 
population is small, this study demonstrates that MMPs alone cannot explain the increased 
ECM turnover and it may also help explain why MMP inhibitors (Prinomastat) were found 
to inefficient in the management of AMD (Behrendt, 2004). Statins and doxycycline also 
inhibit MMPs (Kadoglou and Liapis, 2004; Guymer et al. 2005). 
Their roles in AMD are also inconclusive Further studies on the up-regulation of other 
elastases and the systemic MMP-TIMP balance may help to better understand ECM 
turnover in AMD. 
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2.5 Abdominal aortic aneurysms and age related macular degeneration 
2.5.1 Introduction 
Abdominal aortic aneurysms (AAAs) represent a degenerative process of the abdominal 
aorta that is often attributed to atherosclerosis (Reed et al. 1992); however, the exact cause 
is not known (Wanhainen et al. 2005). Other causes include infection, cystic medial 
necrosis, arteritis, trauma and inherited connective-tissue disorders. The disease generally 
affects elderly white men. Smoking and hypertension are the risk factors that are strongly 
associated with AAA (Fassiadis et al. 2005). 
The most important mechanisms involved in the pathogenesis of AAA are proteolytic 
degradation of aortic wall connective tissue, inflammation and immune responses, 
biomechanical wall stress, and molecular genetics. The aortic wall contains smooth muscle, 
elastin, and collagen arranged in concentric layers in order to withstand arterial pressure. 
Elastin is the principal load-bearing element in the aorta. Elastin fragmentation and 
degeneration are observed in aneurysm walls. The decrease in content coupled with the 
histological changes of this matrix protein contributes to the development of AAA (Carmo 
et al. 2002). S-EDP is an important predictor of rupture of AAA (Petersen et al. 2002). 
The aortic media appear to degrade in AAA by means of a proteolytic process. This implies 
an increase in the concentration of proteolytic enzymes relative to their inhibitors in the 
abdominal aorta as the individual ages. Reports have documented increased expression and 
activity of MMPs in subjects with AAAs. The amount of circulating MMP-9 has not only 
been reported to be significantly higher in patients with AAA (McMillan and Pearce, 
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1999), but has also been significantly associated with the size and expansion rate of these 
aneurysms (Lindholt et al. 2000).  
The BM consists of a similar composition of extracellular matrix proteins as the vascular 
matrix, with a central core of elastin sandwiched between two collagenous layers. This 
penta-laminar membrane is strategically located between the RPE and its nutrition (the 
choriocapillaris). Age related changes in the BM are akin to the changes in the vascular 
wall (section 2.1). Earlier studies in this thesis also show that S-EDP correlates with 
severity of AMD (section 2.2) and it was also observed that circulating MMP-9 is raised in 
subjects with AMD compared to age matched controls (section 2.3). 
The hypothesis in this study is that if AAA and AMD undergo similar remodelling of 
ECM, subjects with AAA may have higher incidence of AMD compared to age matched 
controls. It is uncertain whether this link exists. If it does, it might help to identify high risk 
individuals of developing AMD from the vascular clinic and likewise, identify high risk 
individuals of developing AAA from the eye clinic. This study looked at the risk of AMD 
in subjects with AAA compared to age matched controls. 
2.5.2 Materials and Methods 
Subjects with AAA were recruited from the vascular laboratory of King’s College Hospital 
during the year April 2003 to April 2004. Inclusion criteria included: age ≥ 55 years; 
ultrasound evidence of AAA (≥ 4 cm); hypertension defined as being on antihypertensives. 
The controls included age-matched hypertensive subjects recruited from oculoplastic 
clinics of King’s College Hospital. Hypertension was defined as being on anti-
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hypertensives. All enrolled subjects underwent a complete ophthalmic examination 
including dilated fundus examination by the recruiting retinal specialist. 
AMD was graded using the nomenclature and classification recommended by The 
International ARM Epidemiological Study Group. The subjects were classified as either 
early age related maculopathy (ARM) or neovascular AMD. Early age-related maculopathy 
was defined as the presence of intermediate soft distinct drusen (> 63 µm) with retinal 
pigment epithelial depigmentation or hyperpigmentation, soft indistinct drusen (> 125 µm), 
or reticular drusen;   Neovascular AMD consisted of subjects with CNV. If the grades in 
the two eyes were different, the subject was categorized according to the severity of 
changes in the worse eye. 
In addition, all co-existent posterior segment pathology were documented in each subject. 
The Statistical Package of the Social Sciences (SSPS version 11.0) was used for the 
analysis. The Mann Whitney-U test was used to compare groups and statistical significance 
was set at 95% (p<0.05). 
 
This research adhered to the tenets of the Declaration of Helsinki. Institutional ethics 
committee approval was obtained and all patients gave their full informed consent. 
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2.5.3 Results 
2.5.3.a) Characteristics of subjects 
During the year April 2003 to April 2004, the vascular laboratory had a potential group of 
seventy subjects with AAA of diameter ≥ 4 cm. However, 28 of them died prior to the 
recruitment for this study. Eight subjects were too ill for the eye examination and 2 subjects 
were non-hypertensive. So, 32 subjects in the AAA group were included in the study. A 
total of 32 hypertensive controls were also included in the study. 
Table 2.5: Age stratification in the two groups 
Age groups (years) AAA control 
55-65 10 2 
66-75 16 18 
>76 6 11 
 
2.5.3.b) Grading of AMD 
One subject from each group had ARM. The subjects with ARM had intermediate soft 
distinct drusen (> 63 µm) with retinal pigment epithelial changes. None of them had soft 
indistinct drusen (> 125 µm), or reticular drusen. There were no subjects with geographic 
atrophy or neovascular AMD. 
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2.5.3.c) Other ocular morbidity 
Many ocular diseases were common in the two groups so the associations were compared. 
Table 2.6 shows the associated ocular co-morbidity in the two groups. 
Table 2.6: Associated ocular co-morbidity in the two groups 
 AAA Control p-value 
Cataract/ pseudophakia 25 30 NS 
POAG/ LTG 4 2 NS 
CRVO 2 0 NS 
BRVO 2 0 NS 
Macular hole 1 0 NS 
NPDR 0 1 NS 
AION 0 1 NS 
Iritis 0 1 NS 
Amblyopia 1 1 NS 
2.5.4 Discussion 
This study showed no significant association of AMD with AAA. Since systemic elastic 
turnover is increased in both AAA and AMD, it was hypothesized that a pilot study like 
this would have established a relation between AAA and AMD. In addition, the two 
conditions share risk factors such as smoking, age and atherosclerosis. Failure to find any 
significant association between AAA and AMD may be due statistical power constraints. A 
reasonable overall estimate of the prevalence of AMD in subjects aged 65-74 years is 1%, 
increasing to 5% in subjects aged 74-84 years and 13% in subjects 85 years and older.  
Therefore, a larger cohort of subjects with AAA is required to obtain a significant 
association. 
 87
However, such comparison is hampered by a survivor cohort effect. That is, those who 
survive to an age when AMD is likely to develop have survived the AAA; those who did 
not survive the AAA may have been more likely to develop AMD if they survived. The 
AAA gradually enlarges (0.2-0.8 mm/y) and eventually ruptures (Brown and Powell, 
1999). The risk for rupture of large AAA increases with age.  Additionally, AAA in women 
has been shown to rupture at smaller diameters in comparison with men; therefore, a lower 
threshold for elective repair has been advocated in this patient population. Other 
contributing factors for rupture include hypertension, continued smoking, or chronic 
obstructive pulmonary disease (COPD) (Sakalihasan et al. 2005). The mortality rate is 1.8-
5% if elective surgery is opted and 85% if ruptured (Thompson, 2003). In general, the 
survival rate of people with successful aortic aneurysm repair is comparable to that of 
people in the age-matched population at large who have never had an aneurysm. So future 
studies of larger cohorts aimed at persons who have survived AAA repair may give a 
definitive answer as to whether there is an association between the two conditions. 
However, the feasibility of recruitment of such patients from a single institution is doubtful. 
Moreover, most persons with AAAs are asymptomatic. This cohort consisted of those who 
have been diagnosed either incidentally or because they are symptomatic. So this cohort 
may not be a true representation of the population with AAA. 
A final possibility is that there is no true association between the two conditions. 
An increased trend was found for open angle glaucoma and retinal veno-occlusive diseases 
in the AAA group compared to controls despite the relatively small number of patients. As 
both groups are matched for hypertension, it appears that AAA may be an independent risk 
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factor for the development of open angle glaucoma (POAG) and veno-occlusive disease. It 
is difficult to make assumptions from the observations made from this study with a small 
sample size. It may be that the lamina cribrosa in patients with AAA undergoes similar 
elastolysis and is therefore more susceptible to intraocular pressure changes and venous 
obstruction. In aneurysmal tissue, a tendency exists for increased MMP activity favouring 
the degradation of elastin and collagen. The mechanism that tips the balance in favour of 
degradation of elastin and collagen in the aortic wall of AAAs by MMPs and other 
proteases is presently unknown. Further research in the role of extracellular matrix 
remodelling in the vascular wall, lamina cribrosa and Bruch’s membrane may help us to 
better understand the pathogenesis of AAA, POAG and AMD. 
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Does inflammation link atherosclerosis and age related 
macular degeneration? 
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CHAPTER 3: INFLAMMATION 
This chapter reviews the evidence of the role of inflammation in AMD, and then presents 
data obtained through investigation of one of the factors which may be involved in 
progression of the disease. 
3.1 Inflammation and Age-related macular degeneration 
 
Age-related macular degeneration (AMD) is the leading cause of severe visual loss in 
patients above the age of 65 years in the western world (Vingerling et al. 1995c; Mitchell et 
al. 1995; Klein et al. 1997b). Despite an exponential increase in research on AMD in the 
last two decades, the aetiology of this heterogeneous condition remains obscure. Several 
clinical and epidemiological studies have suggested that inflammation may play a role in 
AMD (Penfold, 2001, Hageman, 2001). With the recent evidence of increased risk of AMD 
in subjects with genetic polymorphism of CFH (Klein et al. 2005; Edwards et al. 2005; 
Haines et al. 2005, Hageman et al, 2005), the inflammatory paradigm in AMD is revisited 
to better understand its role in the pathophysiology of AMD 
3.1.1 The concept of inflammation 
 
Inflammation is a local response to a site of injury. The cardinal signs of inflammation, 
dolor, tumor, calor and rubor actually represent secondary reaction of blood vessels to an 
initiating stimulus and merely amplify the inflammatory response (Metchnikoff, 1892). 
Chronic inflammation occurs when there is a failure to eliminate the initiating targets and 
tissue destruction and attempts to repair proceed simultaneously (Cotran et al. 1999). The 
fundamental reaction in AMD represents a chronic fibroproliferative response, the hallmark 
of chronic inflammation. 
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3.1.2 Inciting Stimuli for inflammation 
 
The inciting stimuli in AMD remain speculative. Basal laminar deposits (BlamD), RPE cell 
debris and focal lipid accumulation in the Bruch’s membrane may serve as powerful 
chemotactic stimuli for inflammation (Anderson et al. 2002). BlamD consist of diffuse 
heterogeneous material that lies between the plasma membrane of RPE and its basement 
membrane. Ultrastructural and histochemical analyses suggest wide-spacing collagen to be 
a dominant constituent of these deposits. Long spacing collagen is selectively 
phagocytosed by macrophages in AMD indicating its chemotactic property (Loeffler and 
Lee, 1986).  
Another potential nidus for inflammation is RPE debris. Though the exact aetiology for 
RPE dysfunction in AMD remains obscure, progressive accumulation of RPE cell debris 
occurs in all layers of the Bruch’s membrane. Drusen, the visible hallmark of AMD, is 
thought to be derived from this debris. A series of elegant studies has documented that the 
accumulation of drusen elicits an inflammatory response (Penfold et al. 1985; Anderson et 
al. 2002; Crabb et al. 2002; Johnson et al. 2001). Similarly, an age-related exponential 
accumulation of lipid occurs in the Bruch’s membrane (Sheraidah et al. 1993; Curcio et al. 
2001; Haimovivi et al 2000). As in atherosclerosis, this lipid pool and its modification may 
also contribute to the inflammatory process. 
Other than these extracellular deposits, vascular injury induced by mechanical or 
biochemical stimuli can also trigger an immune response. Recent evidence of systemic 
chronic infections in AMD suggests that these agents might initiate the vascular injury in 
AMD (Kalayoglu et al. 2003). 
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3.1.3 Evidence of Inflammation 
 
a) Cellular response 
 
Macrophages are the principal inflammatory cells in all stages of AMD. Several 
histological studies have suggested the spatiotemporal correlation of macrophages with 
drusen, geographic atrophy, CNV and breaks in the Bruch’s membrane (Caicedo et al. 
2005; Cousins et al. 2004; Sarks et al. 1997, Penfold et al. 1985; Killingsworth et al. 1990). 
The precise role of macrophages in AMD is still not fully understood. Though they play an 
important role as scavengers to remove cell debris in the RPE-choroid complex, they are 
also antigen presenting cells for T-lymphocytes and are inflammatory effector cells. The 
macrophages are mainly recruited from the circulating monocytes but resident 
macrophages in retinal microglia also contribute significantly to the inflammatory and 
angiogenic response (Forrester et al. 2005). The activation of monocytes (defined as TNF-
alpha expression) is a pre-requisite for entering the leucocyte inflammatory cascade. 
Activation of macrophage results in accumulation of inflammatory mediators, free radicals, 
pro-apoptotic factors and matrix metalloproteinase’s. Patients with CNV have more 
activated monocytes than controls suggesting a pro-inflammatory state with resultant 
damage to host tissues (Cousins et al. 2004). These activated macrophages usually 
transform to epitheloid cells and multinucleated giant cells and these cells co-exist in both 
atrophic AMD and neovascular AMD. 
AMD lesions are also infiltrated by T-lymphocytes, suggesting a local immune response 
(Penfold et al. 1985).  T-cells play a key role in initiating and perpetuating inflammation, 
not only via the production of soluble mediators but also via inter-cellular interactions 
through membrane receptors and their ligands. Other than T-lymphocytes, a distinct array 
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of active participants of the humoral and cellular immune processes has also been identified 
in drusen such as dendritic cells, immune antigen-presenting cells, HLA-DR and 
immunoglobulin light chains indicating the role of immune mediated biogenesis of drusen 
(Forrester et al, 2005, Anderson et al, 2002). Mast cells induce angiogenesis and mediate 
cell injury and have been shown to accumulate in the choroidal vasculature and the Bruch’s 
membrane in CNV due to AMD (Penfold et al. 1984).
b) Cytokines 
Cytokines are a heterogeneous group of small molecules that act in combination in 
inflammatory reactions. They include interleukins (ILs), interferons (INFs), tumour 
necrosis factors (TNFs), growth factors, colony-stimulating factors and chemokines. 
Cytokines activates T-cells which in turn activate monocytes/ macrophages, endothelial 
cells and fibroblasts to produce chemokines and matrix metalloproteinase’s, responsible for 
tissue destruction. In addition, CD40 ligand at inflammatory sites stimulates fibroblasts and 
tissue monocyte/macrophage production of VEGF, leading to angiogenesis, which 
promotes and maintains the chronic inflammatory process (Tsutsumi et al. 2003). The RPE 
can produce certain cytokines such as the chemoattractant molecule, monocyte 
chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) (Bian 
et al. 2004). MCP-1 binds to its receptor CCR2 and this interaction is responsible for the 
transendothelial migration and differentiation of monocytes into lesional macrophages. 
High levels of MCP-1 have been shown in RPE cells in AMD probably acting as the 
chemoattractant for the macrophages. It has also been demonstrated that mice deficient 
either in MCP-1 or its receptor CCR2 develop cardinal features of AMD, including 
accumulation of lipofuscin in and drusen beneath RPE, photoreceptor atrophy and CNV 
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(Ambati et al. 2003b). Moreover, the number of infiltrating macrophage and the area of 
CNV are reduced in CCR2 knock-out mice indicating the active role of macrophages in the 
development of CNV. 
c) Adhesion molecules 
A family of adhesion molecules is expressed on the surface of vascular endothelial cells. 
They are essential for the adherence and transmigration of leucocytes through the vascular 
endothelium. These adhesion molecules are membrane bound and their soluble 
counterparts in plasma indicate their presence in circulation. At least four super families of 
adhesion molecules participate in these events: the selectins, the integrins, certain members 
of the immunoglobulin super family and cadherins. In CNV secondary to AMD, the 
activated vascular endothelial cells express various cellular adhesion molecules such as 
ICAM-1 and VCAM-1 and selectin-E (Yeh et al. 2004). A recent study on serum ICAM-1 
in AMD did not show a significant association with the development of CNV (Seddon et 
al. 2005; Klein et al. 2005). 
d) Complement activation 
 
Recent evidence suggests that the complement system may play a significant role in the 
pathogenesis of AMD. Inflammatory and immune mediated events involving complement 
proteins have been implicated in the biogenesis of drusen.  
The complement system consists of a group of soluble plasma proteins, mainly serine 
proteases that interact in three enzymatic activation cascades: classical, alternative and 
lectin pathways. When activated, the complement cascade performs diverse biological 
functions including pro-inflammatory and immunoregulatory functions. 
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CFH is an immunoregulatory protein. It controls the complement system in the fluid phase 
and on cellular surfaces. It inhibits the activation of C3 to C3a and C3b and also directly 
controls C3b. It is a major inhibitor of the alternate complement pathway. It also binds to 
C-reactive protein (CRP) which may help to arrest CRP-dependent complement activation 
induced by damaged tissues (Jarva et al. 1999). 
Linkage studies and candidate gene screening have suggested that a locus associated with 
AMD may exist at the region 1q25-32. Though many other loci are also associated with 
AMD, the gene of CFH (HF1/CFH) is also located in 1q31. The mutational screening of 
CFH gene in independent series of patients resulted in the identification of a polymorphism 
in the CFH gene that confers susceptibility to AMD. (Klein et al. 2005; Edwards et al. 
2005; Haines et al. 2005, Hageman et al, 2005). The risk allele has been identified as a 
tyrosine-histidine substitution at amino acid 402. Although the genetic studies have clearly 
demonstrated the involvement of CFH in AMD, the precise role the CFH plays in this 
heterogeneous condition is unknown. The cause of AMD is probably still multifactorial. 
Inherited complement defects may represent a predisposing condition that increases the risk 
of the condition in combination with other intercurrent environmental or acquired factors. 
Established risk factors for AMD such as smoking have been shown to decrease the plasma 
CFH levels (Klein et al. 2005). The exposure of the RPE-choroid complex to these risk 
factors may initiate local tissue response that activates complement. In normal conditions, 
CFH may effectively limit the complement activation and extension of tissue damage. 
When the bioavailability or activity of CFH is congenitally defective, it may lead to 
uncontrolled complement activation and further tissue damage.  
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CFH deficiency can also cause type II membranoproliferative glomerulonephritis (MPGN 
II), a rare renal inflammatory disease with coexistent drusen that share similar molecular 
composition to those in AMD (Mullins et al. 2000). A high proportion of these patients are 
also shown to harbour the AMD at-risk haplotype of CFH suggesting that both diseases 
may be the result of uncontrolled trigger of the alternate complement pathway. 
In addition, up-regulation of the mRNAs for the complement proteins and 
immunohistochemical evidence of their presence have been found in the RPE-choroid 
complex in AMD (Anderson et al. 2002; Crabb et al. 2002; Johnson et al. 2001). A murine 
model of laser-induced CNV in C57BL/6 mice revealed the deposition of C3 and 
membrane attack complex (MAC) in the neovascular complex. The CNV was inhibited by 
complement depletion using cobra venom factor. Thus, activation of complement, 
specifically the formation of MAC, is essential for the development of laser- induced 
choroidal angiogenesis in mice (Bora et al. 2005). Though most of the complementary 
proteins are derived from the circulation, local sources include macrophages and T-
lymphocytes, RPE cells in AMD.  These proteins may be activated by modified 
lipoproteins, cholesterol, fibrillar proteins, and damaged cell debris that exists in RPE-
choroid complex. The activation of complement induces cell lysis which in turn may 
account for at least a part of the cell debris characteristic of drusen. Moreover, sub lethal 
injury by complement proteins permits release of growth factors and serve as powerful 
chemotactic stimulus, reinforcing the inflammatory process and angiogenesis (Johnson et 
al. 2000).
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e) Inflammatory markers 
The inflammatory process in AMD is further strengthened by the presence of inflammatory 
markers in the circulation in AMD. Pentraxins are important activators of the complement 
system. C-reactive protein (CRP) is a non-specific marker of chronic low-grade 
inflammation. A strong link has been shown between baseline elevations of CRP and risk 
of AMD (Seddon et al. 2004; Seddon et al. 2005). 
Other acute phase proteins that are raised in AMD include fibrinogen (Smith et al. 1998; 
Klein et al. 2003a) and ceruloplasmin (Newsome et al. 1986). High leucocyte count has 
been noted in AMD (Klein et al. 1993). Other indirect evidence of systemic inflammation 
in AMD is the association with raised serum oxLDL and leptin levels (Evereklioglu et al. 
2003, Ikeda et al. 2001). 
f) Association with infectious agents
Epidemiological studies have implicated periodontal disease, Chlamydia pneumonia, and 
CMV virus as risk factors for the development of AMD (Miller et al. 2004; Kalayoglu et al. 
2004). Neovascular AMD has been associated with serological anti-Chlamydia pneumonia 
antibodies, and high cytomegalovirus IgG titres. It remains obscure whether these 
infectious agents have a causal effect on AMD or are merely an epiphenomenon of the 
inflammatory process. It may be that localized persistent infection may influence systemic 
levels of inflammatory mediators which in turn potentially impact inflammation-associated 
processes including AMD or it may be that these agents induce vascular endothelial injury 
and predispose the eyes to CNV. 
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g) Co-morbidity with other diseases 
Age-related multifactorial conditions such as atherosclerosis and Alzheimer’s disease seem 
to share some aetiological factors with AMD in which inflammatory mechanisms provide a 
possible common basis. Though chronic inflammation may not be causative, it may greatly 
influence the pathogenesis of these disorders. The Beaver Dam study found that subjects 
with gout and emphysema were associated with increased risk of advanced AMD (Klein et 
al. 2003).  Aging by itself is accompanied by an increase in systemic inflammatory 
mediators indicating that low-grade inflammation provide a common link between aging on 
the one hand and age-related diseases on the other (Krabbe et al. 2004).  It is still 
controversial on how systemic low grade inflammation is related to local disease in 
peripheral tissues such as the RPE-choroid complex. McGeer et al introduced the term 
‘auto toxicity’ to define a macrophage –directed attack on self proteins. It may be that a 
similar mechanism of action exists in AMD (McGeer et al. 2001). 
h) Anti-inflammatory agents in AMD 
The inflammatory response in AMD may represent an epiphenomenon or a true 
inflammatory process. A true inflammatory process would suggest the possible use of anti-
inflammatory drugs as therapeutic agents. 
Several investigators have studied the role of steroids as a treatment option for neovascular 
AMD (Penfold et al. 1995; Challa et al. 1998; Danis et al. 2000). Steroids have both anti-
inflammatory and anti-angiogenic properties. Initial reports on the use of intravitreal 
triamcinolne in neovascular AMD were promising. However, a prospective randomised 
controlled study failed to demonstrate a significant treatment effect in the long term (Gilles 
et al. 2003). Despite these equivocal results, intravitreal triamcinolone is being investigated 
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as an adjuvant to other therapies in various trials on the management of neovascular AMD 
(Spaide et al. 2005). 
Studies that examined a possible relation between the use of Aspirin and AMD found no 
relation (Christen et al, 2001). 
The recent evidence of the serological association of anti-chlamydia pneumonia antibodies 
and AMD makes oral tetracyclines a potential anti-inflammatory agent in AMD. 
Tetracyclines suppress leucocyte chemotaxis, inhibit lymphocyte proliferation, limit 
cytokines, inhibit angiogenesis and inactivate MMPs, collagenases and lipases. Wirostko et 
al proposed a trial with oral minocycline for early AMD as this drug is rapidly absorbed 
and attains high intraocular concentration (Wirostko et al 2004). 
The association of non-steroidal anti-inflammatory agents (NSAIDs) and the incidence of 
early ARM was investigated in a pooled cohort from three population based, prospective 
studies and no association was noted (van Leeuven et al. 2004b). However, a recent study 
indicated that patients with rheumatoid arthritis had reduced risk of AMD compared to 
controls suggesting that NSAIDs may be protective in AMD (McGeer and Sibley, 2005). 
COX-2 inhibitors such as celecoxib are known to be effective in arthritis. Clearly, more 
positive evidence of the role of NSAIDs in AMD is required before embarking on properly 
designed clinical trials on these agents in AMD. 
Statins are used universally in the prevention of cardiovascular end-points secondary to 
atherosclerosis. In addition to its action as a lipid lowering agent by inhibiting HMG-CoA 
reductase, statins display a pleiotropic effect on several mechanisms involved in the 
atherosclerotic plaque formation. Their anti-inflammatory activity and particularly their 
ability to down regulate endothelial cell activation induced by different stimuli strongly 
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suggest their possible use in conditions in which the systemic inflammation and the 
endothelial activation/damage are thought to represent key pathogenic mechanisms.  Statins 
exert their anti-inflammatory action by inhibiting mononuclear cell proliferation, 
decreasing secretion of cytokines, modulating lymphocyte function and reducing serum 
CRP levels. In addition, it is anti-angiogenic (Bocan, 2002). Despite having the ideal 
properties required to prevent and/ or treat AMD, the role of statins in AMD remains 
inconclusive. Though retrospective studies on the use of statins in AMD show a protective 
effect, prospective population based studies failed to show any benefit (Guymer et al. 
2005). 
3.1.4 Conclusion from Literature Review 
 
Much interest has recently been shown on the possible association between polymorphisms 
in genes encoding inflammatory mediators (CFH gene) and AMD. It is possible that the 
CFH gene is a permissive gene that plays a vital role in the elderly with low-grade systemic 
inflammation. We believe it would be appropriate to evaluate the biological effects of CFH 
gene and other inflammatory mediators in the elderly versus the young population (without 
low grade inflammation). Such studies will contribute to the development of new strategies 
in preventing and controlling chronic diseases in the growing elderly population. 
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3.2 Plasma Complement C3a des Arg in Age-related Macular 
Degeneration 
3.2.1. Introduction 
 
The complement system comprises of a complex of at least thirty enzymes and regulators 
and provides an innate immune defence mechanism. Three principal pathways are involved 
in complement activation: the classical, alternate and the mannose-binding lectin (MBL) 
pathways. Activation occurs when the components are cleaved into smaller pro-
inflammatory and larger proteolytic fragments, which subsequently activates the next step. 
Initiation of the classical complement pathway relies on the adaptive immune system and 
occurs by the interaction of antigen-antibody complexes with the C1q portion of the 
complement activation (fig. 3.1). The alternate pathway complement pathway is activated 
in an antibody-independent manner on microbial surfaces, biomaterials and by tissue type 
plasminogen activator leading to the formation of the converatase C3bBb. This convertase 
is also formed when factor D cleaves factor B bound to the C3b generated by the classical 
and the MBL pathway. In this way, the C3 convertase accelerates the classical and the 
MBL pathway. The MBL pathway is activated when MBL binds to carbohydrate structures 
on microbial surfaces.  
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 Fig 3.1: The complement pathways. 
All the pathways converge on the activation of the third component C3. Activation of C3 
results in a common trail to the development of membrane attack complexes (MAC) and 
other smaller pro-inflammatory molecules. C3 undergoes proteolytic cleavage into C3a and 
C3b. The C3a is a chemokine and is also called anaphylatoxins. C3a des Arg is produced 
through a two-step process involving three proteins of the alternate pathway: C3, adipsin 
(Factor D) and Factor B all of which are produced and stored in the adipocytes. The 
terminal Arg (arginine) of the parent molecule C3a is cleaved at the carboxy terminus by 
carboxypeptidase N to generate C3a des Arg. Though C3a des Arg by itself is not an active 
immunomodulator, only the des Arg form of C3a is present in normal human plasma and 
therefore, its plasma concentration is an indirectly reflection of complement activation, 
independent of individual complement component levels. It should be pointed out that C3a 
des Arg can potentially be generated from all three complement pathways.  
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This protein also has a distinct metabolic property from the parent C3a molecule in  
adipocyte lipogenesis. It is also called acylation stimulating protein (ASP) and stimulates 
triacylglycerol synthesis. By estimation of plasma complement C3a des Arg in subjects 
with age related macular degeneration (AMD) compared to age-matched controls, it is 
therefore possible to determine indirectly the role of systemic complement activation with 
particular emphasis on the pathways that link the host defence to the adipocyte biology in 
the pathogenesis of AMD. 
3.2.2 Materials and Methods 
3.2.2 a) Subjects 
 
Eighty one subjects with a clinical diagnosis of AMD were included in the study. The 
control group consisted of 38 healthy subjects without AMD (defined as the absence of 
drusen, pigmentary abnormalities and neovascular AMD). All enrolled subjects underwent 
a complete ophthalmic examination as described in section 2.2.2.  
3.2.2 b) Blood samples 
 
Venous blood was collected from all subjects in heparin tubes (SST-BD Vacutainer, BD 
Diagnostics, Oxford UK), centrifuged for 10 minutes at 1500 g at room temperature and 
the plasma was aliquoted and stored at –70°C within an hour of collection and then thawed 
when required. The samples were randomized so that the scientist who analyzed the 
samples was masked  of the clinical history of the subjects.  
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3.2.2 c) Competitive Enzyme linked Immunosorbent assay (ELISA) 
 
A commercially available competitive ELISA kit was used for the assay of C3a des Arg 
(Assay designs, Metachem, Northampton, UK). A brief outline of the assay design is given 
below (see protocol in appendix 2 for details). 
i) Plasma precipitation: Frozen sera were thawed and plasma proteins were precipitated 
from the sample as whole proteins compete with the complement in the assay. The 
supernatant was then diluted 1:200 fold in fresh tubes. 
ii) ELISA:  Microtiter plates coated with goat antibody specific to rabbit IgG were used in 
this competitive ELISA. First, 100µl of the serially diluted standards and the diluted 
samples were placed in each well in duplicate. Controls included zero standard (B0) and 
assay buffer only (for non-specific binding or NSB). Then 50µl alkaline phosphatase 
conjugated with C3a des Arg was added to each well except the blank wells. The capture 
antibody used was 50µl of rabbit polyclonal antibody to C3a des Arg. The plate was then 
incubated at room temperature for 2 hours at 500 rpm. Following 3 washes with 200µl 
wash buffer (0.5ml v/v Tween 0.05% in l litre of tris buffered saline), 200µl of p-Npp 
substrate (p-nitrophenylphosphate in buffer) solution was added to each well and incubated 
at 370C for one hour. The reaction was stopped by the addition of 50µl of stop solution 
(Trisodium phosphate in water) to each well. Absorbance was read at 405nm using an 
automated plate reader (Dynex Technologies, UK). The ELISA was repeated thrice on the 
same day and on 3 separate days to note precision and reproducibility of the ELISA. 
iii) Calculation of results: The net OD bound for each standard and sample was calculated 
by subtracting the average NSB OD from the average OD bound. The percent bound was 
calculated as Net OD/ Net Bo OD x 100. 
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The standard curve was plotted with the percent bound in the y-axis and the log of the 
concentrations of the standards in the x-axis. The concentration of C3a des Arg in the 
samples were determined by interpolation. 
3.2.2.d) Statistical Analysis 
 
The Statistical Package of the Social Sciences (SSPS version 11.0) was used for the 
analysis. The age and sex match was determined by ANOVA one-way. Results were 
reported as mean ± standard error of means (SEM). Plasma C3a des Arg concentrations 
between groups were tested by student’s t-test. Statistical significance was set at 95% 
(p<0.05). 
3.2.3. Results 
3.2.3.a) Characteristics of subjects 
Plasma complement C3a des Arg was analysed from 119 subjects consisting of 39 with 
ARM, 42 with neovascular AMD, and 38 controls. Age and gender distribution were 
similar in both groups of AMD and controls as shown in table 3.1. 
Table 3.1: Patient demographics 
 Control ARM CNV 
Age in years (SD) 78 (8) 76 (10) 81 (6) 
Sex (M:F) 16:22 15:24 21:21 
 
 
3.2.3.b) Estimation of Complement C3a des Arg 
The standard curve was consistent with the manufacturer’s values (Fig. 3.2.). The ELISA 
was reproducible and accurate. 
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Fig 3.2 Typical standard curve for C3a des Arg  
 
The mean ± SEM of plasma complement C3a des Arg in ARM (n=39) was 70.98 ± 8.97 
ng/ml compared to control group (n=38) with 65.98 ± 8.59 ng/ml (p=0.67, student’s t-test). 
The mean ± SEM of plasma complement C3a des Arg in neovascular AMD (n=42) was 
97.07 ± 14.68 ng/ml and was significantly raised compared to the control group (p=0.05, 
student’s t-test) and showed a positive trend compared to the ARM group (p=0.1, student’s 
t-test). The descriptive statistics of the plasma complement C3a des Arg in the three groups 
is shown in table 3.2 and depicted by the box-plot in fig. 3.3 
Table 3.2: Plasma C3a des Arg in the three groups 
  CONTROL ARM CNV 
Ist Quartile 23.6 23.6 38.2
Minimum 6.51 2.78 3.13
Median 54.6 54.7 71.9
Maximum 198 198 250
3rd Quartile 78.1 81.7 168
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Fig 3.3 Plasma C3a des ARG in the three groups 
3.2.4 Discussion 
 
The estimation of plasma C3a des Arg indirectly reflects systemic complement activation, 
independent of individual complement component levels. The liver is the main source of 
complement synthesis and the complement molecules constitute approximately 5% of the 
total serum proteins. Many extra-hepatic cells such as monocytes, endothelial cells, 
epithelial cells, adipocytes, glial cells and neurons also produce complements (Laufer et al. 
2001).  
This study showed an increase of plasma complement C3a des Arg in neovascular AMD 
compared to controls and patients with early disease. It suggests that systemic activation of 
the complement system may play a role in the development of CNV. Angiogenesis is a 
complex multi-step process that leads to neovascularization generated from pre-existing 
blood vessels. Sub-lethal injury by complement proteins permits release of growth factors. 
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In addition, products of the complement cascade also serve as powerful chemotactic 
stimulus, reinforcing the inflammatory process required for angiogenesis. A murine model 
of laser-induced CNV in mice revealed the deposition of C3 and membrane attack complex 
(MAC) in the neovascular complex and the CNV was inhibited by complement depletion 
using cobra venom factor. It is also interesting to note that CNV did not develop in C3 (-/-) 
mice (Bora et al. 2005). It may be that the systemic complement activation compounds the 
local complement concentration to initiate the process of angiogenesis. This is 
substantiated by studies that showed that systemic acute phase proteins such as C-reactive 
protein (CRP) are raised in AMD especially in advanced disease (Seddon et al. 2004). CRP 
activates the classic pathway and inhibits binding of C5b-9 through the direct binding of 
CFH (Mold et al. 1999).  
Moreover, Chlamydia pneumonia and cytomegalovirus which are also activators of 
complement system were recently implicated in the pathogenesis of AMD especially in the 
neovascular stage (Kalayoglu et al. 2003; Miller et al. 2004). These data are suggestive of 
the existence of multiple activators of complement system in neovascular AMD. 
The study also demonstrated that the plasma C3a des Arg did not alter significantly in the 
patients with early disease indicating that systemic activation of complements is not 
involved in ARM. Drusen are the hallmark for early disease. Several components of the 
complement cascade including C3 complement fragments, C5 and the membrane attack 
complex C5b-9 have been identified in drusen, the sub-RPE space and within the capillary 
pillars of the choroid. In addition, both fluid phase and membrane bound regulatory 
proteins such as vitronectin, clusterin, MCP and CR1 have also been immunolocalised in 
drusen (Johnson et al. 2000; Johnson et al. 2001; Crabb et al. 2002). Recent evidence also 
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indicates that transcripts for CFH and FHL1 (truncated isoform gene) in RPE-choroid 
complex approaches levels observed in liver (Hageman et al. 2005). The results of this 
study suggest that the complements identified in the drusen and surrounding area in the 
early stage of the disease may be from a local source and not from the circulation. Several 
components of the chronically sequestrated debris in AMD may be potential activators of 
the proteolytic cascade including apoptotic cells, nuclear fragments and membrane bound 
vesicles. Metabolic end products such as lipofuscin, phospholipids, advanced glycation end 
products, cholesterol and microfibrillar proteins may also serve as powerful chemotactic 
stimuli for leucocytes via the complement cascade (Johnson et al. 2001). 
The multiple biological activities of this complement cascade include control of 
inflammatory reactions and chemotaxis, clearance of immune complexes, cellular 
activation and antimicrobial defence. This depends on the balance between complement 
activators and regulatory proteins. Recent studies have shown that polymorphism in the 
regulatory protein, CFH is a risk factor for the pathogenesis of AMD (Klein et al. 2005; 
Edwards et al. 2005; Haines et al. 2005, Hageman et al, 2005).  It may be that the 
biogenesis of drusen is a result of the imbalance between potential activators and inhibitors 
of the complement cascade. The activation of complement induces cell lysis which in turn 
may account for at least a part of the cell debris characterised of drusen thus initiating a 
vicious cycle. 
It is also important to note the the complement component C3a des Arg has an active role 
in adipocyte lipogenesis. It is also called acylation stimulating protein (ASP). It is produced 
through cleavage of its precursor complement C3 by interaction of adipsin and factor B. All 
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three factors are made by adipocytes in a differentiation-dependent manner which results in 
an increased production of C3a des Arg.  
This protein in turn, increases triglyceride synthesis as well as glucose transport, therefore 
increasing overall fat storage. These changes can occur without changes in lipid 
parameters. Both C3a des Arg and C3 have been shown to be associated with 
cardiovascular disease in adults (Cianflone et al. 2003). It is interesting to note that that C3 
may be a strong predictor of cardiovascular disease (Cianflone et al. 2003). C3a des Arg 
has also been used as a systemic marker of lipid peroxidation.  
The conversion of C3 to C3a des Arg requires multiple factors. Adipsin is needed to cleave 
factor B to generate the membrane-attached active convertase (C3bBb), a properidin 
dependent pathway. Factor H, the main regulator of this activation, prevents formation and 
promotes dissociation of this C3 convertase enzyme, and, together with factor I, mediates 
the proteolytic inactivation of C3b. Therefore, Factor H deficiency, allows unhindered 
activation of C3.  The recent evidence of CFH mutation in AMD may explain the increased 
C3 activation in AMD. Increased C3 activation is also reported in membranoproliferative 
glomerulonephritis. Although, the role of C3 dysregulation in the pathogenesis of MPGN is 
not fully understood, it has been reported that uncontrolled C3 activation is essential for the 
development of MPGN associated with deficiency of factor H (Pickering et al, 2002). 
In conclusion, this work demonstrates a potential role for systemic complement activation 
in the pathogenesis of neovascular AMD. With the recent evidence of the risk of AMD in 
subjects with CFH mutation, it may be that C3 dyregulation mainly through the alternate 
pathway may be primary source of insult in AMD. Further studies are needed to clarify the 
influence of C3 activation in AMD. 
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Do changes in ocular haemodynamics contribute to the 
pathogenesis of age related macular degeneration? 
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Chapter 4: OCULAR BLOOD FLOW 
 
This chapter reviews the evidence published to date which suggests that AMD is associated 
with ocular perfusion defects, then describes experimental investigations carried out in 
attempt to provide further evidence of these defects in various stages of AMD. 
4.1 Ocular haemodynamics in age related macular degeneration  
4.1.1 Introduction 
 
Several studies have observed ocular perfusion defects in AMD. It is not possible to 
determine if these perfusion abnormalities play a causal role or is a consequence of AMD. 
Despite this, many therapeutic options for AMD are based on improving the macular 
perfusion in order to prevent or delay disease progression. This section reviews the ocular 
haemodynamics and the various techniques used to measure ocular blood flow in AMD. 
4.1.2 Anatomy of the ocular circulation 
 
Approximately 98% of the total ocular blood flow supplies the uvea, with 85% to the 
choroid making it the most vascular tissue in the human body. The choroid is responsible 
for the nutrition of the RPE and outer layers of the retina. In addition to providing the 
metabolic requirements of the outer retina, it also aids in temperature regulation. 
The choroidal circulation is characterized by high blood flow rate (approximately 1400 
ml/100 g per minute), low oxygen extraction and low vascular resistance.  The choroidal 
blood flow is mainly controlled by sympathetic innervations and is not auto regulated. 
Because of these features the choroidal vessels may be more susceptible to systemic 
vascular changes than the retinal circulation. The retinal circulation is characterized by low 
blood flow and high oxygen extraction. Retinal circulation lacks autonomic innervation, 
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shows an efficient auto regulation and is mainly influenced by local factors. The retinal 
circulation provides oxygen and nutrients to the inner aspect of the neural retina. The 
retinal capillary microvasculature has two distinct beds: the superficial capillary layer in 
the nerve fibre/ganglion cell layer, and the deeper capillary layer extending into the inner 
nuclear and outer plexiform layers. Unlike the choroidal circulation, the retinal blood 
vessels are end arteries.   
4.1.3 Aging changes in the ocular circulation 
 
Aging changes in the ocular circulation are similar to those found in general circulation. 
Arteriosclerosis affects both the retinal and choroidal circulation. In the adult retinal 
circulation, the endothelial cell: pericyte ratio is 1:1. Aging is associated with a decrease in 
the endothelial cells followed by a decrease in pericytes leading to sectors of acellular 
channels. Thickening of the basement membrane with the cellular loss leads to narrowing 
of the vascular lumen resulting in decreased retinal microcirculatory flow and reduced 
tissue perfusion (Lee et al. 1987). Decreased retinal macular circulation have been 
observed clinically using the Blue Field Entoptic Phenomenon in which a reduction of 
leucocyte density and velocity have been noted in the retinal macular capillaries with 
increasing age (Grunwald et al. 1993). 
Age related changes of the choroid may compound to RPE dysfunction. The thickness of 
the choroid and the diameter of the lumen of choriocapillaris vessels decrease with age 
(Ramrattan et al.1994). Moreover, there is an increase and elongation of the intercapillary 
space and a decrease in number of choroidal capillaries with resultant decreased choroidal 
blood flow with age (Sarks, 1976; Grunwald et al. 1998). 
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4.1.4 Physiology of ocular blood flow 
 
Blood flow through an organ is determined by perfusion pressure and local resistance to
blood flow. The perfusion pressure of the ocular circulation is related to systemic blood 
pressure and intraocular pressure by a relationship: ocular blood flow = (mean arterial 
blood pressure intraocular pressure)/vascular resistance (Riva et al. 1985). 
The potential causes of reduced ocular blood flow can therefore be caused by reduced 
perfusion pressure or increased local resistance. Increased resistance may be due to 
structural changes in the vessel wall or extrinsic anatomical changes that induce increase 
resistance to blood flow through the vessels.  
4.1.5 Ocular perfusion defects in AMD 
 
Ocular perfusion defects in AMD may either be a cause or effect of AMD. In support of 
primary ocular perfusion anomalies, Friedman proposed a vascular model (Friedman, 
1997). He suggested that increased lipid accumulation in the Bruch’s membrane and sclera 
leads to increased vascular resistance and impaired choroidal perfusion, which in turn 
affects the function of the RPE. This theory is supported by studies demonstrating an 
association between increased scleral rigidity and AMD (Friedman, 1989). 
The heterogeneous nature of AMD can also be explained based on increased choroidal 
resistance. An increase of choroidal resistance more than the cerebral vascular resistance 
leads to the accumulation of drusen due to an increased osmotic gradient against which the 
RPE must pump. On the contrary, if the increased choroidal vascular resistance is less than 
the cerebral vascular resistance, the high choroidal perfusion pressure facilitates the 
development of CNV in the presence of Bruch’s membrane cracks and an angiogenic 
growth factor milieu. 
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Earlier proponents of this theory thought ‘angiosclerosis of the choriocapillaris’ is a 
predisposing factor for disciform macular degeneration (Verhoeff and Grossman, 1937). 
The relationship of drusen to choriocapillaris associated with the collecting venules of the 
vortex vein points further in the direction of primary increased vascular resistance 
(Friedman, 1963). A recent study also demonstrated that equatorial autofluorescent drusen 
had specific spatial relationship to choroidal vessel walls (Lengyel et al, 2004).  
On the other hand, ocular perfusion defects may be secondary to the RPE senescence. The 
RPE plays a permissive role in the maintenance of the choriocapillaris. The growth factors 
such as VEGF that are physiologically secreted by the RPE cells maintain the integrity and 
conformation of the choroidal circulation. So RPE senescence coupled with the thickened 
and lipid laden Bruch’s membrane in AMD may result in the decreased density and 
diameter of the choriocapillaris and secondary ocular perfusion defects (Henkind et al. 
1983).  
4.1.6 Measurement of ocular blood flow 
 
It is difficult to quantify ocular perfusion defects. Different techniques have been tried to 
assess various aspects of the ocular perfusion to better understand the changes induced in 
AMD. They include fundus fluorescein angiography, indocyanine angiography, laser 
Doppler flowmetry, Colour Doppler Imaging, pulastile ocular blood flow, retinal laser 
Doppler and Heidelberg retinal flowmeter (HRF).  
 
a) Fluorescein angiography 
Fluorescein angiographic evidence of choroidal filling delay in AMD has been noted in 
several studies (Pauleikhoff et al 1990; Piguet et al. 1992; Chen et al. 1992; Holz et al. 
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1994). Morphologically, delayed choroidal perfusion correlates with diffuse thickening of 
Bruch’s membrane and functionally it correlates with discrete areas of increased threshold 
on static perimetry (Pauleikhoff et al 1990; Piguet et al. 1992). These eyes with choroidal 
perfusion defects are at risk of unfavourable visual prognosis (Chen et al. 1992). Holz et al 
noted that subjects with coexistent soft drusen and delayed choroidal filling were prone to 
progress to geographic atrophy than neovascular AMD (Holz et al. 1994). This finding 
substantiates the theory of primary ocular perfusion defects causing secondary RPE 
defects. 
b) Indocyanine angiography (ICG) 
The ICG better delineates the choroidal circulation than fluorescein because ICG is bound 
to plasma proteins which prevent its diffusion through the fenestrated choroidal capillaries. 
Secondly, the near infrared light absorbed by ICG penetrates the RPE better than the 
shorter wavelength absorbed by fluorescein and is therefore a better modality to assess 
choroidal circulation. Dilated arterial loops in the macula of patients with AMD 
substantiate the fact that macular choriocapillaries are subjected to relatively high 
intramural pressure. Increased frequency of presumed macular watershed filling (PMWF) 
in early phase indocyanine videoangiographic has been associated with neovascular AMD. 
These watershed areas represent ‘characteristic vertical, angled or stellate-shaped zones of 
assumed hypoperfusion’. Choroidal neovascularisation was found to arise from these zones 
(Ross et al. 1998).  
This subjective evaluation of choroidal perfusion defects has been supported by more 
objective area dilution analysis using ICG and scanning laser ophthalmoscope. The 
researchers evaluated the relative concentrations of ICG in four areas in the macula and 
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two areas in the temporal peripapillary retina and showed macular predilection of delayed 
choroidal filling in subjects with non-exudative AMD, with correlation to the severity of 
the disease and visual acuity (Ciulla et al. 2002). This technique has also been used to 
evaluate blood flow in feeder vessels of CNV (Yamamoto et al. 2003).  
 c) Laser Doppler flowmetry 
Pathologic changes in AMD have a predilection for the macula. The short posterior ciliary 
arteries that supply the choroid enter the globe in the macular area, each artery having its 
own territory in the choroid. The macula is also a watershed zone to the drainage of blood 
by the four vortex veins. Therefore, an age related decrease of macular blood flow by about 
20% may have a significant effect on the macular perfusion. The laser Doppler flowmetry 
measures the foveal blood flow and is a more specific test of the compromise of macular 
choroidal circulation in AMD. This technique cannot be readily applied outside the foveal 
centre as the overlying retinal circulation would Doppler shift the reflected light from the 
laser and prevent analysis of the choroids (Grunwald et al, 1998). 
Grunwald et al. confirmed alterations in the foveal blood flow in non-exudative AMD. In a 
recent study, they also observed that the mean foveolar choroidal blood velocity, foveolar 
choroidal blood volume and foveolar choroidal blood flow decreases with increased risk 
for CNV, suggesting a role for ischemia in the development of CNV (Grunwald et al. 
2005).  
d) Colour Doppler Imaging 
Evaluation of the retrobulbar vasculature gives an indirect estimation of ocular blood flow 
velocities. Studies using this technique have noted a reduction of blood flow velocities in 
both the central retinal artery and short posterior ciliary arteries indicating a global 
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reduction of blood flow favouring primary ocular perfusion defect in AMD (Friedman et al. 
1995; Ciulla et al. 1999). Other research groups observed significant increase in resistance 
in the posterior ciliary arteries in patients with unilateral exudative AMD compared to 
normal controls (Uretman et al. 2003; Hosal et al. 1998). 
e) Laser interferometric method 
Local fundus pulsation amplitudes (FPAs) are reduced at classic neovascular membranes in 
patients with AMD (Schmetterer et al. 1998). The mechanism behind this finding remains 
unclear. Future studies have to ascertain whether this observation is associated with 
changes in choroidal perfusion abnormalities. 
f) Pulsatile ocular blood flow (POBF) 
POBF reflects the total pulsatile component of ocular blood flow. The pulsatile component 
of the total blood flow ranges from 50% to 80% and is thought to represent the choroidal 
circulation. It is measured by a pneumotonometer based on a pressure volume relationship. 
This provides a non-invasive, reliable, reproducible and inexpensive method of calculating 
the average POBF from the IOP (Silver et al. 1989). POBF may be influenced by various 
factors such as age, sex, blood pressure, scleral rigidity, refractive error and axial length 
(Mori et al. 2001). A group-wise comparison between exudative AMD, non-exudative 
AMD and age matched controls in a Japanese cohort using pneumo-tonometry showed a 
significant decrease in POBF in exudative AMD (Mori et al. 2001b).  In addition, 
significant difference in POBF was found between eyes in asymmetric AMD in a 
Taiwanese group (Chen et al. 2001). This supports the notion that there is a global decrease 
in choroidal blood flow in AMD.  
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 g) Retinal laser Doppler 
Using the retinal laser Doppler, increased retinal blood flow pulsatility was observed in the 
retinal arteries of eyes with AMD compared to controls with no differences noted in mean 
blood velocity, arterial diameter or blood flow rate among the groups. The researchers 
suggested that an increasing vascular rigidity in the systemic arterial circulation is directly 
associated with an increasing severity of AMD (Sato et al. 2005).  
h) Heidelberg retinal flowmeter (HRF) 
HRF measurements in patients with AMD indicated an increased macular retinal capillary 
blood flow in patients with the exudative AMD and a decreased macular perfusion in those 
with the fibrotic form (Remsch et al. 2000). 
4.1.7 Retinal microvascular anomalies in AMD 
 
Arteriosclerosis results in generalised retinal arteriolar narrowing and is caused by intimal 
thickening, medial hyperplasia and hyalinisation and sclerosis. As the retinal arterioles can 
be visualised, the measurement of retinal arteriolar narrowing appears a feasible method of 
assessing arteriosclerosis.  However, retinal arterioles are small (50µm-200µm in width) 
and a wide variation in vessel calibre exists in the normal population. Moreover, retinal 
vascular calibre alters with age, sex, hypertension, smoking, diabetes and variations of 
intraocular pressure. Therefore significant confounding factors exist in the quantitative 
estimation of retinal vessel calibre. Several techniques have been used to assess blood 
vessel calibre in AMD.    
Hirvela et al. measured retinal vasculature using enlarged projected images (micrometric 
 120
methods) and observed significant retinal arteriolar narrowing in AMD (Hirvela et al. 
1996). However, the technique is rather subjective. With the advent of digital photography, 
newer techniques have been developed for retinal image acquisition. The retinal vessel 
analyzer (Seifertl and Vilser, 2002; Vilser et al. 2002) allows real-time assessment of 
retinal vascular diameters at a maximum frequency of 50 Hz and has demonstrated 
reproducible results (Polak et al. 2000; Pache et al. 2002). A major limitation of the retinal 
vessel analyzer is that it does not adjust for refractive errors. 
The scanning laser ophthalmoscope (SLO) (Nagel et al. 1992) provides a high-quality 
image of the fundus using less than 1: 1000 of the light necessary to illuminate the fundus 
with conventional light ophthalmoscopy. Because the SLO only illuminates a small area of 
the fundus at any one time, only a small amount of the patient's pupil is used for 
illumination. This means that pupil dilation is not usually necessary when acquiring fundal 
images with the SLO. However, the optical resolution of the SLO is currently only 10
20 µm per pixel, and therefore is currently insufficient to be able to produce accurate 
measurements of retinal vessels.  
The laser doppler flow meter also measures individual vessels and it takes numerous 
measurements over a 2-s time period, and therefore can be averaged to account for the 
different stages of the cardiac cycle. However, a significant drawback of the technique is 
that the resolution is limited to vessels greater than approximately 60 µm in diameter (Guan 
et al. 2003; Yoshida et al. 2003; Jonescu- Cuypers et al. 2004). 
Recently, computer driven micro densitometry based on the vessel’s gray scale profile have 
been used by Hubbard et al to evaluate arteriolar and venular diameters (Hubbard et al. 
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1991). They reported good intra-observer and inter-observer reliability. The ARIC study, 
Blue Mountain Eye Study and the Rotterdam study have used this technique to note retinal 
microvascular changes in AMD. Data from these epidemiological studies are consistent 
with respect to the retinal microvascular abnormalities associated with incident early ARM. 
The Beaver Dam study reported that retinal arteriolar diameters were not related with 10-
year incidence of early ARM (Klein et al. 2004). The Blue mountain eye study noted 
borderline significant association between retinal arteriolar focal narrowing and 
arteriovenous nicking with incident ARM but found no relation with generalized retinal 
arteriolar diameter (Wang et al. 2004b). The Rotterdam study found that smaller arterioles 
are associated with higher blood pressure while larger venules were related to 
atherosclerosis and inflammation (Ikram et al. 2005). However, both the retinal arteriolar 
and venular diameters were not related to the risk of incident ARM.  
4.1.8 Therapies based on ocular blood flow 
Although most of the studies above indicate the presence of ocular perfusion defects in 
AMD, it is not possible to determine if these perfusion abnormalities play a causal role or is 
a consequence of AMD. Despite this, many therapeutic options for AMD are based on 
directly or indirectly improving the macular perfusion in order to prevent or delay disease 
progression. 
 Friedman suggested that lamellar scleral resection could decrease scleral rigidity and 
thereby enhance choroidal perfusion and in turn arrest the progression of the disease 
(Friedman et al. 1989). Similarly, rheopheresis is a safe and effective modality of 
therapeutic apheresis to treat microcirculatory disorders and represents a novel treatment 
option for patients with dry AMD. Elimination of a defined spectrum of high molecular 
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weight proteins from human plasma including pathophysiologically relevant risk factors for 
AMD such as fibrinogen, cholesterol, von Willebrand factor, and alpha 2-macroglobulin 
results in the reduction of blood and plasma viscosity as well as erythrocyte and 
thrombocyte aggregation. It also decreases the circulating macromolecules involved in 
drusen formation, Bruch’s membrane degradation, and retinal pigment endothelial cell 
dysfunction. Lowering blood and plasma viscosity also increases ocular blood flow, 
subsequently inducing sustained improvement of microcirculation and recovery of retinal 
function (Pulido et al. 2005a). Two controlled randomized clinical trials demonstrated the 
safety and efficacy of rheopheresis for the treatment of AMD patients, especially for those 
with the dry form (Klingel et al. 2003). Recently the interim analysis of the sham-
controlled, double blind, randomized multicenter Multicenter Investigation of Rheopheresis 
for AMD (MIRA-I) trial confirmed these results (Pulido 2005b). 
Though rheopheresis is postulated to decrease drusen biogenesis by increasing blood flow, 
laser induced resolution of drusen is not associated with an increase in choroidal blood 
flow. The Complications of AMD Prevention Trial (CNVPT research group, 1998) used 
low intensity laser treatment to enable resolution of the drusen load. A study aimed at 
determining whether choroidal blood flow alterations were responsible for the resolution of 
drusen found no significant alterations in choroidal blood flow at three months after low 
intensity laser therapy (Figueroa et al. 2004). 
Several topical and systemic pharmaceutical agents that enhance ocular blood flow have 
been evaluated as treatment option in AMD. A Cochrane review on the role of Ginkgo 
Biloba, a drug that is postulated to increase blood flow and prevent oxidative stress, found 
 123
no evidence to inform clinical practice on the role of this drug in AMD (Evans, 2000). 
Therapeutic doses of niacin were also found to have no change in the net choroidal blood 
flow in AMD patients (Metelitsina et al. 2004). Similarly, Dorzolamide, a topical carbonic 
anhydrase inhibitor, was observed to increase peripapillary choroidal perfusion in non-
exudative AMD patients (Harris et al. 2003) while animal studies showed that drugs that 
increase nitric oxide production could specifically increase the choroidal blood flow (Xuan 
et al. 2003). Crocin analogs isolated from Crocus sativus L. were found to significantly 
increase the blood flow in the retina and choroid and to facilitate retinal function recovery 
(Xuan et al. 1999). Increased blood flow due to vasodilation presumably improves 
oxygenation and nutrient supply of retinal structures. A 3-month course of oral 
pentoxifylline treatment has been shown to increase choroidal but not retinal blood flow in 
patients with AMD (Kruger et al. 1998). 
A theoretical model that showed that occlusion of either Sattler arteriole or venules in the 
vicinity of the capillary-like vessels connecting a CNV to the underlying choriocapillaris 
resulted in significant blood flow reduction in the CNV (Flower et al. 2001). These results 
suggest that reduction of blood flow in the choriocapillaris may be the common 
haemodynamic event associated with the successful application of several currently 
practiced methods of treatment of CNV, including feeder vessel photocoagulation, 
photodynamic therapy and transpupillary thermotherapy. Ciulla et al. noted that 
transpupillary thermal therapy is associated with transiently decreased volumetric blood 
flow in the retinal circulation 24 hours after treatment while alterations in choridal blood 
flow existed at one month post-treatment (Ciulla et al. 2001, Chen et al. 2004).  
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4.1.9 Conclusion from Literature Review 
 Several techniques have been used to indirectly assess the changes in retinal and choroidal 
blood flow in AMD. Most studies provide qualitative evidence of choroidal perfusion 
defects at the macula. The fact that some studies show decreased choroidal perfusion in the 
stage of early disease suggests that choroidal insufficiency may be a primary cause rather 
than result of AMD. Nevertheless, none of the techniques seem to give an accurate 
assessment of the vascular disturbances. The results from epidemiological studies on retinal 
vascular disturbances in early ARM suggest that retinal blood flow is not affected in early 
disease though decreased blood flow through central retinal artery were noted using colour 
Doppler imaging. Further studies are required to accurately assess the choroidal and retinal 
circulatory changes in various subtypes of ARM to better understand its role in the 
pathogenesis of ARM.  
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4.2 Pulsatile blood flow and retinal microvascular calibre changes in 
patients with asymmetric age related macular degeneration 
4.2.1 Introduction 
 
Evidence from epidemiological studies has suggested associations between atherosclerosis, 
cardiovascular risk factors and AMD. One of the hypotheses that explain this association is 
Friedman’s vascular model (Friedman, 2000). He reported increased scleral rigidity, 
decreased blood velocity and increased blood pulsatility in the central retinal artery and 
short posterior ciliary arteries in subjects with AMD (Friedman, 1995). Based on these 
findings, he proposed that AMD is associated with an increase in resistance of the 
choroidal vasculature caused by a decrease in compliance of the sclera and the choroidal 
vessels. The resultant decreased choroidal blood flow is thought to alter the metabolism in 
the macular region impeding supply and removal of waste products.  
Several techniques have been used to measure ocular blood flow in AMD. Most techniques 
assessed the focal macular perfusion abnormalities. This study aimed at measuring the 
pulsatile ocular blood flow (POBF) in patients with asymmetric AMD. In addition, the 
retinal microvascular calibre changes especially generalized retinal arteriolar narrowing has 
been shown to predict the development of stroke, dementia and sub clinical cerebral 
vascular diseases (Ikram et al, 2005). Therefore, the retinal vascular calibre was assessed in 
this cohort to note if eyes with neovascular AMD (active CNV and/or disciform disease) 
have significantly more generalized arteriolar narrowing than fellow eyes with early 
disease (ARM).  
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4.2.2 Materials and Methods 
4.2.2.a) Sample size 
The sample size was calculated using UCLA power calculator. We designed this study to 
have a power of 80% to detect a difference in mean POBF of 20% between fellow eyes and 
a difference of mean equivalent arteriole: venule ratio (AVR) of 0.02 between eyes in 
asymmetric AMD subjects, at the 5% significance level. The sample size calculated was 15 
per group. 
4.2.2.b) Subjects 
The inclusion criteria were: age ≥50 years; Caucasian; evidence of asymmetric AMD. 
Exclusion criteria were: high myopia, history of any associated ocular conditions such as 
coexistent glaucoma, diabetic retinopathy and vascular disorders including veno-occlusive 
disease. Eyes with intra-ocular surgeries done in the previous year or laser treatment for 
CNV were also excluded.  
All subjects underwent slit-lamp biomicroscopy, fundus photography and fluorescein 
angiography to classify them into two groups. In addition, each subject had applanation 
tonometry, pulse rate, blood pressure and axial length measurement using the IOL Master 
(Carl-Zeiss, Germany).  
4.2.2.c) Definition of asymmetric AMD  
Group 1: Subjects with active CNV in one eye and early ARM in the fellow eye. 
Group 2: Subjects with disciform scar in one eye and early ARM in the fellow eye 
Early ARM was defined as the absence of late stage ARM and presence of either: (1) large 
(>125 µm diameter) indistinct soft or reticular drusen or (2) both large distinct soft drusen 
and retinal pigment abnormalities (hyper or hypopigmenation) within the macular area 
(Stage 2a to 3 as per Rotterdam study criteria). Disciform macular scar was defined as 
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presence of sub retinal fibrosis at the macula with blocked fluorescence and/ or staining on 
angiography with no associated haemorrhage or hard exudates. Active CNV was defined as 
the presence of serous or haemorrhagic detachment of the RPE or sensory retina, presence 
of subretinal or sub-RPE haemorrhages or exudates and angiographic evidence of classic 
and/ or occult CNV with a fibrotic component of less than 25% of the total lesion.   
4.2.2.d) Assessment of Choroidal blood flow 
The pulsatile ocular blood flow (POBF) was measured using the OBF Analyser (Ocular 
Blood Flow Analyser, Dicon Diagnostics, Paradigm, U.S.A, and Fig 4.1). Subjects were 
assessed in the sitting position by the same examiner who was masked to the diagnosis in 
each eye. The measurements were taken with a mounted probe after instillation of topical 
anaesthetic (0.5 % proxymetacaine). The computer software of the OBA identifies five 
pressure pulses out of a longer train of pulses that are closest to each other in beat to beat 
variation over 10-14 second interval. These five pulses are then averaged and used to 
calculate the pulse amplitude (PA). The software also calculated the pulse volume (PV) and 
POBF were also calculated from five pulses using previously described theory and methods 
(Silver et al. 1989). 
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 Fig 4.1 OBF analyser 
4.2.2.e) Retinal microvascular changes 
 
Retinal microvascular abnormalities were assessed using the methodology adapted from 
the ARIC Study (Klein et al. 2004). A 35° colour retinal photograph of each eye of each 
participant was taken after pharmacological mydriasis using a fundus camera (TOPCON 
fundus camera, Topcon Optical Co., Tokyo, Japan.). Centred between the optic disc and the 
macula, the photograph documented the optic disc, the macula, substantial portions of the 
temporal vascular arcades, and approximately 2 disc diameters of retina nasal to the optic 
disc. Using Adobe Photoshop 6.0 computer software, the photographs were cropped to 
include the disc and surrounding blood vessels and the ARIC grid (Fig. 4.1) was overlaid 
on the photograph to establish the measurement zone, the annulus between 1/2 and 1 disc 
diameter from the disc margin (zone B) as shown in fig. 4.2. 
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 Fig 4.2: ARIC grid overlaid on fundus photograph  
 
Before measuring the vessels coursing through the zone, the arterioles and venules were 
identified in the original colour slide and checked to avoid focally narrowed or distended 
parts. Vessels < 25 µm were ignored, since their edges often are not sufficiently resolved to 
measure accurately, and they have little impact on the central arteriolar or venular 
equivalent. It was then magnified four times in a separate window. The vessel edges were 
located by identifying the points at which the vessel became uniformly darker than the 
adjacent retinal pigment epithelium. Then, the segment of each vessel within zone B most 
suitable for measurement (based on image quality and straightness of the vessel) was 
identified. A mouse was used to mark the two edges of the vessel, drawing a circle with its 
centre on one edge of the vessel and its circumference on the opposite edge so that the 
radius gave the perpendicular width). The measurement of generalized arteriolar narrowing 
took approximately 10 to 15 minutes per eye. To monitor reproducibility of the grading 
technique, grading of selected samples were replicated.  
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Computation of summary variables 
To quantify generalized narrowing as an arteriole to venule ratio (AVR), measurements of 
individual arterioles and venules were combined according to the formulas developed by 
Parr et al (1974) and Hubbard et al (1999) respectively: 
 
 
  
in which Wc is the calibre of the trunk vessel, Wa the calibre of the smaller branch, and Wb 
the calibre of the larger branch. The largest vessel was combined with the smallest, the next 
largest with the next smallest, and so on until all were accounted for. If the number of 
vessels to be combined was odd, the single remaining vessel was carried over to the next 
iteration. The pairing process was repeated until the central equivalents of the arteriolar and 
venular diameters (CRAE and CRVE) were obtained, and their ratio (AVR) was calculated. 
(See appendix for details).  
4.2.2.f) Statistical analysis 
Multivariate logistic regression analysis was used to adjust the POBF for axial length (AL), 
intra-ocular pressure (IOP) and pulse rate (PR). POBF and its parameters were taken as 
dependant variables and IOP, AL and PR taken as the independent variables. Multiple 
regression analysis was also done to adjust CRAE, CRVE and AVR for age, sex and blood 
pressure. The paired Student t- test was used to compare the mean POBF between fellow 
eyes of each subject. P values of <0.05 were considered statistically significant. 
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4.2.3 Results 
4.2.3.a) Characteristics of subjects 
 
Thirty nine subjects with asymmetric AMD in the fellow eye were included in the study. 
This included 12 (31%) males and 27 (69%) females. 21 subjects were included in group 1 
(active CNV in one eye, drusen in the fellow eye) and 18 were included in group 2 
(disciform scar in one eye with drusen in the fellow eye).  The demographic details of 
subjects are given in table 4.1. No statistically significant difference in age or sex was 
noted between the groups. 
Table 4.1: Patient demographics 
 
 
Characteristics 
Group 1 
CNV/ARM 
Group 2 
Disciform/ARM 
 
p-value 
No. of pts 21 18  
Age in years (SD)  80 (7.87) 80.05 (6.2) 0.9 
Sex (M/F) 8/13 6/12 0.8 
 
4.2.3.b) POBF 
 
Table 4.2 shows the mean value of IOP, PA and POBF in the two groups. The mean IOP 
and PA showed no significant differences between the fellow eyes in both groups. The 
adjusted mean POBF was not statistically different between fellow eyes in either group.  
           
 
 
 
 
 
 
 
 
 
           Table 4.2 Mean value of IOP, PA and POBF in the two groups 
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 Mean IOP 
mmHg (SD) in 
each eye in the 
two groups 
Mean PA (SD) in 
each eye in the two 
groups 
Mean POBF µl/min 
 (SD) in each eye in 
the two groups 
Group 1 
(n=21) 
CNV 
ARM 
 
 
12.3 (4.6) 
11.7 (3.4) 
p=0.3 
 
 
3.2 (0.9) 
3.2 (1.0) 
p=0.8 
 
 
1153.2 ( 402.8) 
1148.6 (369.0) 
 p= 0.9 
*p= 0.3 
Group 1 
(n=18) 
Disciform 
scar 
ARM 
 
 
13.3 (3.4) 
 
13.8 (3.4) 
p= 0.4 
 
 
3.0 (0.9) 
 
3.0 (0.7) 
p= 0.9 
 
 
1052.0 (439.7) 
 
1000.8 ( 338.6) 
 p=0.4 
*p=0.4 
      *p= adjusted p value for IOP, PR and axial length; SD=standard deviation 
      The mean % increase in POBF in the CNV eyes compared to the fellow eye with early 
disease was 7% while the mean decrease in POBF in the eyes with disciform scar was 
0.01%. As the statistical significance was set at 20%, the change of POBF did not reach 
clinical significance in either group.  
Table 4.3: The mean differences in the PA and POBF in the two eyes in each group 
   Mean % change in PA 
between eyes 
Mean  % change in 
POBF between eyes 
Group 1 (n=21) 
CNV/ARM 
-1% +7% 
Group 2 (n=18) 
Disciform scar/ ARM 
0.09% -0.01% 
 
4.2.3.c) Changes in retinal vessels calibre 
 
Retinal microvascular changes are shown in table 4.3. The photographic quality was too 
poor to measure the vascular diameters in one subject in the ARM-CNV group and three 
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subjects in the ARM- disciform degeneration group. Therefore, a total of 20 patients were 
included in the ARM-CNV group and 15 patients in the ARM- disciform scar group. 
Table 4.4 illustrates that there is no significant change in calibre of the equivalent venular 
or arteriolar diameter in both groups. 
 
Table 4.4: Mean retinal vascular calibre in the two eyes of the patients in each group 
 Mean CRVE 
(SD)  
Mean  CRAE 
(SD) 
Mean AVR 
(SD) 
Group 1 
CNV 
ARM 
 
212.27 (34.86) 
215.17 (34.31) 
 
134.32 (29.91) 
139.94 (28.43) 
 
0.65 (0.18) 
0.66 (0.14) 
Group 2 
Disciform scar 
ARM 
 
222.91 (17.20) 
221.21 (17.60) 
 
147.86 (29.52) 
148.77 (29.84) 
 
0.66 (0.11) 
0.67 (0.11) 
 
4.2.4 Discussion 
 
The results of this study show that there is no significant change in POBF in the various 
stages of AMD in patients with asymmetric AMD. POBF measures the global choroidal 
blood flow. So the total choroidal blood flow remains practically unaltered in the various 
stages of AMD. However, various studies have observed focal perfusion defects in the 
macula in AMD. This may be because the macula is the watershed zone for the short 
posterior ciliary arteries and is therefore more susceptible to subtle changes in choroidal 
circulation.  
Studies assessing POBF in AMD show inconsistent results. Mori et al compared POBF 
between single eyes of Japanese subjects with neovascular AMD (11 eyes), non-
neovascular (10 eyes) and age matched healthy controls (69 eyes). The results were 
expressed as median with POBF being significantly lower in neovascular group (30% 
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decrease) compared to non-neovascular group AMD (p=0.02) and healthy controls 
(p=0.01). No significant difference was noted between non-neovascular AMD and controls 
(Mori et al. 2001b). When the data of the present study are analysed similar to the study by 
Mori et al., the median POBF in the neovascular group (CNV group 1087 µl/min and 
disciform group 950 µl/min) averaged at 1019 µl/min. The median POBF of all the eyes 
with early disease in this study was 1016 µl/min and therefore this study did not show any 
statistical difference in POBF on group wise comparison. However, group-wise inter-
individual comparison of POBF shows high inter-individual variation and therefore the 
validity of the methodology is threatened. In addition, Mori et al. did not define the 
neovascular group as eyes with disciform scar in this study were found to have lower 
POBF than the eyes with active CNV. 
A second study by Chen et al investigated differences in POBF in a Taiwanese cohort with 
asymmetric AMD between fellow eyes of the same subject thus eliminating the high inter-
individual variation in POBF (Chen et al. 2004). As the methodology and sample size was 
similar to this study, it enabled us to compare the blood flow characteristics in the two 
groups. In the Taiwanese cohort, the mean value of POBF, after adjusting for IOP and PR, 
was significantly lower in the eyes with drusen compared to fellow eyes with CNV but 
higher than fellow eyes with disciform scar. Though my study also adjusted for these 
factors, I found only a trend of increased POBF in the CNV group (mean increase of 7%) 
compared to fellow eyes with ARM. No change in POBF was found between eyes with 
disciform scar and ARM. It may be that other confounding factors exist. Both studies did 
not adjust for scleral rigidity and refractive errors that may influence the readings obtained 
by POBF.  
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Moreover, despite stringent measures in accurate assessment of POBF, the OBA may not 
be the ideal tool for assessment of total choroidal blood flow. The pulsatile component of 
the total ocular blood flow ranges from 50 to 80%. Further studies using other techniques 
to assess total choroidal blood flow may explain these inconsistencies and help us to 
understand better choroidal blood flow in AMD.  
In brief, even if the total choroidal blood flow may be reduced in AMD due to 
atherosclerosis, this study shows that the severity of AMD does not correlate with the 
amount of total choroidal blood flow in asymmetric AMD measured by OBA.    
This study also assessed the retinal vascular calibre in the same cohort. A semi-automated 
technique of computer analysis of the arteriolar and venular diameter was adapted from the 
ARIC study (Klein et al. 2004). There are inherent advantages in using AVR to quantify 
retinal vascular calibre. It adjusts for the wide range of vessel diameter in the normal 
population and offers protection against variable magnification from different refractive 
errors, poor photographic focus or ocular media clarity and inter-observer variations.  
 An AVR of 1.0 indicates the equivalent arteriolar diameter is equivalent to the venular 
diameter. Smaller AVR, in general, indicates retinal arteriolar narrowing though  
Ikram et al. noted that arteriolar narrowing may be an indicator of hypertension while 
venular dilation may be due to inflammation or atherosclerosis (Ikram et al, 2004). The 
mean AVR is smaller in men than women probably due to hormonal influence. Changes in 
AVR is less significant in the elderly population (>80 years old). This may be because the 
rigidity of the arteriolar wall caused by age related involutional sclerosis of the retinal 
arterioles may prevent the same degree of narrowing as seen in the younger counter parts. 
Logistic regression analysis was done to adjust for age and sex of the cohort and the retinal 
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vascular calibre did not alter significantly between eyes with asymmetric AMD in this 
study.  
Epidemiological studies such as the ARIC study, Blue Mountain Eye Study and the 
Rotterdam study have used this technique to note retinal microvascular changes in AMD 
and consistently found no association of generalized arteriolar narrowing with incident 
early ARM. This study, though of small sample size further points out that there are no 
significant changes in retinal microvascular abnormalities between eyes with varying 
severity of AMD. However, it should be stressed that this study is cross-sectional and it 
does not clarify the natural history of retinal changes and their temporal relationship with 
the progression of AMD.  Another limitation of this study is that adjustment for history of 
smoking was not done. Measurement of AVR using the methodology in this study is 
practical only in a research setting and is too tedious to be used in clinical setting. As a 
fully-computerized retinal analysis software package is now available, it may be useful to 
consider a longitudinal study to assess the changes in retinal vascular calibre in late 
incident ARM.  
4.2.5 Conclusion 
 
This study shows that there is no significant change in pulsatile component of the ocular 
blood flow or retinal microvascular abnormalities between eyes of patients with 
asymmetric AMD. Even if generalized retinal and choroidal vascular insufficiency due to 
atherosclerosis may play a role in AMD, this study shows that the severity of AMD does 
not correlate with generalized ocular blood flow or retinal vascular calibre changes.  
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CHAPTER 5: GENERAL DISCUSSION 
Since the introduction of the vascular hypothesis by Verhoff and Gossmann, the exact 
contribution of atherosclerosis to the development of AMD still remains unclear (Verhoff and 
Gossmann, 1937). Most epidemiological studies have addressed this hypothesis by studying 
various cardiovascular risk factors in AMD and the resultant data is inconsistent. 
5.1 Objectives 
The objectives in this thesis were to address ways in which AMD is linked to atherosclerosis. In 
the review on the disease related changes in the Bruch's membrane and the vascular wall, it is 
noted that the common primary pathogenic event is the accumulation of debris in both structures 
and this is postulated to initiate a pathologic cascade resulting in the ultimate clinical syndrome 
associated with atherosclerosis and the various subtypes of AMD. 
From an early life, the vascular wall is subject to injury such as lipid deposition, hypoxia, reactive 
oxygen species, enzymatic degradation and products of inflammation. ECM remodelling is an 
important response to injury. Similar insults affect the RPE-Bruch's membrane complex. So the 
first hypothesis in this thesis is that the pathogenesis of AMD, akin to atherosclerosis, is a 
response to injury that partly manifest as ECM remodelling. 
Secondly, atherosclerosis is re-defined as an inflammatory disease. The recent finding of a strong 
link of CFH gene with AMD supports our hypothesis that the injury in AMD similar to 
atherosclerosis may be due to inflammation induced by the various insults mentioned above. So 
both diseases are parallel response to injury as shown if fig 5.1. 
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Fig 5.1: Schematic diagram of the first hypothesis that link atherosclerosis and AMD 
The second hypothesis is that AMD may be secondary to vascular insufficiency induced by 
atherosclerosis as depicted in fig 5.2. Thickening and stiffening of the ophthalmic artery and 
retinal and choroidal circulation by atherosclerosis which may lead to decreased vascular lumen 
diameter, an increased blood flow resistance, diminished blood flow and reduced tissue perfusion. 
This process may then directly impair the metabolism of the RPE or lead to leakage and 
deposition of proteins and lipids due to elevated hydrostatic pressure as proposed by Friedman 
(Friedman, 1997). 
                                               
 
 
 
 
 
 
 
 
 Inflammation  Enzymatic 
Degeneration
Lipid 
deposition 
Hypoxia ROS 
Damage to vascular wall 
and RPE-BM complex 
Atherosclerosis AMD 
Reduced blood flow through choriocapillaris 
 
Atherosclerosis
Fig 5.2: Sch
 Reduced metabolism of RPE/ elevated hydrostatic pressure AMD 
ematic diagram of the second hypothesis  
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5.2 Methodology 
5.2.1 Study design: All studies in this thesis are prospective case control studies. The 
prospective study made it possible to determine a temporal relationship. However, the studies 
were clinical based and had a potential for selection bias. To the best of our knowledge, all basic 
science studies done to test the first hypothesis in this thesis are novel and have not been done 
before. Therefore, these were pilot projects done with small sample sizes though they were 
sufficiently powered to obtain a statistical significance.  
5.2.2 Definition of ARM: Definition of ARM was based on the nomenclature suggested by the 
International Epidemiological Study Group for ARM. The Rotterdam study divided ARM into 5 
mutually exclusive groups to quantify the progression of ARM. In the basic science projects in 
this thesis, ARM was classified into two groups: ARM group signified early disease (group 2 and 
3 of Rotterdam study) and CNV signified the neovascular AMD group. Larger sample sizes will 
be required to classify the subjects into the 5 groups of Rotterdam study in order to obtain 
statistical power. Secondly, subjects with geographic atrophy were excluded from the study 
because of the relatively low incidence of these subjects in clinics. 
5.2.3 Confounding factors: Even though many potential confounders were adjusted, the 
possibility of insufficient measurement of confounders or the presence of unknown confounders 
should be considered in these cross-sectional studies. None of the studies in this thesis adjusted 
for factors related to oxidative stress. In Chapter 4.2, the work would have been more robust if 
smoking and refractive error were adjusted for the calculation of retinal vessel calibre in this 
cohort though it could be argued that it should not affect the results as the comparison was 
between eyes of the same subject.. 
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5.3 Results 
In the second chapter, S-EDP and circulating MMP-9 were found to be increased in both early and 
neovascular AMD compared to age- matched controls. These findings support the hypothesis that 
AMD share similar extra cellular matrix changes to atherosclerosis. The degradation of ECM 
protein is tightly regulated and is essential for cellular migration. Macrophages are the main 
effector cell types in chronic inflammation and several studies have observed increased activity of 
macrophages in AMD. Macrophages are important sources of MMPs especially MMP-9. The 
leucocyte derived MMPs are predominant early mediators of matrix degradation. The finding in 
this thesis that circulating MMP-9 is raised in AMD may indicate that a state of chronic low-
grade inflammation exists in these subjects elaborating sufficient systemic MMP-9 that may 
partly be responsible for the matrix turnover as evidenced by increased S-EDP in AMD. AMD 
may contribute to or is the result of systemic elastin turnover.  
The precise source of circulating S-EDP is unclear though the vascular wall is the most likely 
source. This may help explain the association of AMD with atherosclerosis. Higher levels of S-
EDP in neovascular AMD suggest that S-EDP may be involved in the pathogenesis of CNV. The 
precise mechanisms of ECM remodelling in AMD remains speculative and require further 
investigations. By correlating MMP-9 and S-EDP, it is noted that MMP-9 is not the sole 
proteolytic enzyme that is responsible for elastin degradation. Systemic MMP-2 is predominantly 
secreted by the endothelial cells and this may explain why it is not raised in AMD. Previous 
studies on other systemic endothelial cell markers have also not observed any significant relation 
to AMD. It is important to investigate the potential role of other elastolytic enzymes and the 
balance of systemic MMP-TIMP in AMD. 
Although S-EDP and plasma MMP-9 were found to be elevated in AMD in this thesis and similar 
elevated levels have been noted in AAA, there was no significant association between AMD and 
 141
AAA in the cohort studied. However, these findings may be attributable to survivor cohort effect 
and statistical constraints. The incidence of neovascular AMD increases with age while patients 
with AAA unless screened early have a high mortality rate at an age at which the rate of 
neovascular AMD is low. The association can only be determined in a cohort of patients who have 
survived AAA repair.  
In order to elucidate whether atherosclerosis and AMD are the common result of low grade 
chronic inflammation, the role of systemic complement activation in varying grades of AMD was 
observed. Raised C3a des Arg was noted in neovascular AMD. The recent evidence that CFH 
mutations are associated with increased risk of AMD in combination with the results of this study 
indicate the need for estimation of other complement proteins in the alternate pathway in larger 
cohorts to better understand the role of complements in AMD. Previous elegant studies have 
shown local complement activation in drusen biogenesis but more work is needed to note the role 
of systemic complements especially in neovascular AMD. 
The second hypothesis is that vascular insufficiency induced by atherosclerosis is associated with 
AMD. I looked at whether the severity of AMD correlates with reduction of global ocular blood 
flow by measuring the POBF in patients with asymmetric AMD. There were no significant 
changes in POBF between eyes in a group of patients with early ARM in one eye and CNV in the 
other or in the second group with early changes in one eye and disciform degeneration in the 
other. As this technique of measurement of ocular blood flow shows high inter-individual 
variations, POBF was compared between eyes of the same subject negating that effect. However, 
no adjustments were done for refractive errors although these factors should not affect the results 
significantly given that, adjustments were made for axial length and pulse variations. Therefore, 
from these findings on this small cohort of patients, it is logical to assume that global choroidal 
blood flow does not correlate with severity of AMD.  
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Retinal vascular calibre changes were also measured in the same cohort using semi-automated 
computer software adapted from the ARIC study and this study found no significant difference in 
retinal vascular calibre between the two eyes of these patients with asymmetric AMD.  
Therefore, from the studies in this thesis, it may be inferred that atherosclerosis and AMD are 
parallel tissue responses to similar noxious stimuli supporting the first hypothesis. The findings 
from this study did not support the second hypothesis. Measures used to test the second hypothesis 
are indirect approaches to measure the effect of vascular insufficiency on the severity of AMD but 
no correlation was obtained.  
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CHAPTER 6: CONCLUSION 
 
Considering the results of the clinical and basic investigations in this thesis, it may be 
postulated that AMD should not be regarded as a single entity. The disease may be part of 
an age-related multi-system disorder probably linked by low-grade inflammation and/ or 
oxidative stress that induce similar ECM changes in various tissues in the body such as the 
vascular wall and the Bruch’s membrane. The effect of multiple inflammatory markers on 
measures of oxidative stress and ECM degradation may be influenced by many genetic and 
environmental factors. The combination of these determinants may decide the age of onset, 
rate of progression and final stage of AMD.  
These issues have to be evaluated together in larger prospective cohorts to test this 
hypothesis. 
The recent emergence of the CFH gene in the pathogenesis of AMD supports the role of 
inflammation in AMD. Complement activation also plays an important role in 
atherosclerosis. It may be that this gene plays a permissive role in the above postulation.  
Although vascular insufficiency due to atherosclerosis may be related to AMD, the results 
of this study on ocular blood flow and retinal microvascular changes suggest that the 
severity of AMD does not correlate with the degree of vascular insufficiency.   
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CHAPTER 7: FUTURE WORK 
 
The studies in this thesis have shown that S-EDP and MMP-9 are raised in AMD 
suggesting that ECM changes in AMD may be of a systemic process. However, correlation  
between S-EDP and MMP-9 was not demonstrated indicating that other elastolytic 
enzymes or the balance of systemic MMP-TIMP may play a role.  
These findings deserve further investigations in a large prospective cohort. An ideal 
prospective study should simultaneously evaluate a number of elastolytic enzymes and the 
role of systemic MMP-TIMP in AMD in order to evaluate if one of these is superior to the 
others or if these enzymes complement each other in elastin degradation. 
In addition, it will be useful to estimate the role of circulating anti-elastin antibodies in 
patients with AMD of varying severity. Another important work related to elastin would be 
to look at the presence of altered elastin gene transcription in patients with AMD compared 
to an age matched control group.  
The study on the association of AAA and AMD did not reveal a link despite the fact that S-
EDP increases with severity in both conditions. Failure to find any significant association 
between AAA and AMD may be due statistical power constraints and survival bias. So 
future studies of larger cohorts aimed at persons who have survived AAA repair may give a 
definitive answer as to whether there is an association between the two conditions. 
However, recruitment of subjects from a single institution may prove difficult. 
Systemic complement activation as measured by plasma C3a des Arg was found to be 
increased in patients with neovascular AMD. Complement C3 is the central protein in the 
complement cascade.  It will be worthwhile to measure multiple complement proteins 
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especially in the alternate pathway, given the recent evidence of CFH gene in the 
pathogenesis of AMD.  
Moreover, oxidative stress activates complement through the lectin pathway and as 
oxidative stress plays an important role in the pathogenesis of AMD, it will be useful to 
estimate the role of the serine proteases in the lectin pathway such as serum MBL 
(mannose binding lectin) in patients with AMD.  
Genetically-engineered deficiencies of specific complement components such as C3 
knockout mice may also offer opportunities for specific evaluation of the role of different 
components of the complement system in the pathogenesis of both early disease and 
neovascular disease.   
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APPENDIX-1 
Ethics Committee Approval I 
 
King's College Hospital Research Ethics Committee 
Research Ethics Office 
2nd Floor Hambledon Wing 
King's College Hospital 
Denmark Hill 
London SE5 9RS 
Email: Sophie.Bonser@kingsch.nhs.uk 
Website:www.corec.org.uk 
Tel: 020 7346 3923 Fax 020 7346 5085 
 
07 October 2003 
 
Mr Victor Chong 
King's College Hospital 
Consultant Ophthalmic Surgeon 
King's College Hospital 
Denmark Hill 
London 
SE5 9RS 
 
Dear Mr Chong 
 
Re: LREC Protocol No. 02-156 
Human DNA and serum sample collection and phenotypic characterisation of age-
related macular degeneration. 
 
Thank you for your letter regarding clarification on the use of blood samples from this 
collection outside King’s College Hospital. 
 
I am happy to confirm that if your protocol allows laboratory analysis of samples in this 
study at laboratories outside King’s, this is satisfactory ethically from our point of view. 
 
King’s College Hospital is compliant with ICH GCP guidelines. 
 
Yours sincerely 
 
Dr. D Jewitt 
Chairman, Research Ethics Committee 
King’s College Hospital 
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King’s College Hospital NHS Trust
King’s College Hospital
Denmark Hill London SE5 9RS
Direct tel: 020 7346 4548  
Direct fax: 020 7346 3738
Patient information Sheet 
 
Title: Human DNA and serum sample collection and phenotypic characterisation of 
age-related macular degeneration 
 
Lead Researcher: Victor Chong 
 
King’s protocol number: 02-156 
 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take the 
time to read the following information and discuss it with others as necessary. Do ask us if 
there is anything that is not clear or if you would like further information. Take time to 
decide whether or not you wish to take part. 
 
Background and purpose of the study 
 
Age-related macular degeneration (AMD) is a disease affecting the central portion 
(macula) of the light sensitive layer of the eye (retina) which mediates accurate vision. 
During ageing, the macula is susceptible to a loss of retinal tissue (atrophy) and growth of 
new blood vessels which destroys the retinal tissue. The condition causes loss of the ability 
to see accurately so that tasks such as driving, reading, watching television, and 
recognising faces are difficult or impossible to perform. Peripheral vision is usually 
preserved and so navigation is possible in familiar surroundings, although more difficult. 
AMD is the commonest cause of visual impairment in the Western world. It accounts for 
over 50% of blind registration and is estimated to affect over approximately 3 million 
people in the UK. Unfortunately, there is no effective treatment for the disorder and 
presently no way of preventing the disease from occurring in those who may be 
susceptible. 
 
Although AMD is not usually inherited in a straight-forward way in families, previous 
work does suggest an important genetic component to the disease, such that a person’s 
chances of developing the disease in old age depends strongly on the genes that they are 
born with and inherit from their parents. Presently the specific genes that may be  
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important in AMD are unknown. The discovery of these genes and their further study 
provides the clearest hope of developing treatments and preventative measures for people 
who suffer from the disease.  
 
In order to help investigators throughout the country and abroad discover these important 
genes, we at King’s College Hospital in collaboration with Moorfields Eye Hospital, are 
asking the help of patients with AMD and those without the disease (controls) and if they 
are willing, entering them into a national study. The study involves taking photographs of 
the eyes after having dilated the pupils with eye-drops and taking a blood sample for the 
research. The study intends to recruit 3000 patients over 3 years. The blood samples will 
then be used by other researchers to detect any differences in the genes that may cause 
AMD, in patients with the disease compared to those without. 
 
Why have I been chosen? 
 
You have been chosen either because you have age-related macular degeneration, or 
because you have some changes that are associated with ageing but do not presently 
threaten your vision, or because you have entirely normal retinas and so would be suitable 
as a control in the study. The doctors and nurses in the clinic will explain to you which of 
these categories you are in. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. If you decide not to take part this 
will not affect the management of your eye problem in the clinic in anyway. 
 
What will happen to me if I take part? 
 
If you do decide to take part, your examination is exactly the same as would happen 
anyway when you are seen in the eye-clinic. The routine examination involves a doctor 
examining your eyes by using a microscope and having some photographs taken after your 
pupils have been dilated with eye-drops. These drops sting for a few seconds but otherwise 
are not uncomfortable. After your examination, we would like to ask you a few questions 
and take a small blood sample from you for our research study. This sample will then be 
available to other scientists who are investigating the genes that may cause AMD in the 
future.  
 
What are the side-effects and possible disadvantages of taking part? 
 
The only side-effects are those of the eye-drops. If you take part in the study you will spend 
longer in the clinic than if you do not as the doctors will be spending time explaining the 
study to you and taking the blood sample. There are no other disadvantages to taking part 
in the study. 
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Will my taking part in this study be confidential? 
 
If you consent to take part in the research, your identity will be known only to the small 
number of doctors at the hospital who have been involved with you during the examination. 
Otherwise the study is entirely confidential. Each patient is assigned a research number and 
the link between this number and your name will be accessible only to the doctors who 
have been involved in your examination. It is intended to make your DNA available to 
other investigators who are trying to discover the genes that might cause AMD. However, 
they will not be able to trace your name or other personal details as they will only have the 
research number for each of the blood samples.  
 
What will happen to the blood sample? 
 
The blood sample will be processed in the laboratory to extract the genetic material (DNA) 
from the cells.  This DNA can then by analysed to look for genes that we think may have 
an effect on the risk of developing AMD.  In addition, some of the sample may be 
processed in a special way to create what is called a cell line. This means that the cells from 
the blood can be kept growing in the laboratory to increase the amount of DNA that can be 
obtained from the sample. This is done in the hope of ensuring that we will have enough 
DNA for the many experiments that will need to be done before the genetics of AMD is 
completely understood. Certain specific components of the blood sample will be analysed 
to look for specific compound in the blood that may have an effect on the risk of 
developing AMD. 
 
What will happen to the results of the study? 
 
Any results that emerge from the study will be published in scientific and medical journals. 
In addition, the information collected will be stored on computer and may also be used by 
pharmaceutical companies in an attempt to develop a therapy for people with AMD. The 
results from the study will be anonymous and the identity of individuals taking part will not 
be declared. It will not be possible for you to learn of the results of tests on your blood 
sample in this study. 
 
Who is funding the research? 
 
The Medical Research Council (MRC) is funding the collection of DNA samples from 
persons with AMD and control persons over a three year period. Future studies on the 
blood samples from this collection will be undertaken by various other groups and funded 
separately. 
 
Who has reviewed the study? 
 
The study has been reviewed by scientific and medical experts recruited by the MRC. The 
research has also been reviewed by the Ethics committee at King’s College Hospital and 
Moorfields Eye Hospital. Any future studies on the blood samples will have also been 
carefully reviewed by a panel of experts, and this fact will be ensured by the investigators 
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and curators of the blood sample collection at King’s College Hospital and Moorfields Eye 
Hospital. 
 
How long will the research last? 
 
Although the collection of blood samples will last three years, it is not known how long the 
research on those samples will last. It is intended that large number of blood samples 
generated from this collection will be available for many years afterwards to doctors and 
scientists as more genes that might cause AMD are discovered. However, the identity of 
the people providing the blood samples would remain unknown to them. 
 
 
How many times do I need to visit the hospital for the study? 
 
You only need to be seen once for the study. However, we are asking each participant if 
they would agree to be contacted for a further examination should this be useful in the 
future for the research. There is no obligation for you to choose to do this. Also, if you do 
choose to agree to be contacted there will still be no obligation for you to be examined 
again in the future should you change your mind. 
 
Contact for further information 
 
Please ask any questions you have about the study before deciding to take part. If you wish 
to contact someone once you have left the hospital about the study please contact the 
doctor/genetic research co-ordinator below who will be able to answer any questions you 
may have. 
 
Victor Chong 
Consultant Ophthalmic Surgeon 
Tel: 020 7346 4548 
 
PIS: Version 2 Date: 3rd September 2002
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King’s College Hospital NHS Trust
King’s College Hospital
Denmark Hill London SE5 9RS
Direct tel: 020 7346 4548  
Direct fax: 020 7346 3738
Consent Form 
 
Title: Human DNA and serum sample collection and phenotypic characterisation of 
age-related macular degeneration 
 
Lead Researcher: Victor Chong 
 
King’s protocol number: 02-156 
Patient Trial Number: 
 
I confirm that I have read and understand the information 
sheet dated 3rd September (version 2) for the above study  
and have had the opportunity to ask questions.  
 
I understand that my participation is voluntary and that I   
am free to withdraw at any time, without giving any  
reason, without my medical care or legal rights being affected. 
 
I understand that sections of any of my medical notes may be looked at by responsible 
individuals authorised by the lead researcher or from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these individuals to have 
access to my records.  
 
I consent for my blood sample to be studied by other researchers at other Institutions 
 for research into age-related macular degeneration.  
 
Print Name…………………….   Signature………………………   
Date…./……../…….../ 
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Ethics Committee Approval II 
Cranfield University 
Silsoe 
Bedfordshire  
MK 45 4DT 
England 
Tel: +44 (0) 1525 863000 
Fax: +44 (0) 1525 863001 
www. silsoe.cranfield.ac.uk 
 
Institute of Bioscience and Technology 
28th June 2004 
 
Dear Sobha 
Re: Human serum sample collection and phenotypic characterisation of age-
related macular degeneration 
I am pleased to confirm that the Cranfield University at Silsoe Clinical Research Ethics 
committee is satisfied that you have taken into account all the appropriate data protection and 
ethical considerations which affect Cranfield University as a result of you undertaking the 
aforementioned study, and are therefore happy for you to proceed subject to the following terms 
and conditions. 
1 wish to remind you that should you make any subsequent alterations to the protocol of 
the aforementioned study which is likely to affect matters concerning data protection 
and/or the ethical position; the committee must be informed immediately. 
Approval to proceed is limited solely to the recruitment of volunteers who are members of staff 
or currently registered for a higher degree at Cranfield University at Silsoe. Barton Road, Silsoe. 
MK.45 4DT. It is your responsibility to obtain appropriate approval to undertake any research 
related to this project in or at any external organisation. Approval is limited to providing 
"control" samples as part the study: Human DNA and serum sample collection and phenotypic 
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characterisation of age-related macular degeneration - Kings College Hospital Study number: 
02-1 56. All conditions imposed under this approval must be adhered to as part of this approval. 
It is your responsibility to ensure that the University is indemnified against legal action incurred as 
a result of you undertaking this research. 
I wish you well in the project 
 
Dr. Anthony Woodman BSc (Hons), MSc, PhD 
Head, Cranfield Biomedical Centre. 
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Volunteer information sheet 
 
Study Title – Estimation of serum elastin derived peptides in patients 
with age related macular degeneration and controls.  
 
You are being invited to take part in a research study.  Before you decide to take part it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with your 
friends, relatives and your GP if you wish.  Ask us if there is anything that is not clear or if 
you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled “Medical Research 
and You”.  This leaflet gives more information about medical research and looks at some 
questions you may want to ask.  A copy may be obtained from CERES, PO Box 1365, 
London N16 0BW. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
 
Age related macular degeneration is the commonest cause of blindness in the elderly in the 
western world. In spite of its public health impact, the cause of the disease remains largely 
unknown. Several theories suggest age related changes in the Bruch’s membrane of the 
choroid layer of the eye to be related to the pathogenesis of the disease.  
The Bruch’s membrane is a penta-laminar structure that separates the retinal epithelium 
from its nutrition. It has a central elastic layer that is shown to fragment with age. 
Fragmentation of elastin releases elastin derived peptides in the circulation. This project 
aims to estimate serum elastin derived peptides in patients with age related macular 
degeneration and an age matched control group to estimate and compare elastin turnover in 
the two groups. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.  If you decide 
to take part you are still free to withdraw at any time without giving a reason.   
 
What will happen to me if I take part? 
 
You will be asked to give one 10ml blood sample, which will be taken by the Medical 
Centre Nurse. 
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What are the possible disadvantages and risks of taking part? 
 
The risks associated with this are minimal and are those normally associated with taking a 
blood sample – you may suffer some discomfort and slight bruising in the area from which 
the blood was taken. 
 
What happens when the research study stops? 
 
Any samples remaining at the end of the study will be destroyed.  The results will be 
analysed and will be used to form the basis of a publication. 
 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this research will be kept 
strictly confidential.   
 
 
Who is organising and funding the research? 
 
The research is being run and funded by Cranfield Biomedical Centre. 
  
Who has reviewed this study? 
 
The Cranfield Biomedical Ethics Committee. 
 
 
Contact for further information 
 
Should you have any queries about this study, please contact: 
 
Dr. Sobha Sivaprasad 
s.sivaprasad.s03@cranfield.ac.uk. 
Or 
Dr. Tracey Bailey 
t.a. bailey@cranfield.ac.uk 
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Volunteer Consent Form 
 
Study Title – Estimation of serum elastin derived peptides in patients 
with age related macular degeneration and controls.  
 
 
 
Please initial all boxes: 
 
1 I confirm that I have read and understand the information sheet for the above 
study and have had the opportunity to ask questions 
 
2 I understand that my participation is voluntary and that I am free to  
withdraw at any time. 
 
3 I agree to take part in the above study. 
 
 
• Name of Volunteer……………………………………………. 
 
 
Signature……………………………..Date……………….. 
 
 
• Name of person taking consent……………………………. 
 
 
Signature……………………………..Date……………….. 
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Ethics Committee Approval III 
King's College Hospital Research Ethics Committee 
Camberwell Building 
King's College Hospital 
Denmark Hill 
London SE5 9RS 
Email: Janet.Browning@kingsch.nhs.uk 
Tel: 020 7346 3923 Fax 020 7346 5085 
 
26 November 2004 
 
Mr Victor Chong 
King's College Hospital 
Consultant Ophthalmic Surgeon 
King's College Hospital 
Denmark Hill 
London 
SE5 9RS 
 
 
Dear Mr Chong 
 
Full title of study: Age-related macular degeneration in patients with abdominal 
aortic aneurysm 
REC reference 
number: 
04/Q0703/121 
   
Thank you for your letter, responding to the Committee’s request for further information on 
the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
The further information was considered at the meeting of the Sub-Committee of the REC 
held on 24 November 2004.   
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
The favourable opinion applies to King’s College Hospital.  
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Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document.  You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Type: Version: Date Received: 
Application  Version 2 dated 17 
November 2004 
17/11/2004 
Investigator CV   27/09/2004 
Protocol  version 1 dated 
23/09/2004 
27/09/2004 
GP/Consultant Information 
Sheets  
GP Letter Version 2 dated 
01.11.04 
17/11/2004 
Participant Information 
Sheet  
Version 2 dated 01.11.04 17/11/2004 
Participant Consent Form  version 1 dated 
23/09/2004 
27/09/2004 
 
Management approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final management approval from the R&D Department for the relevant NHS care 
organisation. 
 
Notification of other bodies 
The Committee Administrator will notify the research sponsor that the study has a 
favourable ethical opinion. 
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
 
Reference: 04/Q0703/121 Please quote this number on all 
correspondence 
 
With the Committee’s best wishes for the success of this project, 
 
Yours sincerely, 
 
 
 
 
Dr David Jewitt 
Chair King’s College Hospital Research Ethics Committee 
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Patient information sheet 
 
Study Title – Age-related macular degeneration in patients with 
abdominal aortic aneurysm 
 
 
You are being invited to take part in a research study.  Before you decide to take part it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with your 
friends, relatives and your GP if you wish.  Ask us if there is anything that is not clear or if 
you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled “Medical Research 
and You”.  This leaflet gives more information about medical research and looks at some 
questions you may want to ask.  A copy may be obtained from CERES, PO Box 1365, 
London N16 0BW. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
Atherosclerosis is the main cause of abdominal aortic aneurysm (AAA). Recent 
epidemiological studies have reported a link between atherosclerosis and age-related 
macular degeneration (AMD). Both the aorta and the vascular coat of the eye share similar 
age-related changes. Studies in both structures suggest that they may be a link between the 
eye findings and the growth of the AAA.  We plan to investigate whether changes in the 
retina and choroids suggestive of these structural changes may be a predictive rupture risk 
parameter for AAA.  
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.  If you decide 
to take part you are still free to withdraw at any time without giving a reason.   
 
What will happen to me if I take part? 
 
You will be asked to come to the Retinal Research Unit in Normandy building with a list of 
medications you are on.  A brief medical history will be noted. You will then have an eye 
test. Your pupils will be dilated with drops for examination of the back of the eye and 
photographs will be taken.  
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What are the possible disadvantages and risks of taking part? 
 
The risks associated with this are minimal. We dilate your pupils and so you are required to 
avoid driving for a few hours after the test.  
 
 
What happens when the research study stops? 
 
The results will be collated and analysed and any significant findings will be published.  
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this research will be kept 
strictly confidential.   
 
 
Who is organising and funding the research? 
 
The research is being run and funded by the Ophthalmic Fund of Kings College Hospital. 
 
Will information from the research be passed to your GP? 
 
Your GP will be informed of your eye test and the findings  
  
 
Contact for further information 
 
Should you have any queries about this study, please contact: 
 
Mr. Victor Chong 
Consultant Ophthalmic Surgeon 
Retinal Research unit 
Kings College Hospital 
Tel: 020 7346 4548   
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 Patient Consent Form 
 
Age-related macular degeneration in patients with abdominal aortic 
aneurysm 
 
Please initial all boxes: 
 
1 I confirm that I have read and understand the information sheet for the above 
study and have had the opportunity to ask questions 
 
2 I understand that my participation is voluntary and that I am free to  
withdraw at any time. 
 
3 I agree to take part in the above study. 
 
 
• Name of Patient……………………………………………. 
 
 
Signature……………………………..Date……………….. 
 
 
• Name of person taking consent……………………………. 
 
 
Signature……………………………..Date……………….. 
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Ethics Committee Approval IV 
 
King's College Hospital Research Ethics Committee 
Camberwell Building 
King's College Hospital 
Denmark Hill 
London SE5 9RS 
Email: Janet.Browning@kingsch.nhs.uk 
Tel: 020 7346 3923 Fax 020 7346 5085 
 
18 March 2005 
 
Mr Victor Chong 
King's College Hospital 
Consultant Ophthalmic Surgeon 
King's College Hospital 
Denmark Hill 
London SE5 9RS 
 
Dear Mr Chong 
 
Full title of study: Pulsatile Ocular Blood flow in Asymmetric Age-Related Macular 
Degeneration 
REC reference number: 04/Q0703/140 
   
Thank you for your letter of 10th March 2005 responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
However, the Committee has not yet been notified of the outcome of any site-specific 
assessment (SSA) for the research site(s) taking part in this study.  The favourable opinion 
does not therefore apply to any site at present.  I will write to you again as soon as one 
Local Research Ethics Committee has notified the outcome of a SSA.  In the meantime no 
study procedures should be initiated at sites requiring SSA. 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document.  You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
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Document Type: Version: Date Received: 
Application  Version 2 dated 10th 
March 2005 
10/03/2005 
Investigator CV   26/10/2004 
Protocol  Version 1 dated 26th 
October 2004 
26/10/2004 
Covering Letter  dated 25th September 
2004 
26/10/2004 
GP/Consultant Information 
Sheets  
GP Letter Version 1 dated 
26th October 2004 
26/10/2004 
Participant Information 
Sheet  
Version 1 dated 26th 
October 2004 
26/10/2004 
Participant Consent Form  Version 1 dated 26th 
October 2004 
26/10/2004 
Response to Request for 
Further Information  
 10/03/2005 
 
R&D approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final management approval from the R&D Department for the relevant NHS care 
organisation. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
Notification of other bodies 
The Committee Administrator will notify the research sponsor and the R&D Department 
for NHS care organisation that the study has a favourable ethical opinion. 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
04/Q0703/140 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project, 
 
Yours sincerely, 
 
 
 
Dr David Jewitt 
Chair King’s College Hospital Research Ethics Committee 
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Patient information sheet 
 
Study Title – Pulsatile ocular blood flow in asymmetric age-related 
macular degeneration 
 
You are being invited to take part in a research study.  Before you decide to take part it is 
important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with your 
friends, relatives and your GP if you wish.  Ask us if there is anything that is not clear or if 
you would like more information.  Take time to decide whether or not you wish to take 
part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled “Medical Research 
and You”.  This leaflet gives more information about medical research and looks at some 
questions you may want to ask.  A copy may be obtained from CERES, PO Box 1365, 
London N16 0BW. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
Age related macular degeneration is the most common cause of blindness in the elderly. 
Despite this, the cause of the disease remains largely unknown. Recent evidence has 
suggested that decrease blood flow to the eyes as a result of hardening of the blood vessels 
may result in the disease.  We plan to investigate whether changes in the retina and 
choroids blood flow is related to the stage of the disease 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form.  If you decide 
to take part you are still free to withdraw at any time without giving a reason.   
 
What will happen to me if I take part? 
 
You will be asked to come to the Retinal Research Unit in Normandy building with a list of 
medications you are on.  A brief medical history and your blood pressure and pulse rate 
will be recorded. You will then have an eye test and the blood flow of the eye will be 
assessed using computer software. Your pupils will be dilated with drops for examination 
of the back of the eye and photographs will be taken.  
 
What are the possible disadvantages and risks of taking part? 
 
The risks associated with this are minimal. We dilate your pupils and so you are required to 
avoid driving for a few hours after the test.  
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What happens when the research study stops? 
 
The results will be collated and analysed and any significant findings will be published.  
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this research will be kept 
strictly confidential.   
 
 
Who is organising and funding the research? 
 
The research is being run and funded by the Ophthalmic Fund of Kings College Hospital. 
 
Will information from the research be passed to your GP? 
 
Your GP will be informed of your eye test and the findings  
  
 
Contact for further information 
 
Should you have any queries about this study, please contact: 
 
Mr. Victor Chong 
Consultant Ophthalmic Surgeon 
Retinal Research unit 
Kings College Hospital 
Tel: 020 7346 4548   
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Patient Consent Form 
 
Pulsatile ocular blood flow in asymmetric Age-related macular 
degeneration. 
 
Please initial all boxes: 
 
1 I confirm that I have read and understand the information sheet for the above 
study and have had the opportunity to ask questions 
 
2 I understand that my participation is voluntary and that I am free to  
withdraw at any time. 
 
3 I agree to take part in the above study. 
 
 
• Name of Patient……………………………………………. 
 
 
Signature……………………………..Date……………….. 
 
 
• Name of person taking consent……………………………. 
 
 
Signature……………………………..Date……………….. 
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APPENDIX – 2 
Formulations 
ABTS buffer 
One ABTS tablet     -50mg 
Dissolved in 50ml of ABTS buffer 
 
0.1 M Sodium Carbonate buffer 
NaCO3                 2.12 g 
Distilled water    200ml 
pH                        9.0 
 
Phosphate Saline Buffer (PBS) 
One tablet of PBS (Invitogen TM, Paisley) 
Distilled water                                                   500ml 
 
PBST 
0.5 ml of 0.05% (v/v) Tween is added to 1 litre PBS 
 
PBST-BSA 
70g of 7% (w/v) Bovine serum albumin (BSA) is added to 1 litre PBST 
 
Tris Saline Buffer (TBS) 
Firstly a 20x solution of Tris saline buffer is made 
Tris                       121.1grams 
NaCl                     175.3grams 
Distilled water      1 litre 
pH                         7.5 
then 50ml of the 20x is diluted with 1 litre of distilled water so a 1xTBS solution is 
obtained. 
 
TBST 
0.5 ml of 0.05% v/v Tween is added to 1 litre 1X TBS 
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MMP-2 ELISA protocol for the R&D Quantikine total human MMP-2 immunoassay 
kits (DMP200) 
 
1. Standard (rMMP-2) preparation: 
a. Add 1ml of sterile dH2O to dissolve the dried MMP-2 powder at RT for 15 
mins. 
b. Prepare 7 Epp-tube each contains 120ul of Calibrator Diluent RD5-32. 
c. Add 120ul of undiluted MMP-2 to Epp-tube1, mix and transfer 120ul to 
Epp-tube2.  Finish the series dilution until Epp-tube7. 
d. The preparation is sufficient for 2 sets of standards of 7 serial dilutions. 
e. Undiluted MMP-2 could be stored frozen at -80’C. 
2. Sample preparation: 
a. Thaw the frozen plasma samples (at -80 0C) on ice and mix content before 
dispensing. 
b. Prepare 3 Epp-tubes; the 1st one contains 230µl of RD5-32, whereas the 2nd 
and 3rd ones contain 120 µl of RD5-32. 
c. Add 10.5 µl of plasma samples to tube1, mix and transfer 120 µl to tube2.  
From tube2 transfer 120 µl to tube3.  Thereby, dilutions of tubes 1-3 are 
1:45, 1:90 and 1:180 respectively. 
d. The preparation is sufficient for 2 sets of samples of 3 serial dilutions. 
3. Plates: 
a. Add 100 µl of Assay Diluent RD1-74 (blue in colour) into each well. 
b. Standards: add 50ul each of the serial diluted MMP-2 into wells along the 
first and second columns (S1 to S7).  To the last well of the first 2 columns 
add 50 µl of RD5-32 (as Blank). 
c. Add 50 µl of the diluted samples into the corresponding wells. 
4. Cover the plate and shake at 250rpm at RT for 2 hrs. 
5. Dilute the Stock Wash Buffer 25 times.  Discard contents of the plate and add to 
each well 400 µl of diluted Wash Buffer.  Repeat the washing 1 more time. 
6. To each well as 200 µl of the MMP-2 conjugate (colourless).  Cover the plate and 
shake at 250rpm at RT for 2 hrs. 
7. Wash the plate 3 times as step5. 
8. Mix equal volume of Reagents A and B and use within 15 mins.  To each well add 
200 µl of the mixture.  Cover the plate and incubate at RT for half an hour in 
darkness. 
9. Terminate the reactions by adding 50 µl of Stop Solution.  Measure ASAP and 
within half an hour. 
10. ELISA reader setting: 
a. Read absorbance at 450 nm. 
b. Enter the concentrations of the standards accordingly. 
c. Plot the OD values and concentrations of the standards. 
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MMP-9 ELISA protocol for the R&D Quantikine total human MMP-9 immunoassay 
kits (DMP900) 
 
1. Standard (rMMP-9) preparation: 
a. Add 1ml of sterile dH2O to dissolve the dried MMP-9 powder at R/T for 15 
mins. 
b. Prepare 6 Epp-tube each contains 240 µl of Calibrator Diluent RD5-10. 
c. Add 240 µl of undiluted MMP-9 to Epp-tube1, mix and transfer 240 µl to 
Epp-tube2.  Finish the series dilution until Epp-tube6. 
d. The preparation is sufficient for 2 sets of standards of 6 serial dilutions. 
e. Undiluted MMP-9 could be stored frozen at -80’C. 
2. Sample preparation: 
a. Thaw the frozen plasma samples (at -80 0C) on ice and mix content before 
dispensing. 
b. Prepare 3 Epp-tubes, the 1st one contains 312 µl of RD5-10, whereas the 2nd 
and 3rd ones contain 220 µl of RD5-10. 
c. Add 13.2ul of plasma samples to tube1, mix and transfer 110 µl to tube2.  
From tube2 transfer 110 µl to tube3.  Thereby, dilutions of tubes 1-3 are 
1:25, 1:75 and 1:225 respectively. 
d. The preparation is sufficient for 2 sets of samples of 3 serial dilutions. 
3. Plates: 
a. Add 100 µl of Assay Diluent RD1-34 (blue in colour) into each well. 
b. Standards: add 100 µl of undiluted MMP-9 (S1), and 100 µl each of the 
serial diluted MMP-9 into wells along the first and second columns (S2 to 
S7).  To the last well of the first 2 columns add 100 µl of RD5-10 (as 
Blank). 
c. Add 100 µl of the diluted samples into the corresponding wells. 
4. Cover the plate and shake at 250rpm at RT for 2 hrs. 
5. Dilute the Stock Wash Buffer 25 times.  Discard contents of the plate and add to 
each well 400ul of diluted Wash Buffer.  Repeat the washing 1 more time. 
6. To each well as 200ul of the MMP-9 Conjugate (pink in colour).  Cover the plate 
and shake at 250rpm at RT for 1 hr. 
7. Wash the plate 3 times as step5. 
8. Mix equal volume of Reagents A and B and use within 15 mins.  To each well add 
200ul of the mixture.  Cover the plate and incubate at RT for half an hour in 
darkness. 
9. Terminate the reactions by adding 50 µl of Stop Solution.  Measure ASAP and 
within half an hour. 
10. ELISA reader setting: 
a. Read absorbance at 450 nm. 
b. Enter the concentrations of the standards accordingly. 
c. Plot the OD values and concentrations of the standards. 
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Protocol for assay of plasma C3a des Arg      
 
 
1. Precipitation of whole proteins from plasma 
To 225 µl of thawed plasma, add 225 µl Complement reagent A and vortex thoroughly. 
Add 50 µl of 10N HCL to the sample and vortex and incubate for an hour, 
Spin at 10,000 rpm in a micro-centrifuge at room temperature for 5 mins.  
Transfer 180 µl supernatant to fresh tube and add 20 µl of 9N NaOH and vortex. 
Add 10.7 µl of assay buffer and vortex to ensure 1:10 dilution. 
Dilute 50 µl of each sample with 950 µl of assay buffer and vortex 
There is a 1: 200 dilution of plasma samples when the above steps are followed. 
 
2. Prepare standards  
Allow the stock standard to warm to room temperature. Label 7 tubes 1-7. In the first tube 
pipet 1 ml assay buffer and 500 µl to tube 2-7. 
Remove 20 µl from tube 1 and add 20 µl of stock standard to it and vortex. Remove 500 µl 
of tube 1 to tube 2 and vortex. Continue this to tube 7. 
 
3. Assay procedure 
Pipet 100 µl of assay buffer into NSB and Blank wells. Pipet standards 1-7 to appropriate 
wells. Also pipet 100 µl of 1: 200 samples into appropriate wells in duplicate. Pipet 50 µl 
of assay buffer into the NSB wells. Pipet 50 µl of conjugate into each well except blank 
well. Then add 50 µl of antibody into each well except blank and NSB.  
Incubate at room temperature on a plate shaker at 500 rpm for 2 hours. 
Use 400 µl of wash buffer to wash wells three times. 
Add 200 µl of the p-Npp substrate solution to each well and incubate for 1 hour at 370 C 
without shaking. 
Add 50 µl of stop solution to every well.   
The plates are read at 405nm. 
 
4. Calculation of Results 
 
Net OD is equal to average of sample OD – average NSB OD 
Percent bound is   Net OD x 100
                              Net Blank OD 
 
Plot standard curve with % bound in y-axis and log of concentrations of standards (ng/ml) 
in x-axis. 
Determine values of C3a des Arg in samples by interpolation.  
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Protocol for AVR calculation 
 
1. Each venular and arteriolar diameter is measured five times. 
2. The mean of each venular and arteriolar diameter are obtained. 
3. The mean is in pixels. So to convert it to micrometers, use a conversion factor of 
1.91. 
4. Place venular and arteriolar mean diameters in ascending order. 
5. Then to calculate CRVE when four venular diameters are available, the formula is: 
SQRT ((0.72*POWER(x, 2)) + (0.91*POWER(y, 2))+450.05), in which x is the 
smaller value and y is the larger value of the venular diameter.  
6.   If there are only 3 venial diameters then the combinations are slightly   different: As 
above, whichever is smaller comes first, thus the formula reads 
SQRT((0.72*POWER(R50,2))+(0.91*POWER(Q52,2))+450.05) 
     7.    A similar process is used for calculating the central retinal artery equivalents    from 
the arteriole measurements but using a different formula: 
       The final formula is now SQRT ((0.87*POWER(x, 2)) + (1.01*POWER(y, 2))-
(0.22*x*y)-10.76), where x is the smaller value and y is the larger of the arteriolar 
diameters 
8.   The CRAE is then divided by the CRVE to give the AV ratio.  
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APPENDIX-3 
Results of analysis of S-EDP 
 
Control group 
 
Sample 
no. age sex S-EDPng/ml 
72 82 F 30.22
75 74 F 7.17
76 72 F 12.46
77 67 M 39.85
98 86 F 11.9
99 81 F 4.67
102 90 F 18.53
107 63 M 4.14
108 67 M 18.37
109 91 M 6.28
113 65 F 7.17
114 79 F 20.5
123 83 M 15.56
126 82 F 23.84
133 61 M 9.87
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 Results of analysis of S-EDP  
ARM group 
Sample 
no. age sex S-EDPng/ml 
29 81 F 22.2
45 70 F 20.9
63 78 F 9.81
65 83 F 19.3
71 65 F 12.96
80 83 M 16.6
90 78 M 39.81
106 80 M 7.9
116 80 M 31.25
117 74 M 28.1
128 73 F 26.6
144 73 F 30.05
1192 85 F 20.92
1266 88 M 17.41
1272 72 F 15.08
1276 74 M 20.08
1280 69 M 38.25
1328 67 F 39.08
1335 68 M 35.08
1356 88 M 19.75
1370 75 F 12.58
1372 85 M 24.58
1373 68 M 21.58
1384 69 F 37.08
1390 84 F 47.75
1394 68 F 31.25
1403 70 F 16.08
1405 88 F 14.75
1406 82 F 14.75
1412 81 F 14.75
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Results of analysis of S-EDP  
CNV group 
Sample 
no. AGE SEX S-EDP ng/ml 
36 92 M 8.07
41 84 F 43.67
73 87 F 42.53
79 86 F 47.35
81 65 F 25.03
82 85 F 88.67
83 88 F 18.42
87 79 M 32.53
88 79 F 40.05
89 81 F 44.36
92 79 M 9.14
103 62 F 59.88
110 85 M 27.89
112 78 M 32.47
115 92 M 17
118 87 F 42.17
127 90 F 40.05
129 66 M 52.47
132 79 F 6.64
134 86 M 50.74
135 79 M 7.8
136 75 M 84.53
140 67 M 55.56
146 75 F 60.56
1269 82 F 14.91
1270 75 F 14.75
1314 69 F 8.916
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Results of analysis of Plasma MMP-2 and MMP-9 
 
 Group 
Sample 
No. 
MMP-2 
ng/ml 
MMP-9 
ng/ml 
Control 66 487 372 
 53 495 241 
  47 686 176 
  17 417 122 
  58 394 323 
  1 426 138 
  20 457 418 
  3 284 174 
  40 583 456 
  5 610 199 
  6 429 208 
  7 378 239 
  8 576 57 
  9 798 160 
  61 417 122 
  48 502 329 
  54 487 543 
 
 
Group 
Sample 
No. 
MMP-2 
ng/ml 
MMP-9 
ng/ml 
ARM 23 427 736
  56 655 1054
  36 917 797
  35 374 667
  8 569 72
  55 327 912
  2 618 483
  73 508 297
  51 496 552
  67 547 559
  29 401 236
  63 452 603
  32 446 706
  18 398 1234
  46 468 978
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Results of analysis of Plasma MMP-2 and MMP-9 
 
Group 
Sample 
No. 
MMP-2 
ng/ml 
MMP-9 
ng/ml 
CNV 50 484 1007
  77 413 393
  24 607 833
  52 507 82
  75 415 159
  30 402 1174
  57 587 769
  76 460 1285
  33 606 906
  20 529 437
  22 486 588
  27 486 249
  19 507 719
  74 583 523
  1 786 2233
  6 538 728
  28 457 703
  70 693 549
 
 
 
 
 
 
 
 
 
 
 
 177
Correlation between S-EDP and plasma MMP-2 and MMP-9  
     
CONTROL 
age 
(yrs) S-EDP ng/ml MMP-2 ng/ml MMP-9 ng/ml 
1 61 39.85 417 494 
2 84 56.25 578 702 
3 63 4.1 686 176 
4 65 7.7 495 225 
5 79 20.5 487 456 
6 83 15.6 525 337 
7 82 24.36 556 846 
8 81 23.84 487 372 
9 62 9.8 508 297 
10 91 7.9 497 225 
          
ARM   S-EDP MMP-2 MMP-9 
1 83 19.32 587 988 
2 96 12.26 432 422 
3 83 11.7 427 1256 
4 80 31.3 655 1054 
5 74 28.2 327 901 
6 73 26.6 250 820 
7 73 30.05 340 1054 
8 79 22.2 430 860 
9 70 20.9 460 875 
10 79 9.81 328 654 
          
CNV   S-EDP MMP-2 MMP-9 
1 80 47.36 486 588 
2 88 25.03 607 833 
3 85 88.67 529 437 
4 88 18.42 507 719 
5 79 32.54 486 249 
6 85 40.05 457 703 
7 81 44.36 402 1174 
8 79 9.1 454 505 
9 85 27.9 484 1004 
10 78 32.47 507 82 
11 92 17 587 769 
12 87 42.2 449 889 
13 90 40.05 574 742 
14 67 52.46 379 372 
15 79 6.64 693 549 
16 86 50.74 413 401 
17 79 6.107 460 1285 
18 85 84.53 415 695 
19 75 55.56 584 1587 
20 75 60.56 497 1003 
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Analysis of Plasma C3a des Arg 
Control group 
 
sample no age sex Plasma C3ades Arg (ng/ml) 
899 72 M 30.87
1395 71 M 59.05
491 84 M 48.76
845 85 M 50.60
556 87 M 15.65
1730 80 M 84.23
791 71 M 62.81
863 83 F 58.13
363 81 F 52.90
1676 72 F 61.80
616 71 F 61.20
1635 64 F 49.60
1732 89 F 55.40
1610 86 F 35.20
1646 81 F 58.20
268 79 M 53.80
1114 85 M 18.82
1340 82 F 49.80
1644 83 M 45.40
1218 83 F 6.52
114 79 F 72.12
97 84 F 11.57
108 67 M 7.82
126 82 F 7.10
123 83 F 6.51
72 82 F 168.28
75 74 F 164.44
76 72 F 100.97
77 67 M 81.74
98 86 F 76.93
99K 81 F 76.93
102K 90 F 23.64
105K 81 F 11.95
107 63 M 198.09
109K 91 M 173.09
113 65 F 168.28
125 81 M 164.44
133 61 M 23.64
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Analysis of plasma C3a des Arg 
 
ARM group 
 
sample no age sex Plasma C3ades Arg (ng/ml) 
1241 84 M 61.00
314 55 F 51.38
453 63 M 64.78
910 69 F 61.00
554 84 M 2.78
672 72 M 49.82
731 94 F 57.26
1049 79 M 45.42
980 65 M 58.14
1030 70 F 49.82
650 73 F 49.82
99 67 M 16.48
441 73 F 22.66
1154 102 F 53.82
1481 71 M 49.82
112 82 F 36.6
569 62 F 51.38
241 73 F 54.66
29 81 F 76.93
106 80 M 23.64
144 73 F 11.95
1192 85 F 23.64
1390 84 F 168.28
1372 85 F 81.74
1403 70 F 76.93
1406 82 F 198.09
1356 88 M 173.09
1384 69 F 11.57
1373 68 M 7.82
1412 81 F 7.10
1405 88 F 6.51
1335 68 M 168.28
1280 69 M 164.44
1370 75 F 100.97
1276 74 M 173.09
1328 67 F 198.09
1266 88 M 100.97
1272 72 F 81.74
1394 68 F 76.93
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Analysis of Plasma C3a des Arg 
 
CNV group 
sample no age sex Plasma C3ades Arg (ng/ml) 
1098 85 M 27.70
1013 83 M 85.90
1521 87 M 56.20
591 79 M 28.87
1542 79 M 43.36
317 78 M 41.31
932 84 M 3.13
1078 81 M 55.50
1021 82 F 25.22
1376 84 M 53.00
1164 87 F 56.80
686 81 M 56.40
1347 79 F 46.20
109 78 F 60.90
787 88 F 16.90
291 85 F 62.80
1268 83 F 66.80
41 84 F 250.02
40 80 M 198.09
112K 78 M 173.09
101 85 M 168.28
134 86 M 164.44
88 79 F 250.02
117 80 M 173.09
89 81 F 76.93
1269 82 F 7.10
1314 69 F 173.09
1270 75 F 168.28
81 65 F 164.44
83 88 F 100.97
82 85 F 81.74
87 79 M 6.51
132 79 F 81.74
135 79 M 100.97
36 92 M 198.09
92 79 M 7.10
110 85 M 250.02
127 90 F 173.09
118 87 F 100.97
140 67 M 7.10
103 62 F 76.93
146 75 F 11.95
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 Pulsatile Ocular Blood Flow in Asymmetric AMD 
First eye 
  No SEX AGE diag_eye1
AL-
eye1 
IOP-
eye1 
PA-
eye1 
PV-
eye1 
PR-
eye1
OBF-
eye1 
GROUP 1 1 F 89 CNV 22.09 14.1 2.9 6.1 72.4 912.0
  2 F 78 CNV 22.15 19.5 3.4 5.7 98.6 1297.2
  3 F 88 CNV 22.78 14.4 3.3 6.8 56.4 766.8
  4 F 89 CNV 22.69 9.0 2.5 7.8 64.0 1087.2
  5 F 90 CNV 21.41 7.3 4.9 16.2 62.4 2053.2
  6 F 81 CNV 25.78 11.4 3.3 8.3 70.2 1198.8
  7 F 78 CNV 22.49 8.1 4.1 13.0 72.4 1926.0
  8 F 87 CNV 23.57 15.1 3.9 7.6 67.2 997.2
  9 M 85 CNV 23.45 25.3 3.7 5.0 60.8 594.0
  10 M 81 CNV 24.75 6.9 4.0 14.2 64.0 1763.5
  11 F 86 CNV 22.73 14.3 4.4 9.0 70.0 1309.8
  12 M 77 CNV 24.32 8.2 2.9 9.5 66.2 1222.0
  13 M 78 CNV 24.14 7.5 1.4 5.4 74.0 850.2
  14 M 80 CNV 22.80 11.4 2.6 6.6 65.4 901.4
  15 F 62 CNV 23.32 17.3 1.7 3.2 86.6 589.2
  16 M 64 CNV 23.25 9.8 3.0 8.7 71.6 1309.2
  17 F 74 CNV 21.53 12.8 4.6 10.0 75.0 1551.6
  18 F 82 CNV 23.14 11.3 2.9 7.3 62.6 937.2
  19 M 68 CNV 24.32 10.2 3.3 9.0 64.0 1124.4
  20 F 84 CNV 21.24 9.6 2.6 7.7 68.0 1062.0
  21 M 79 CNV 23.38 14.7 2.0 4.3 83.6 763.4
GROUP2 1 F 90 Disciform 20.62 7.9 3.1 10.4 85.5 1869.0
  2 F 78 Disciform 21.77 11.8 2.9 7.0 96.0 1466.4
  3 F 80 Disciform 22.49 9.2 4.0 11.6 67.6 1563.6
  4 F 75 Disciform 22.29 9.1 4.1 11.8 69.6 1713.0
  5 M 84 Disciform 21.89 17.6 3.5 6.2 68.2 918.4
  6 M 71 Disciform 24.75 15.9 1.8 3.6 83.2 646.4
  7 M 85 Disciform 22.25 13.0 1.8 4.3 77.8 673.2
  8 F 79 Disciform 22.53 18.9 3.7 6.1 62.4 826.8
  9 M 84 Disciform 23.58 17.2 1.7 3.2 78.2 534.0
  10 F 82 Disciform 23.17 14.3 4.6 9.3 54.6 981.6
  11 M 89 Disciform 23.59 13.5 3.1 6.8 63.0 816.0
  12 F 79 Disciform 21.43 13.8 3.5 7.4 79.8 1232.4
  13 M 66 Disciform 23.03 8.8 3.0 9.3 57.0 1237.2
  14 F 78 Disciform 22.83 11.6 2.1 5.3 75.2 820.8
  15 F 84 Disciform 22.53 9.9 3.3 9.2 75.0 1620.0
  16 F 72 Disciform 23.24 15.5 2.2 4.4 57.4 546.0
  17 F 81 Disciform 20.84 14.2 2.9 6.2 75.6 1004.4
  18 F 84 Disciform 24.59 17.5 2.0 3.6 66.2 466.8
 
AL-axial length; PA- pulse amplitude; PR-Pulse rate; OBF- ocular blood flow 
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 Pulsatile Ocular Blood Flow in Asymmetric AMD  
Second eye 
 
No diag_eye2 
AL-
eye2 
IOP-
eye2 
PA-
eye2 
PV-
eye2 
PR-
eye2 
OBF-
eye2 
GROUP 1 1 Drusen 21.96 10.6 3.0 7.2 74.4 1224.0
 2 Drusen 22.32 20.4 3.5 5.6 101.6 1220.4
 3 Drusen 22.63 11.4 3.1 7.7 56.5 856.5
 4 Drusen 22.56 9.4 2.7 8.1 63.4 1063.2
 5 Drusen 21.86 8.5 5.0 14.8 64.8 1909.2
 6 Drusen 25.88 10.9 3.3 8.5 71.6 1224.0
 7 Drusen 22.60 9.1 4.3 12.4 71.6 1813.2
 8 Drusen 23.80 15.5 3.8 7.3 63.3 939.0
 9 Drusen 23.56 17.3 4.4 7.7 58.6 922.8
 10 Drusen 24.79 6.8 3.6 13.2 57.6 1673.2
 11 Drusen 22.79 13.6 4.6 9.6 70.8 1441.4
 12 Drusen 23.74 9.6 2.8 8.2 65.4 1039.4
 13 Drusen 24.25 9.1 1.8 5.8 74.0 874.4
 14 Drusen 22.94 10.3 2.2 6.1 65.2 809.4
 15 Drusen 23.49 14.6 1.8 3.9 89.4 760.8
 16 Drusen 23.07 9.4 2.9 8.6 69.0 1245.6
 17 Drusen 21.87 12.4 5.0 11.2 74.6 1752.0
 18 Drusen 24.04 10.9 2.7 7.2 62.0 896.4
 19 Drusen 24.68 14.9 2.9 6.0 66.2 861.6
 20 Drusen 21.55 8.2 1.7 5.9 68.0 894.0
 21 Drusen 23.35 13.7 1.9 4.3 80.4 700.4
GROUP 2 1 Drusen 21.72 10.7 4.1 10.6 83.2 1792.8
 2 Drusen 21.90 16.7 2.5 4.7 94.2 952.8
 3 Drusen 22.78 12.3 3.5 8.3 67.8 1136.2
 4 Drusen 23.00 9.3 3.5 10.1 68.4 1375.2
 5 Drusen  22.08 20.4 3.1 4.8 70.0 712.8
 6 Drusen 24.71 14.1 1.7 3.9 84.6 684.4
 7 Drusen 23.36 12.9 2.3 5.4 74.4 805.6
 8 Drusen 22.59 17.2 3.7 6.6 64.8 812.4
 9 Drusen 23.85 16.6 1.9 3.7 80.8 618.0
 10 Drusen 23.02 11.6 4.4 10.5 55.8 1153.5
 11 Drusen 24.33 8.5 2.7 8.8 63.6 1164.0
 12 Drusen 21.83 11.3 3.1 7.8 82.8 1364.4
 13 Drusen 23.21 11.0 3.3 8.6 68.2 1159.2
 14 Drusen 21.41 13.1 2.8 6.3 75.6 990.0
 15 Drusen 23.24 11.3 3.2 8.1 71.0 1272.0
 16 Drusen 23.14 17.3 2.3 4.2 57.6 500.4
 17 Drusen 22.14 16.0 3.2 6.0 78.6 996.0
 18 Drusen 24.39 17.8 2.0 3.7 70.0 524.4
AL-axial length; PA- pulse amplitude; PR-Pulse rate; OBF- ocular blood flow 
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Retinal vascular calibre changes in asymmetric AMD  
Group 1: ARM-CNV group 
        DRUSEN         CNV   
  age sex CRVE CRAE AVR     CRVE CRAE AVR 
1 89 F 180.19 133.30 0.74   1 169.53 131.03 0.77
2 78 F 299.21 152.02 0.51   2 295.22 148.22 0.50
3 88 F 207.03 136.43 0.66   3 213.20 130.36 0.61
4 89 F 191.50 167.46 0.87   4 201.98 117.62 0.58
5 90 F 145.51 138.24 0.95   5 144.45 134.15 0.93
6 81 F 214.36 150.83 0.70   6 203.33 151.23 0.74
7 78 F 209.36 113.81 0.54   7 208.39 110.87 0.53
8 87 F 200.83 129.15 0.64   8 177.30 203.24 1.15
9 85 M 242.98 113.60 0.47   9 212.40 111.70 0.53
10 81 M 200.97 175.92 0.88   10 192.56 179.20 0.93
11 86 F 178.35 125.36 0.70   11 196.43 117.85 0.60
12 77 M 220.91 120.09 0.54   12 210.33 108.44 0.52
13 78 M 219.24 120.96 0.55   13 234.36 128.58 0.55
14 80 M 215.34 129.29 0.60   14 203.50 103.04 0.51
15 62 F 207.75 123.72 0.60   15 217.49 115.23 0.53
16 64 M 259.20 146.85 0.57   16 225.78 130.52 0.58
17 74 F 265.34 236.47 0.89   17 270.04 203.44 0.75
18 82 F 246.48 142.34 0.58   18 269.43 141.98 0.53
19 68 M 199.85 128.30 0.64   19 195.95 113.01 0.58
20 84 F 199.03 114.67 0.58   20 203.77 106.63 0.52
Mean  80   215.17 139.94 0.66   Mean 212.27 134.32 0.65
SD  8   34.31 28.43 0.14    SD 34.86 29.91 0.18
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Retinal vascular calibre changes in asymmetric AMD  
Group 2: ARM-Disciform group 
        ARM       
DISCIFORM 
SCAR     
  age sex CRVE CRAE AVR     CRVE CRAE AVR 
                      
1 78 F 246.31 186.68 0.76   1 242.35 180.25 0.74
2 80 F 223.16 135.99 0.61   2 225.32 133.24 0.59
3 75 F 248.98 157.04 0.63   3 250.23 155.36 0.62
4 84 M 223.35 146.32 0.66   4 221.64 142.35 0.64
5 71 M 198.32 116.13 0.59   5 201.37 120.56 0.60
6 85 M 210.37 118.32 0.56   6 215.65 115.64 0.54
7 79 F 208.39 118.32 0.57   7 208.39 117.45 0.56
8 82 F 204.55 131.04 0.64   8 200.53 134.65 0.67
9 89 M 202.12 184.65 0.91   9 205.32 189.32 0.92
10 79 F 215.66 118.96 0.55   10 215.66 123.24 0.57
11 66 M 232.48 186.76 0.80   11 230.25 176.86 0.77
12 78 F 231.76 136.98 0.59   12 235.64 132.65 0.56
13 84 F 206.80 119.98 0.58   13 210.32 117.29 0.56
14 72 F 252.24 190.35 0.75   14 255.13 198.65 0.78
15 81 F 228.63 183.99 0.80   15 225.78 180.38 0.80
mean 79   222.21 148.77 0.67   mean 222.91 147.86 0.66
SD 6   17.60 29.84 0.11   SD 17.20 29.52 0.11
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